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Polypharmacy: Patterns And Policy Propositions
Abstract
Sixty percent of U.S. adults report frequent use of prescription medications, a prevalence that is higher
than ever before. Although medications are lifesaving when used properly, they can produce side effects
ranging from minor problems like dizziness to severe events such as an increased risk of cancer.
Polypharmacy – a phenomenon typically defined as concurrent use of multiple medications – may
present unique risks for medication side effects, amplifying the effects of each of the medication in a set.
Given the growing medication use across the country, this dissertation examined the causes of
polypharmacy and the consequences of concurrent use of medications with side effects on population
health and health care use. The first chapter provided background information on polypharmacy and
medication side effects. The second chapter used the National Health and Nutrition Examination Survey
(NHANES) to investigate whether and how the introduction of Medicare Part D, a large and sudden
change to health care financing for Medicare beneficiaries, affected medication use for older adults.
While Part D increased the use of lifesaving medications, it also increased polypharmacy. The third
chapter used the NHANES to show that concurrent use of three or more medications with cognitive
impairment side effects among U.S. older adults increased three-fold in the past two decades. Individuals
who used three or more such medications experienced increased risks of cognitive deficits compared to
non-users. The fourth chapter used the Medical Expenditure Panel Survey (MEPS) to document a growth
of 36% in the concurrent use of at least three medications with mental health side effects among U.S.
adults in the past two decades. Concurrent use of these medications was associated with an increase in
psychiatric symptoms and the use/costs of mental health services. In the fifth chapter, I discussed how
the processes of medicalization and pharmaceuticalization contributed to rising medication use and
disparities in such use, which in turn had implications for population-level health disparities. Collectively,
these findings shed light on patterns and disparities in population health associated with polypharmacy
and speak directly to the role of broader social, economic, cultural, and institutional inequalities in
generating and maintaining health disparities.
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ABSTRACT
POLYPHARMACY: PATTERNS AND POLICY PROPOSITIONS
Duy Do
Jason Schnittker
Sixty percent of U.S. adults report frequent use of prescription medications, a prevalence
that is higher than ever before. Although medications are lifesaving when used properly,
they can produce side effects ranging from minor problems like dizziness to severe
events such as an increased risk of cancer. Polypharmacy – a phenomenon typically
defined as concurrent use of multiple medications – may present unique risks for
medication side effects, amplifying the effects of each of the medication in a set. Given
the growing medication use across the country, this dissertation examined the causes of
polypharmacy and the consequences of concurrent use of medications with side effects
on population health and health care use. The first chapter provided background
information on polypharmacy and medication side effects. The second chapter used the
National Health and Nutrition Examination Survey (NHANES) to investigate whether
and how the introduction of Medicare Part D, a large and sudden change to health care
financing for Medicare beneficiaries, affected medication use for older adults. While Part
D increased the use of lifesaving medications, it also increased polypharmacy. The third
chapter used the NHANES to show that concurrent use of three or more medications with
cognitive impairment side effects among U.S. older adults increased three-fold in the past
two decades. Individuals who used three or more such medications experienced increased
risks of cognitive deficits compared to non-users. The fourth chapter used the Medical
Expenditure Panel Survey (MEPS) to document a growth of 36% in the concurrent use of
at least three medications with mental health side effects among U.S. adults in the past
two decades. Concurrent use of these medications was associated with an increase in
psychiatric symptoms and the use/costs of mental health services. In the fifth chapter, I
discussed how the processes of medicalization and pharmaceuticalization contributed to
rising medication use and disparities in such use, which in turn had implications for
population-level health disparities. Collectively, these findings shed light on patterns and
iii

disparities in population health associated with polypharmacy and speak directly to the
role of broader social, economic, cultural, and institutional inequalities in generating and
maintaining health disparities.
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CHAPTER 1:
Introduction
Polypharmacy
Almost 60 percent of U.S. adults report frequent use of prescription medications, a
prevalence that is higher than ever before (Kantor et al., 2015). The use of medications
varies significantly by demographic characteristics. Adults over 65 years of age, nonHispanic Whites, women, and U.S. born citizens are more likely to consume prescription
medications than their counterparts. Much of the increase in medication use between
1999 and 2012 could be attributed to growing use of certain drug classes such as
antihyperlipidemic agents (6.9% to 17%), antidepressants (6.8% to 13%), prescription
proton-pump inhibitors (3.9% to 7.8%), and muscle relaxants (1.2% to 2.5%) (Kantor et
al., 2015). The growth in popularity of these drug classes in part reflected the increasing
availability of medications, as well as rising occurrences of disease such as high
cholesterol (Superko et al., 2019), depression (Weinberger et al., 2018), gastroesophageal
reflux diseases (El–Serag, 2007), and chronic pain (Nahin et al., 2019).

While the use of at least one medication increased by almost 18% between 1999 and
2012 among community-dwelling adults, the use of five or more medications increased
by nearly 83% – a phenomenon typically referred to as polypharmacy (Kantor et al.,
2015). Although there is no scientific consensus or clinical definition for polypharmacy,
this term is typically used interchangeably to describe multiple, concurrent, excessive,
unnecessary, or unindicated medication consumption. A handful of studies defined
polypharmacy as consuming at least five medications concurrently for older adults and at
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least two medications for young adults, because researchers typically detected adverse
effects of medications at these thresholds in various health care settings (Mortazavi et al.,
2016). Given that the prevalence of polypharmacy is likely to increase even more in the
future, it is important to examine the causes of polypharmacy and its potential
consequences on health.

Causes of polypharmacy
Causes of polypharmacy are multifactorial. Potential risk factors for polypharmacy
include the rise in chronic conditions and comorbidity, failure to consider comorbidity in
clinical practice guidelines, health care fragmentation, and the use of medications to treat
adverse drug reactions.

Chronic conditions and comorbidity. The rise in chronic conditions in the United States
may partly explain for growing prevalence of polypharmacy. In 2010, approximately half
of U.S. adults had at least one chronic condition1 (Ward & Schiller, 2013). When one
condition occurs, more conditions await backstage. Therefore, among individuals with at
any chronic conditions, half had at least two conditions (Ward & Schiller, 2013). The
proportion of U.S. adults having multiple chronic conditions is not only high and
alarming, but it has also been increasing over time. The prevalence of having at least two
chronic conditions in 2001 was 21.8%, while it was 25% in 2010 (Ward & Schiller,
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Chronic conditions in the study by Ward and Schiller (2013) included hypertension, coronary heart

disease, stroke, diabetes, cancer, arthritis, hepatitis, weak or failing kidneys, chronic obstructive pulmonary
disease, and current asthma.
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2013). The growth in comorbidity has also been observed across various demographic
subgroups, such as men (19.1% to 24%), women (24.3% to 27.7%), adults aged 45-64
(30.7% to 33.8%), adults aged 65+ (56.2% to 62.1%), and non-Hispanic Whited (23.4%
to 28.1%) (Ward & Schiller, 2013). An increase in comorbidity, combined with rapid
pharmaceutical advancements and an overconfidence in medicine as a solution to disease,
may have given rise to polypharmacy.

Failure to consider comorbidity in clinical practice guidelines. Clinical practice
guidelines help manage chronic conditions. However, most guidelines only address a
single disease outcome in accordance with modern medicine’s practice and fail to
acknowledge the presence of comorbidity, especially among older patients. Take an
example of a hypothetical patient that has hypertension, diabetes mellitus, osteoporosis,
osteoarthritis, and chronic obstructive pulmonary disease. Strict adherence to the national
guidelines for these conditions easily results in 12 prescriptions that require 19 doses
taken five times per day (Boyd et al., 2005). Under the recent pay-for-performance
initiative in the health care system, which rewards physicians who follow interventions
that reflect national clinical guidelines, one should expect that polypharmacy may
increase as a result.

Health care fragmentation. Medical care delivery in the U.S. often involves multiple
providers and organizations, without a single entity that effectively coordinates all
aspects of care (Elhauge, 2010). Although the ideal physician-to-patient ratio is one,
many patients may see several physicians to manage the same medical condition (Cebul
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et al., 2008). Marked variation in physicians’ practice styles may contribute to various
treatment plans for patients. It has been well-established that health care delivery varies
across small geographical areas, or even within the same hospital or health care system
(Keating et al., 2006; Zhang et al., 2012). Cutler, Skinner, Stern, & Wennberg (2019)
found that although patients’ characteristics and preferences fail to explain for the
geographical variation in end-of-life care delivery, 35% of the variation is explained by
physician beliefs. Similarly, Zhang, Baicker, & Newhouse (2010) found a substantial
variation in the quality of prescribing – defined as prescribing medications that are
potentially high-risk for older adults – among local hospital markets even after
controlling for patients’ characteristics. The lack of care coordination across providers
who have different beliefs, training, and knowledge about a patient’s medical history may
result in polypharmacy and adverse outcomes associated with polypharmacy. In fact, Col,
Fanale, & Kronholm (1990) found that the number of physicians seen regularly is
positively associated with the likelihood of being admitted to hospital for drug-related
illnesses.

Adverse drug reactions. All medications have adverse side effects. Although
pharmaceutical therapies are typically lifesaving when used correctly, consuming a
medication that has adverse side effects may lead to the onset of another condition for
which the medication was not intended. Symptoms that are due to adverse drug reactions
are often mistakenly diagnosed as a new disease. As a result, 80% of drug adverse
reactions are treated with another drug (Tamblyn, 1996).
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Consequences of polypharmacy
Although medications are critical for disease management and prevention, growing
concerns have emphasized the consequences of polypharmacy on adverse drug reactions,
drug-drug interactions, medication nonadherence, and excessive medical interventions
that do more harm than good for patients’ health. Previous studies have documented
adverse medical outcomes of polypharmacy on health in various settings. Among
outpatients of all ages, using at least five medications is associated with an increase of
88% in experiencing adverse drug events (Bourgeois et al., 2010). For nursing home
residents, the bar is higher. Using at least nine medications is associated with an
increased risk of adverse drug reactions by 2.33 times (Nguyen et al., 2006). Concurrent
use of medications can also lead to drug-drug interactions when the effectiveness or
toxicity of a medication is altered by the other. Lindblad et al. (2005) found that the risk
drug-drug interaction increased 4 times and 9 times among elderly veterans who
consumed 5-8 medications and at least 9 medications simultaneously, compared to
nonusers. Polypharmacy also has direct impacts on health: those who consumed at least
five medications are more likely to experience cognitive impairment and falls, and these
associations have been observed across all age groups (Huang et al., 2010; Jyrkkä et al.,
2011; Kool et al., 2012). Adverse medical outcomes associated with polypharmacy may
in turn lead to higher medical costs (Akazawa et al., 2010; Hovstadius & Petersson,
2013).
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Limitations
Causes of polypharmacy. While a handful of previous studies has documented medical
outcomes associated with polypharmacy, we know little about causes of this
phenomenon. Even though the current literature has suggested some potential causes of
polypharmacy – such as the rise in chronic conditions and comorbidity, failure to address
comorbidity in clinical practice guidelines, health care fragmentation, and adverse drug
reactions – many of these causes are suggestive and they lack adequate empirical
evidence. Moreover, there are other causes that have not been frequently discussed in the
literature, such as the role of health insurance expansion and increased access to medical
services. From the late 1990s until the mid-2010s, the U.S. health care system witnessed
multiple significant health care expansions. Examples include the Children’s Health
Insurance Program (CHIP) in 1997 that expanded Medicaid to cover uninsured lowincome children; the Medicare Prescription Drug, Improvement and Modernization Act
of 2003 that, for the first time, covered outpatient prescription medications for Medicare
beneficiaries; and most recently the Affordable Care Act that allowed young adults under
the age of 26 to remain as dependents on their parents’ insurance plans and expanded
Medicaid eligibility to cover more than 15.5 million uninsured low-income adults (Gates
et al., 2016). Although these expansions significantly eliminated financial burdens and
provided access to medical treatments that were otherwise unaffordable to some of the
most vulnerable segments of population (Committee on Child Health Financing, 2014;
Engelhardt & Gruber, 2011; Mazurenko et al., 2018), little is known about their
unintended impacts on polypharmacy.
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Consequences of polypharmacy. Although the literature on adverse consequences of
polypharmacy is relatively more extensive than that of the causes of polypharmacy,
further investigation of this topic is warranted due to two main reasons. First, studies that
investigated the consequences of polypharmacy on health and health care utilization
failed to address a possibility that not all medications result in adverse reactions, even
when consumed in a set. It is possible that some groups of medications are more harmful
when combined with others. For example, Qato, Ozenberger, & Olfson (2018) provided
evidence that concurrent consumption of multiple medications with depression as a
potential side effect was significantly associated with an increased risk of depressive
symptoms. The authors also found a dose-response relationship, such that the association
increased for every additional medication consumed that has depression as a potential
side effect. In contrast, using medications without known depression side effect was not
harmful to mental health, even when consuming multiple simultaneously. As such,
policies that aim to address polypharmacy should target the simultaneous use of multiple
medications with serious side effects, instead of reducing the use of all medications. It is
possible that medications without side effects are indeed beneficial for disease
management, and that reducing the use of these medications may be harmful to patients.

Second, the literature on polypharmacy typically focuses on older adults because they are
at higher risks of adverse drug reactions due to biological and medical reasons, such as
decreases in hepatic metabolism and renal clearance (Leon, 2011; Shi & Klotz, 2011), the
presence of comorbidity (Ward & Schiller, 2013), and the use of multiple medications
simultaneously (Kantor et al., 2015). Regardless, the consequences of polypharmacy
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among young adults are also of important policy and clinical concerns. For young and
healthy adults, the selection into using multiple medications simultaneously may be
attributed to the early onset of chronic conditions that can be more debilitating to health
than those that occur at older ages. Moreover, the threshold at which polypharmacy
results in negative consequences for young adults may be even lower than that for older
adults. Huang et al. (2010) found that using four to five medications simultaneously
increased the risk of falls among young adults with diabetes compared to those using one
or no medications. For older adults with diabetes, the authors did not observe a
significant relationship between polypharmacy and falls until patients consumed six to
seven medications. From an economic perspective, experiencing adverse effects of
medications at young ages not only have cumulative effects on health, but also on
productivity, human capital, and income throughout the lifetime. While the prevalence of
polypharmacy among young adults is much lower than that among older adults (3.1% vs.
39% in 2011-2012), the significantly increasing trend in polypharmacy over time among
young adults prompts further investigation into this population (Kantor et al., 2015).

Given the limitations in the literature, this dissertation aims to address the following
questions:
Chapter 2:
•

What is the impact of expanding the Medicare Part D prescription medication
insurance on polypharmacy among older adults?

•

Did polypharmacy increase significantly more for some socio-demographic subgroups compared to others?
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Chapter 3:
•

What are the trends in the using medications with cognitive impairment side
effects from 1999 to 2016 among adults aged 60 and older?

•

What is the relationship between cognitive function and concurrent use of
medications with and without cognitive side effects for older adults?

•

Does the relationship vary by subgroups?

Chapter 4:
•

What are the trends in using medications that have insomnia, depression, suicide,
and anxiety as potential side effects among U.S. adults?

•

What is the association between concurrent use of medications with and without
these side effects and nonspecific psychological distress, as well as utilization and
costs of mental health services?

•

Does the association differ by age?
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CHAPTER 2:
The Impact of Medicare Part D on Polypharmacy

Objective: To investigate whether and how the introduction of Medicare Part D
increased polypharmacy – the concurrent use of five or more medications – among older
adults.
Data source: Nationally representative sample of adults aged 55-74 from the National
Health and Nutrition Examination Survey (NHANES) in 1999-2016 without public
health insurance.
Study design: I used a difference-in-differences approach to compare medication use and
polypharmacy between Medicare eligible adults (aged 65-74) and Medicare ineligible
adults (aged 55-64) before and after Part D was introduced in 2006, while controlling for
socio-demographic characteristics, health insurance coverage, health conditions, and
secular trends.
Principal findings: Among Medicare-ineligible respondents (aged 55-64), the number of
prescription medications consumed was not significantly different before and after Part D
took effect (2.30 medications and 16.6% for polypharmacy before 2006 vs. 2.36
medications and 16.1% for polypharmacy after 2006). In contrast, prescription
medication use increased considerably among Medicare-eligible respondents (aged 6574) after Part D (3.24 medications and 26.6% for polypharmacy before 2006 vs. 3.77
medications and 32.4% for polypharmacy after 2006). The implementation of Part D was
associated with an increase in the odds of polypharmacy by 1.57 times (p < 0.01). In
multiple sensitivity and placebo analyses, Part D did not have any effects on the use of
dietary supplements or poly-supplementation (the concurrent use of five or more dietary
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supplements), which were not covered under standard Part D plans. In addition, Part D
did not alter the use of prescription medications among publicly insured respondents who
already received some prescription medication benefits prior to Part D. The results were
also robust to the unobserved impacts of the Great Recession and different definitions of
medication use and polypharmacy.
Conclusion: Although prescription medications are lifesaving when used properly, using
five or more medications simultaneously has been linked to adverse medical outcomes
for older adults, including mortality, drug-drug interactions, adverse drug events, medical
nonadherence, falls, and cognitive impairment. While the benefits of gaining access to
life-saving prescription medications as a result of Medicare Part D may outweigh the
unintended effects of polypharmacy, efforts that focus on addressing the adverse effects
of polypharmacy may generate additional health benefits for Medicare beneficiaries.
Using Medicare Part D as a case study, I demonstrated that other health insurance
program expansions might have similar effects on polypharmacy (i.e. the Medicaid
expansion under the Affordable Care Act or a Medicare-for-All initiative).
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Introduction
Understanding the effects of health insurance on health and health behavior is a central
question in every debate on the U.S. health care reform. On the one hand, health
insurance may improve health by improving access to medical services and financial
security (Currie & Gruber, 1996; Engelhardt & Gruber, 2011; Goldin et al., 2019;
Hanratty, 1996; F. Lichtenberg, 2002). On the other hand, receiving additional medical
care as a result of gaining health insurance may provide few clinical benefits at the
margin (Baicker et al., 2013; Brook et al., 1983). One of the most heated public policy
debates in recent U.S. presidential elections is whether a Medicare-for-all initiative
improves the well-being of Americans. Since its inception, Medicare is a national health
insurance program that primarily provides coverage to Americans aged 65 and older,
young adults with disability, and individuals with end-stage renal disease. The original
Medicare program covered most medical expenditures, such as hospital and doctor costs,
but it excluded prescription medications. Public concern about rising medication prices
and the potential consequences of medication unaffordability on health of older adults in
the U.S. drove efforts to provide prescription medication coverage to Medicare
beneficiaries. This resulted in the introduction of Medicare Part D in January 2006, which
for the first time expanded the Medicare program to include coverage for outpatient
medications.

The current paper revisits the implementation of Part D and examines its effects around a
previously understudied margin: whether and how the program resulted in polypharmacy
– the use of five or more medications simultaneously – among older adults. Although
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there is no scientific consensus or clinical definition for polypharmacy, this term is
typically used interchangeably to describe multiple, concurrent, excessive, unnecessary,
or unindicated medication consumption (Mortazavi et al., 2016). Previous research has
shown that expanding prescription medication coverage under Part D increased access to
lifesaving medications that were otherwise unaffordable to older adults (Ayyagari &
Shane, 2015; Engelhardt & Gruber, 2011; Ghosh et al., 2019), but coverage expansion
might also increase the risk of polypharmacy, which has more ambiguous effects on
health. Prior studies have documented the negative health consequences of polypharmacy
for older adults, including adverse drug events, drug-drug interactions, medication
nonadherence, falls, and cognitive impairment (Bourgeois et al., 2010; Hovstadius &
Petersson, 2013; Huang et al., 2010; Jyrkkä et al., 2011; Lindblad et al., 2005; Maher et
al., 2014; Marcum & Gellad, 2012; Sergi et al., 2011). The causes of polypharmacy are
multifactorial. Potential risk factors for polypharmacy include the rise in chronic
conditions and comorbidity (Ward & Schiller, 2013), failure to consider comorbidity in
clinical practice guidelines (Boyd et al., 2005), and visiting multiple physicians or filling
medications at multiple pharmacies (Col et al., 1990). Regardless, little is known about
the role of health insurance expansion in the rising prevalence of polypharmacy.

I add to the existing literature by using the introduction of Medicare Part D in 2006, a
large and sudden change to health care financing for Medicare beneficiaries, to study the
relationship between health insurance expansion and polypharmacy. Part D benefits are
provided by private stand-alone prescription medication plans or Medicare Advantage
plans that offer both prescription medication and health care coverage. Although benefits
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varied across plans, beneficiaries were typically entitled to the following coverage for
prescription medication in 2006: no coverage for the first $250 in medication spending
each year, coverage of 75% of the next $2,250, no coverage for the next $3,600, then
coverage of 95% of costs above $5,100. Before Part D, Medicare beneficiaries had access
to prescription medication coverage through employer-sponsored retirement health
benefits, Medicare managed care plans, or through dual eligibility with Medicaid or other
public insurance programs. Only two-thirds of Medicare enrollees had prescription drug
coverage (Safran et al., 2005; Schneeweiss et al., 2009). While enrollment in Part D was
voluntary, any Medicare beneficiaries who enrolled in the program after May 15, 2016
were subjected to a financial penalty to alleviate adverse selection into the program. In
the first year after Part D took effect, 67% of Medicare beneficiaries without prescription
medication insurance gained coverage through a stand-alone prescription medication
plan, a Medicare Advantage plan, or through their current employer’s plan provided that
the benefits were as generous as those of standard Part D plans (Levy & Weir, 2009).
Before Part D, 90% of Medicare beneficiaries reported taking prescription medication
and almost half of them used five or more medications concurrently (Safran et al., 2005).
Given a high prevalence of medication use, 30% of Medicare enrollees spent over $100
per month on prescription medications in 2003 (Safran et al., 2005). Out-of-pocket
medication expenditures also increased with age: individuals aged 50-64 paid on average
$237 annually for prescription medication in 1998 while those aged 65-79 paid $456 and
those aged 80 and older paid $530 (Ihara, 2002).
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Prior research found a modest reduction in out-of-pocket medication spending as a result
of gaining Part D benefits (Khan & Kaestner, 2009; Lichtenberg & Sun, 2007; Yin et al.,
2008). The cost reduction mainly concentrated among high-spending beneficiaries who
often required long-term pharmaceutical therapies (Engelhardt & Gruber, 2011). Other
studies demonstrated that Part D increased the consumption of prescription medications
(Kaestner & Nasreen Khan, 2012), improved mental health (Ayyagari & Shane, 2015),
reduced hospitalization and emergency department visits (Afendulis et al., 2011;
Ayyagari et al., 2017), and reduced medication nonadherence (Madden et al., 2008).
However, little is known about whether increased access to prescription medications
under Medicare Part D gave rise to polypharmacy. While prescription medications are
lifesaving when used properly, polypharmacy may increase the risk of adverse medical
outcomes and medical costs associated with these outcomes (Sergi et al., 2011). To the
extent that the results are generalizable to other health insurance programs, this paper
speaks directly to the potentially unintended impact of health insurance expansion on
polypharmacy. It also highlights the importance of addressing polypharmacy among
older adults.

Methods
I used the 1999-2016 National Health and Nutrition Examination Survey (NHANES), a
nationally representative two-year cycle survey of the civilian noninstitutionalized U.S.
population. NHANES was obtained using a multistage probability sampling design to
represent the general population but with an oversampling of Black, Hispanic, and adults
aged 60 and older. The average non-response rate was 22%. All analyses used survey
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weight to produce nationally representative estimates and to avoid non-response bias. I
removed respondents interviewed in 2005-2006 because this survey cycle overlapped
with the introduction of Medicare Part D in January 2006. I also dropped respondents
interviewed in the 2013-2014 and 2015-2016 survey cycles to avoid spillover effect of
the Medicaid expansion in 2014 onto the analysis. Previous studies suggested that the
Medicaid expansion in 2014 influenced physicians’ prescribing practice and medication
use (Ghosh et al., 2019; Saloner et al., 2018). Since many physicians treat both Medicaid
and non-Medicaid patients, changes in prescribing practice as a result of Medicaid
expansion may have a spillover effect to Medicare beneficiaries. I selected respondents
aged 55 to 74 because their ages were close to the Medicare’s age eligibility of 65 (N =
9,319). I classified respondents into two distinct groups based on the likelihood that the
introduction of Part D affected their prescription drug coverage. Medicare eligible
respondents aged 65-74 qualified for Medicare Part D at the time of the survey interview,
while ineligible respondents aged 55-64 did not qualify. I excluded respondents aged 5564 who received Medicare benefits (N = 529) and respondents who had public health
insurance – including Medicaid, military insurance, Indian health service programs,
Children's Health Insurance Program, and other state-sponsored or government health
plans (N = 1,464). The former mainly consisted of individuals with disability whose
unobservable characteristics might be different from those of their peers. The latter
included individuals with public insurance who already received some prescription drug
coverage before Part D. I excluded respondents who had missing information on
medication use and control covariates (N = 1,271). I imputed missing data for control
covariates using multiple imputation with chained equations, but the results were similar
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to when not using imputation. As such, the results were restricted to a final sample of
6,055 respondents without missing data.

Prescription medications were collected during the prescription medication interviews.
Interviewers asked respondents to show the containers of all prescription medications
they had taken in the past 30 days. Respondents who could not show a container were
asked to verbally report the medication’s name. When interviewers entered the
medication names into a computer, more than 95% of entries resulted in exact or similar
matches with an existing drug. The drug database used for the match was obtained from
Lexicon Plus, a proprietary database of Cerner Multum that provided, on an annual basis,
a comprehensive list of all prescription and some non-prescription medications available
in the U.S. market. Using reported use of medications in the past month, I constructed
two main outcomes: the number of medications used last month, and whether a
respondent used at least five medications last month (polypharmacy).

Covariates in this paper included demographic characteristics, health insurance, income,
and health conditions. Demographic covariates were age, age squared, race (nonHispanic Whites: reference category, non-Hispanic Blacks, non-Hispanic others,
Hispanic), gender, marital status (married or cohabiting: reference category,
widowed/divorced/separated, never married), education (less than high school graduate:
reference category, high school graduate, some college, college graduate or above), and
nativity/citizenship status (U.S. citizen born in the U.S. or its territories: reference
category, U.S. citizen born abroad, not a citizen). Health insurance covariate indicated
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whether a person had any type of health insurance. Income covariates included household
poverty level as a series of dummy variables (less than 100%: reference category, 100199%, 200-299%, 300-399%, 400-499%, 500% or more). Health covariates included the
number of chronic conditions (none: reference category, one or two, three or more
conditions), whether a person was overweight or obese (BMI of at least 25), and selfreported health status (excellent: reference category, very good, good, fair, poor). Chronic
conditions in this study included a series of self-reported diagnoses of asthma, arthritis,
cancer, congestive health failure, coronary heart disease, heart attack, angina,
emphysema, bronchitis, stroke, hypertension, and diabetes.

I assessed the impact of Medicare Part D on medication use using a difference-indifferences approach:

RxUseit = α0 + α1Eligibleit*Post2006it + α2Eligibleit + α3Post2006it + α4Xit + ɛit

where RxUseit was either the number of prescription medications consumed in the last 30
days by person i at time t, or whether the person used at least five medications in the last
30 days (polypharmacy). Eligibleit took the value of 1 if the person qualified for Medicare
(ages 65-74), and 0 if the person was 55-64 years of age. Post2006it indicated if the
person was interviewed after Part D took effect. Eligibleit*Post2006it is the variable of
interest, and α1 reflected the reduced-form effect of Part D on medication use. Xit
included a set of demographic characteristics, health insurance, income, and health
covariates, as described earlier. I controlled for time trends in the outcomes by including
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the year fixed effect. The main assumption of the difference-in-differences method,
referred to as the parallel assumption, is that any differences in medication use between
Medicare eligible and ineligible adults are constant over time prior to Part D. This
assumption is empirically tested and presented in the result section.

I conducted multiple additional sensitivity analyses. First, I assessed the impact of Part D
on the number of dietary supplements consumed and whether a respondent used at least
five supplements (“poly-supplementation” hereafter) last month. Part D did not subsidize
dietary supplements, thus there should be no impact of Part D on such use. Similar to the
prescription medications interview section, respondents reported all dietary supplements2
and non-prescription antacids3 that they consumed in the past 30 days. Second, I
investigated whether Part D affected the use of prescription medication for publicly
insured individuals. Most public insurance programs provided their beneficiaries with
some prescription medication benefits prior to Part D. Therefore, there should be no
impact of Part D on medication use among the publicly insured population (Basu et al.,
2010; Millett et al., 2010). Third, I included in the analysis survey cycles from 2013 to
2016 that were previously removed because they overlapped with the Medicaid

2

Dietary supplements included vitamins or minerals (i.e. Calcium, Vitamin C, Calcium and Iron, Vitamin

E, Magnesium, Zinc, Calcium plus Vitamin D), multi-vitamins or multi-minerals (i.e. Flintstones, One a
Day, Prenatals, Tri-Vi-Flor, B-Complex, Centrum), herbs and botanicals (i.e. Echinacea, garlic, Saw
Palmetto, Ginkgo, Ginseng), fiber (i.e. Metamucil, Fibercon, Benefiber), amino acids (i.e. Lysine,
Methionine, Tryptophan), and others (i.e. fish oil, Chondrotin, Glucosamine).
3

Only non-prescription antacids containing calcium or magnesium were included in the dietary supplement

files.
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expansion in 2014. Fourth, the post-Part-D period coincided with the recession from
2007 to 2009, which might have affected Medicare eligible and ineligible respondents in
systematic ways. While Medicare eligible adults were relatively insulated from the
recession due to their access to Social Security benefits, Medicare ineligible adults were
heavily affected by unemployment and the loss of private health insurance associated
with their jobs. The lack of health insurance in turn affected medication use among
Medicare ineligible adults. To address this possibility, I propose two sets of sensitivity
analyses, including (1) removing survey cycles in 2007-2008 and 2009-2010 that
overlapped with the recession and (2) excluding all uninsured individuals who might
have lost health insurance due to the recession. The interpretation of the results should be
similar to that of the main analysis if the use of medication was not driven by unobserved
heterogeneity during the recession. Fifth, I propose a stricter definition of polypharmacy.
In previous analyses, I counted all prescription medications that a person used in the past
month. Nevertheless, although a respondent reported taking at least five medications last
month, the simultaneous consumption of these medications might not have occurred
daily, as the definition of polypharmacy implies. I reconstructed the outcome variables
and only included prescription medications that a person consumed every day in the last
month and repeated the analysis in equation (1). I also repeated the same analysis for
daily use of dietary supplements. Finally, I relaxed the numerical threshold of
polypharmacy. While there is no clinical definition of polypharmacy, previous studies
typically defined polypharmacy as concurrent use of five or more medications. In a set of
sensitivity analyses, I created ten outcome variables, ranging from whether a respondent
used at least one prescription medication in the last month to whether a respondent used
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at least ten prescription medications. I repeated the same analyses for dietary
supplements.

Results
Figure 1 presents the gender and age adjusted average number of outpatient prescription
medications (Panel A) and dietary supplements (Panel B) consumed by Medicare eligible
and ineligible adults from 1999 to 2016. Prior to Part D, Medicare eligible adults
consumed more prescription medications than ineligible adults (Panel A). Regardless, the
difference in medication consumption of two groups was relatively constant over time
before Part D. After Part D took effect, prescription medication use increased
significantly among Medicare eligible adults, although it leveled off and declined during
the 2007-2009 recession. In contrast, the trend in prescription medication use among
Medicare ineligible adults was relatively stable after Part D took effect. Medication use
slightly declined during the recession for the ineligible group, possibly because they were
affected by unemployment and the loss of health insurance during this period. In Panel B,
the use of dietary supplements was not significantly different between Medicare eligible
and ineligible adults in all survey cycles. There was no evidence that Part D affected the
use of dietary supplements for Medicare eligible adults, mainly because Part D did not
subsidize dietary supplements.

-Insert Figure 1 About Here-

Figure 2 demonstrates the gender and age adjusted prevalence of polypharmacy (Panel A)
and poly-supplementation (Panel B). The results mirror those observed in Figure 1. In
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Panel A, the prevalence of polypharmacy was relatively parallel between two groups
before 2006, then diverged after Part D took effect. In contrast, Part D did not have any
effect on poly-supplementation (Panel B).

-Insert Figure 2 About Here-

Table 1 compares descriptive statistics of medication use and control variables between
Medicare eligible and ineligible respondents, before and after Part D. Among ineligible
respondents (aged 55-64), prescription medications consumed was not significantly
different before and after Part D (2.30 medications and 16.6% for polypharmacy before
2006 vs. 2.36 medications and 16.1% for polypharmacy after 2006). In contrast,
prescription medication use increased considerably among eligible respondents (aged 6574) after Part D (3.24 medications and 26.6% for polypharmacy before 2006 vs. 3.77
medications and 32.4% for polypharmacy after 2006). In contrast, the use of dietary
supplements among Medicare eligible and ineligible adults remained relatively
unchanged before and after Part D.

Overall, Medicare ineligible respondents tend to be more racially and ethnically diverse,
less likely to be female, more likely to be married, are more educated, less likely to have
been born in the U.S., less likely to have health insurance, have higher household income,
have fewer chronic conditions, less likely to be overweight or obese, and more likely to
report excellent or very good health than Medicare eligible respondents. This is
potentially due to the cohort effect and mortality selection in older ages. Regardless, I did
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not detect any significant differences between Medicare eligible and ineligible
respondents before and after Part D for all control variables after controlling for age.

-Insert Table 1 About Here-

Panel A of Table 2 presents difference-in-difference results for the impact of Part D on
medication use and polypharmacy. In the unadjusted model 1, being eligible for Part D
after the program took effect resulted in an increase of 0.467 medications used in the last
30 days, compared to Medicare ineligible adults before and after Part D and Medicare
eligible adults before Part D (p<0.05). Adjusted for socio-demographic characteristics,
health insurance, income, health conditions, and time trends (model 5) did not
significantly alter the impact of Part D on medication use (coefficient = 0.460, p < 0.01).
I observed similar patterns for polypharmacy. Medicare Part D resulted in an increase of
1.368 times the odds of polypharmacy in the past month (p < 0.05, model 1). Adjusting
for all covariates in model 5 increased the estimate (OR = 1.572, p < 0.01), although two
estimates were not significantly different from one another.

In Panel B of Table 2, I presented the difference-in-differences results with year fixedeffect interactions. Results in models 1 to 5 indicate that the number of medications used
did not increase until 2007 after Part D was introduced. There were no statistically
significant differences in medication use between eligible and ineligible respondents
before 2006, implying that the parallel assumption for the difference-in-difference model
was valid. Any changes in medication use in 2006 onward were potentially due to the
introduction of Part D. The results for polypharmacy were quite similar. However, the
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difference-in-difference models with year fixed-effect did not detect significant
differences in polypharmacy between Medicare eligible and ineligible adults in each year,
both before and after the implementation of Part D. Regardless, when pooling all years
before and after Part D, I detected an increase in polypharmacy as a result of the program
implementation.

-Insert Table 2 About Here-

Figures 3 to 11 present the heterogeneous effects of Part D on polypharmacy by
race/ethnicity, gender, marital status, educational attainment, nativity and citizenship
status, household income, comorbidity, obesity status, and self-reported health status.
Overall, the effect of Part D on polypharmacy was particularly large for subgroups that
had limited access to prescription drug insurance prior to Part D. The introduction of Part
D was associated with an increase in polypharmacy for non-Hispanic Whites, nonHispanic Blacks, and Hispanic respondents (Figure 3). Regardless, the effect of Part D
was larger for non-Hispanic Black and Hispanic respondents compared to that of nonHispanic Whites, potentially because racial/ethnic minorities were less likely to have
access to prescription medication insurance prior to Part D, such as employer-sponsored
coverage or Medicare Advantage plans (Briesacher et al., 2003). Similarly, married and
widowed/divorced/separated respondents were more likely to experience polypharmacy
than their non-married peers as a result of Part D (Figure 5), in part because they were
less likely to have prescription medication insurance prior to Part D (Poisal et al., 1999). I
found that the effects of Part D on polypharmacy were particularly large and statistically
significant among respondents who were college educated (Figure 6), native-born
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citizens (Figure 7), and middle-class (Figure 8), compared to their peers. While highincome respondents may purchase private prescription medication insurance and noncollege-educated individuals, naturalized citizens, migrants, and low-income respondents
may qualify for government programs that help pay for prescription medication costs
such as Medicaid or Low-Income Subsidy4 (Stuart et al., 2012), college educated, nativeborn, and middle-class respondents typically did not qualify for low-income government
programs before Part D. This lack of coverage in part explained why gaining Part D
benefits had a particularly large impact on polypharmacy among college educated,
native-born, and middle-class respondents. Finally, respondents who had at least three
chronic conditions (Figure 9), who were not obese (Figure 10), and who reported
excellent or very good health (Figure 11) were more likely to experience polypharmacy
due to the implementation of Part D. Respondents who were obese or who reported poor
or fair health often required extensive pharmaceutical treatments and had high out-ofpocket medication expenditures (Jackson et al., 2004; Kit et al., 2012, pp. 2005–2008),
and might have already had prescription medication coverage through public insurance or
the Low-Income Subsidy program before Part D, which explained why Part D did not
significantly affect their prevalence of polypharmacy.

-Insert Figures 3 to 11 About Here-

4

Although I excluded respondents with public health insurance because they already had some prescription

medication benefits prior to Part D, I wasn’t able exclude respondents who received other forms of
prescription medication assistance such as the Low-Income Subsidy due to the lack of data in the
NHANES.

30

I conducted multiple additional sensitivity analyses. First, I assessed the impact of Part D
on the use of dietary supplements and poly-supplementation. Since Medicare did not
cover non-prescription medications, there should be no impact of Part D on the use of
dietary supplements. In Table 3, results from unadjusted and adjust models indicated that
there was no impact of Medicare Part D on the number of dietary supplements used and
poly-supplementation. This sensitivity analysis reinforced my findings in Table 2: that
Medicare Part D only affected the use of prescription medications.

-Insert Table 3 About Here-

Second, I repeated the analyses in Table 2 for publicly insured respondents who already
received some prescription medication benefits prior to Part D. I hypothesized that Part D
did not affect prescription medication use among this population. As demonstrated in
Table 4, there was no effect of Part D on prescription medication use, and in some cases,
medication use and polypharmacy even declined for Medicare eligible respondents after
Part D compared to the control group.

-Insert Table 4 About Here-

Third, I included in my analysis the 2013-2016 survey cycles that were previously
excluded to avoid the spillover effect of the Medicaid expansion in 2014 onto the
analyses. In Panel A of Table 5, I replicated results in Table 2 using all survey cycles
(1999-2016). The inclusion of data in 2013 onward did not significantly alter the results.

-Insert Table 5 About Here-
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Fourth, I assessed whether the 2007-2009 Great Recession affected the results. The
recession might have had differential consequences for Medicare eligible and ineligible
adults that in turn influenced their use of prescription medications in systematic ways that
confounded the effects of Part D. For instance, Medicare ineligible adults might have
been more affected by unemployment during the recession than Medicare eligible adults,
which reduced their ability to obtain health insurance and to purchase prescription
medications. Thus, an increase in medication use after 2006 among Medicare eligible
adults compared to those who were ineligible might have been attributed to the loss of
health insurance among Medicare ineligible adults, rather than Part D per se. In Panel B
of Table 5, I included in the analysis all survey cycles, except for those in 2007-2008 and
2009-2010 that overlapped with the recession. Exclusion of such survey cycles did not
significantly alter the interpretation of the results. In Panel C of Table 5, I repeated the
main analysis in Table 2 for all survey cycles in 1999-2016, but I excluded all uninsured
individuals who might have lost their health insurance due to the recession. I found that
the interpretation of the results remained relatively unchanged. Collectively, while the
Great Recession might have affected Medicare eligible and ineligible adults differently, it
did not affect the results in this paper.

Fifth, I proposed a stricter definition of polypharmacy. In previous analyses, I defined
polypharmacy as the use of five or more medications in the past month. However, even
though respondents consumed at least five medications, it was unclear whether they
consumed those medications simultaneously. I repeated the analyses using a revised
measure of polypharmacy that indicated polypharmacy on a daily rather than monthly
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basis. I did the same for poly-supplementation. In Table 6, I found that Part D
significantly increased the number of medications consumed daily and polypharmacy for
Medicare eligible adults, compared to control groups (Panel A). In contrast, I did not
detect any effects of Part D on the use of dietary supplements (Panel B).

-Insert Table 6 About Here-

Finally, I estimated the impact of Part D on polypharmacy using different numerical
thresholds for polypharmacy. I created ten outcome variables, ranging from whether a
respondent used at least one prescription medication in the last month to whether a
respondent used at least ten prescription medications. Results in Panel A of Table 7
suggested that Part D affected the use of multiple medications more than single
medications, starting at four or more prescription medications to at least ten medications
in the past month. As before, I did not find any significant impacts of Part D on the use of
dietary supplements, regardless of which cutoff points that were used to define polysupplementation (Panel B).

-Insert Table 7 About Here-

Discussion
Medicare Part D was one of the most expensive health insurance expansion programs in
the United States since the inception of Medicare. Federal spending in 2019 on the
program is expected to be more than $95 billion (Centers for Medicare and Medicaid
Services, 2019). However, evidence as to the extent to which Part D improves health
tends to be ambiguous.

33

To my knowledge, this paper is the first to provide evidence that health insurance
expansion is associated with an increase in polypharmacy. While Part D might have
increased the use of prescription medications that were otherwise unaffordable to older
adults, it had a more substantial impact on polypharmacy. In various placebo analyses, I
found that Part D did not have any effects on the use of dietary supplements, which were
not covered under standard Part D plans. In addition, Part D did not alter the use of
prescription medications among publicly insured respondents who already received some
prescription medication benefits before Part D. The results were also robust to the
unobserved impacts of the Great Recession and different definitions of medication use
and polypharmacy.

Results in this paper are within the range of estimates from prior studies. In Table 2, I
found that Part D was associated with an increase of 16.3% in the number of prescription
medication consumed last month. Using Walgreen’s 2004-2007 claims data and a similar
difference-in-differences approach, prior studies found that Part D led to an increase of
6%-13% in prescription fills (F. R. Lichtenberg & Sun, 2007; Yin et al., 2008). Using
pharmacy data in 2005-2006, another study suggested an increase of 11%-37% in
medication use as a result of Part D (Schneeweiss et al., 2009). In contrast to these
studies, I used a nationally representative sample of older adults and a longer post-Part-D
period. Although claims data provide detailed information on medication fills and
alleviate recall bias, they are not representative of the population and typically exclude
uninsured individuals – one of the population segments that benefited the most from the
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introduction of Part D. In addition, the effect of Part D on medication use was likely
accumulated over time as more Medicare beneficiaries gained coverage and Part D
coverage became more generous over time (Cubanski et al., 2018), which might explain
why the estimate in this study was slightly higher than some estimates in prior studies.

Although the benefits of gaining access to life-saving prescription medications as a result
of Part D may outweigh the unintended effects on polypharmacy, efforts that focus on
addressing polypharmacy may improve health for Medicare beneficiaries. In 2006, the
Center for Medicare and Medicaid Services required that all Part D plans included
Medication Therapy Management (MTM) services. The MTM program is free for Part D
beneficiaries who meet three eligibility criteria: enrollees must have at least two chronic
conditions, they must use multiple medications covered under their Part D plan, and they
must be at risk at spending more on annual Part D covered medication costs than a certain
cost threshold. Through the MTM program, eligible beneficiaries meet with a health
professional annually to conduct a comprehensive review of their medications. Health
professionals then inform beneficiaries if their medications have any potential side
effects, if there are any potentially serious drug-drug interactions among their
medications, and if their medication costs can be lowered. The program can potentially
address the issue of polypharmacy, but it is significantly underused. A study in Maryland
and Delaware found that 60% of Medicare respondents were unaware of the MTM
program, and 80% had never received a medication therapy review (Truong et al., 2009).
In addition, program eligibility is not universal, but rather varies across plans (Touchette
et al., 2006). Private Part D plans can select their own MTM criteria within the general
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guidelines from the government: they can select the types of chronic conditions on which
they want to focus, the number of chronic conditions that a beneficiary has, or the
number of Part D medications required for the beneficiary to be eligible for the program.
In 2008, half of Part D plans opened enrollment to their MTM program for beneficiaries
who had two chronic conditions, while the other half restricted enrollment to
beneficiaries with a minimum of three to five chronic conditions (Wang et al., 2015). In
2010 and onward, approximately 80% of Part D plans required beneficiaries to have three
or more chronic conditions to enroll in the MTM program (Wang et al., 2015). Such
variation across plans can prevent beneficiaries who are at risk of polypharmacy from
receiving a comprehensive review of their medications. Given the benefits of MTM
programs on reducing drug-related adverse outcomes (Perlroth et al., 2013; Welch et al.,
2009), more efforts should focus on increasing enrollment in the MTM program in order
to address the adverse consequences of polypharmacy.

Other program expansions might have similar effects. For example, the Medicaid
expansion in 2014 expanded enrollment eligibility to nonelderly adults with family
incomes at or below 138% of the federal poverty level. The expansion resulted in an
increase of 15.5 million new enrollees two years following its implementation (Gates et
al., 2016). Prior research found that Medicaid expansion improved access to medical
care, medical affordability, and health outcomes (Mazurenko et al., 2018; Mulcahy et al.,
2016). Since Medicaid covers most major pharmacological therapy, expanding coverage
may have had similar effects on polypharmacy.
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Although this paper has several strengths, including the use of Medicare ineligible group
to control for secular trends and a longer post-Part-D period, it faces some limitations.
First, Medicare ineligible adults may differ from eligible adults in terms of employment,
health, health insurance’s coverage generosity, and preferences toward medical care.
Such unobserved heterogeneity may result in marked differences in medication use
between Medicare ineligible and eligible adults, which can bias the estimates towards the
null. Regardless, Table 1 provides evidence that there were no significant differences in
medication use and other characteristics between two groups before and after Part D.
Second, I may underreport the prevalence of polypharmacy since NHANES lacks
information on medications administered to inpatients. However, many inpatient
medications were already covered under the traditional Medicare program prior to Part D.
Thus, missing data on inpatient medications was unlikely to affect the estimates of the
impact of Part D on polypharmacy.

Conclusion
This study presents a strong relationship between expanding public health insurance and
polypharmacy among older adults. Despite the well-documented negative consequences
of polypharmacy, little is known about the role of health insurance programs in overusing
prescription medications. Efforts that address polypharmacy among Medicare
beneficiaries can potentially generate additional health benefits by promoting proper
prescribing practices.
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Figure 1: Gender and Age Adjusted Weighted Average Number of Prescription
Medications and Dietary Supplements Consumed Last Month by Medicare Eligible
(Aged 65-74) and Ineligible (Aged 55-64) Adults, with 95% Confidence Intervals.
Data Source: NHANES 1999-2000 to 2015-2016.
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Figure 2: Gender and Age Adjusted Weighted Prevalence of Medicare Eligible
(Aged 65-74) and Ineligible (Aged 55-64) Adults Consuming At Least Five
Prescription Medications and Dietary Supplements Last Month, with 95%
Confidence Intervals. Data Source: NHANES 1999-2000 to 2015-2016.
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Table 1: Descriptive Statistics of Medication Use and Characteristics of Medicare Eligible (Aged 65-74) and Ineligible (Aged
55-64) Adults Before and After Medicare Part D Took Effect. Data Source: NHANES 1999-2012.

Outcomes
Number of prescription medications used
last 30 days, meanb (SE)

Medicare ineligible (ages 55-64)

Medicare eligible (ages 65-74)

Before Part D
(1999-2004)

Before Part D
(1999-2004)

After Part D
(2007-2012)

After Part D
(2007-2012)

p-value a
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2.30

(0.08)

2.36

(0.09)

3.24

(0.11)

3.77

(0.12)

p = 0.012

Used >= 5 prescription medications last 30
days, Nc (%d)

196

(16.6)

307

(16.1)

332

(26.6)

534

(32.4)

p = 0.031

Number of dietary supplements used last 30
days, meanb (SE)

1.97

(0.13)

1.80

(0.10)

2.07

(0.10)

2.11

(0.12)

p = 0.252

Used >= 5 dietary supplements last 30 days,
Nc (%d)

128

(13.4)

168

(10.6)

144

(15.1)

175

(15.3)

p = 0.149

645
231
339
50
59.01
671

(78.4)
(8.4)
(8.5)
(4.7)
(0.11)
(53.9)

793
439
494
144
59.12
942

(78.4)
(8.4)
(7.1)
(6.0)
(0.09)
(52.5)

741
216
347
32
69.18
663

(82.9)
(7.4)
(6.6)
(3.1)
(0.10)
(54.5)

846
343
307
88
69.04
801

(81.6)
(8.2)
(5.9)
(4.3)
(0.10)
(53.7)

p = 0.595
p = 0.578
p = 0.724
p = 0.880
N/A
p = 0.779

926
290
49

(75.6)
(20.5)
(3.8)

1254
482
134

(72.6)
(21.2)
(6.2)

903
395
38

(70.4)
(27.6)
(2.0)

975
531
78

(67.8)
(29.1)
(3.1)

p = 0.792
p = 0.810
p = 0.820

413
266
297
289

(18.8)
(23.5)
(27.3)
(30.4)

445
429
502
494

(11.8)
(23.9)
(28.9)
(35.3)

530
322
272
212

(25.1)
(30.3)
(23.7)
(20.9)

507
390
374
313

(20.3)
(24.7)
(28.2)
(26.8)

p = 0.122
p = 0.049
p = 0.325
p = 0.555

982
160

(86.9)
(9.0)

1338
310

(87.2)
(7.8)

1089
160

(89.6)
(7.6)

1240
236

(89.6)
(7.6)

p = 0.873
p = 0.461

Socio-demographic characteristics
Race, Nc (%d)
Non-Hispanic White
Non-Hispanic Black
Hispanic
Non-Hispanic others
Age (in years), meanb (SE)
Female, Nc (%d)
Marital status, Nc (%d)
Married
Widowed, divorced, separated
Never married
Educational attainment, Nc (%d)
Less than high school
High school graduate
Some college
College graduate or above
Nativity and citizenship, Nc (%d)
Citizen, born in the U.S.
Citizen, born abroad
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123 (4.1)
222 (5.0)
87 (2.8)
108 (2.9)
Not a citizen
Insurance coverage
962 (84.8)
1328 (83.8)
1281 (98.6)
1506 (97.7)
Has any health insurance, Nc (%d)
Income
Household poverty thresholds, Nc (%d)
117 (4.9)
257 (6.2)
173 (7.0)
238 (7.5)
< 100%
254 (12.7)
383 (11.7)
411 (26.6)
482 (23.8)
100-199%
189 (13.9)
301 (16.0)
273 (22.5)
304 (19.3)
200-299%
185 (16.1)
173 (11.0)
147 (13.7)
174 (12.9)
300-399%
154 (15.4)
194 (13.6)
128 (11.6)
121 (11.1)
400-499%
366 (37.1)
562 (41.5)
204 (18.5)
265 (25.5)
500% or higher
Health
Number of chronic conditions, Nc (%d)
345 (29.4)
557 (28.9)
215 (15.5)
203 (13.7)
None
702 (53.5)
993 (53.8)
718 (53.0)
832 (52.2)
One or two
218 (17.1)
320 (17.2)
403 (31.5)
549 (34.1)
Three or more
963 (73.4)
1441 (74.6)
1003 (74.2)
1196 (74.7)
Whether overweight or obese, Nc (%d)
Self-reported health status, Nc (%d)
219 (21.6)
239 (17.1)
177 (16.1)
167 (14.4)
Excellent
343
(32.9)
511
(34.3)
329
(28.8)
393 (31.1)
Very good
389 (28.7)
670 (33.2)
437 (32.1)
564 (34.5)
Good
252 (13.3)
366 (13.2)
303 (17.6)
365 (15.7)
Fair
62 (3.5)
84 (2.3)
90 (5.4)
95 (4.2)
Poor
1,265
1,870
1,336
1,584
No. respondents
a: p-value for the difference between eligible and ineligible groups before and after Part D was introduced, controlling for age.
b:

weighted mean

c:

unweighted frequency

d:

weighted percentage

p = 0.482
p = 0.148

p = 0.465
p = 0.839
p = 0.103
p = 0.130
p = 0.709
p = 0.297

p = 0.434
p = 0.801
p = 0.466
p = 0.837
p = 0.439
p = 0.726
p = 0.454
p = 0.472
p = 0.626

Table 2: Linear and Logit Regressions of The Impact of Medicare Part D on Medication Use and Polypharmacy Among U.S.
Adults Aged 55-74 Without Public Insurancea. Data Source: NHANES 1999-2012.
Model 1:
no covariates

Outcomes: Use
of prescription
medications

Rx
count

Model 2:
Model 1 +
demographic
covariates

Model 3:
Model 2 + health
insurance

Model 4:
Model 3 + income

Model 5:
Model 4 + health
conditions

Used 5+
Rx

Rx
count

Used 5+
Rx

Rx
count

Used 5+
Rx

Rx
count

Used
5+ Rx

Rx
count

Used 5+
Rx

Coeff.
OR
(SE)
(SE)
Panel A: Difference-in-differences
Ages 65-74 (vs.
0.937*** 1.823***
55-64)
(0.123)
(0.188)

Coeff.
(SE)

OR
(SE)

Coeff.
(SE)

OR
(SE)

Coeff.
(SE)

OR
(SE)

Coeff.
(SE)

OR
(SE)

0.102
(0.223)

1.063
(0.200)

0.002
(0.225)

1.000
(0.187)

-0.027
(0.225)

0.965
(0.180)

-0.172
(0.179)

0.834
(0.163)

0.058
(0.119)

0.966
(0.129)

0.367*
(0.160)

1.435*
(0.241)

0.374*
(0.152)

1.440*
(0.239)

0.371*
(0.154)

1.433*
(0.242)

0.299+
(0.167)

1.399
(0.308)

Ages 65-74 *
post 2006

0.467*
(0.190)

1.368*
(0.202)

0.497**
(0.186)

1.389*
(0.205)

0.497**
(0.185)

1.389*
(0.207)

0.501**
(0.181)

1.408*
(0.207)

0.460**
(0.156)

1.572**
(0.250)

Panel B: Difference-in-differences with year fixed-effect
Ages 65-74
0.794*** 2.177***
-0.008
1.287
(0.171)
(0.437)
(0.246)
(0.336)

-0.157
(0.266)

1.184
(0.320)

-0.187
(0.265)

1.145
(0.306)

-0.198
(0.231)

1.196
(0.369)

Ages 65-74 * years 1999-2000 (reference)
Ages 65-74 *
0.011
0.772
years 2001-2002
(0.249)
(0.200)

0.000
(0.254)

0.762
(0.198)

0.073
(0.264)

0.789
(0.214)

0.077
(0.265)

0.779
(0.210)

-0.042
(0.243)

0.619
(0.199)

Ages 65-74 *
years 2003-2004

0.279
(0.306)

0.796
(0.210)

0.343
(0.318)

0.818
(0.223)

0.342
(0.318)

0.819
(0.224)

0.090
(0.260)

0.624
(0.188)

Ages 65-74 * years 2005-2006 (dropped)
Ages 65-74 *
0.564*
1.073
years 2007-2008
(0.248)
(0.267)

0.589*
(0.250)

1.086
(0.272)

0.648*
(0.262)

1.118
(0.291)

0.653*
(0.261)

1.122
(0.291)

0.421+
(0.249)

0.973
(0.306)

Ages 65-74 *
years 2009-2010

0.704*
(0.276)

1.197
(0.342)

0.667*
(0.281)

1.175
(0.339)

0.716*
(0.293)

1.203
(0.360)

0.718*
(0.294)

1.215
(0.362)

0.450+
(0.258)

1.035
(0.351)

Ages 65-74 *
years 2011-2012

0.551
(0.363)

1.157
(0.320)

0.568
(0.352)

1.166
(0.331)

0.609+
(0.357)

1.191
(0.347)

0.618+
(0.349)

1.210
(0.350)

0.563+
(0.306)

1.264
(0.416)
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Post 2006

0.304
(0.299)

0.815
(0.211)

p-value for F-test of null hypothesis H0: Ages 65-74 * (years 2001-2002 + years 2003-2004) = Ages 65-74 * (years 2007-2008 + years 2009-2010 +
years 2011-2012):
p < 0.01
p = 0.05
p < 0.01
p < 0.05
p < 0.01
p < 0.05
p < 0.01
p < 0.05
p < 0.01
p < 0.05
Mean outcome
2.822
0.218
2.822
0.218
2.822
0.218
2.822
0.218
2.822
0.218
No. respondents
6,055
6,055
6,055
6,055
6,055
6,055
6,055
6,055
6,055
6,055
Notes: + p < 0.1, * p < 0.05, ** p < 0.01, *** p<0.001. All analyses excluded survey cycle in 2005-2006 that overlapped with the introduction of Part D.
a: Public insurance includes insurance programs that likely provided their beneficiaries with prescription drug benefits before Medicare Part D took
effect in 2006, including Medicaid, military insurance, Indian health service programs, Children's Health Insurance Program, and any other statesponsored or government health plans.
Demographic covariates include age, age squared, race (non-Hispanic Whites, non-Hispanic Blacks, non-Hispanic others, and Hispanic), gender, marital
status (married or cohabiting, widowed/divorced/separated, never married), education (less than high school graduate, high school graduate, some
college, college graduate or above), and nativity/citizenship status (citizen born in the US, citizen born abroad, not a citizen). Health insurance indicates
whether a person has any type of health insurance. Income covariates include household poverty level (less than 100%, 100-199%, 200-299%, 300399%, 400-499%, 500% or more). Health condition covariates include the number of chronic conditions (none, one or two, and three or more
conditions), whether a person is overweight or obese (BMI of at least 25), and self-reported health status (excellent, very good, good, fair, and poor).
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Figure 3: Marginal Effects (with 95% Confidence Intervals) of Medicare Part D on
Polypharmacy by Race/Ethnicity Among U.S. Adults Aged 55-74 Without Public
Insurancea. Data Source: NHANES 1999-2012.

a

: Public insurance includes insurance programs that likely provided their beneficiaries with prescription
drug benefits before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian
health service programs, Children's Health Insurance Program, and any other state-sponsored or
government health plans.
NH: Non-Hispanic
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Figure 4: Marginal Effects (with 95% Confidence Intervals) of Medicare Part D on
Polypharmacy by Gender Among U.S. Adults Aged 55-74 Without Public
Insurancea. Data Source: NHANES 1999-2012.

a

: Public insurance includes insurance programs that likely provided their beneficiaries with prescription
drug benefits before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian
health service programs, Children's Health Insurance Program, and any other state-sponsored or
government health plans.
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Figure 5: Marginal Effects (with 95% Confidence Intervals) of Medicare Part D on
Polypharmacy by Marital Status Among U.S. Adults Aged 55-74 Without Public
Insurancea. Data Source: NHANES 1999-2012.

a

: Public insurance includes insurance programs that likely provided their beneficiaries with prescription
drug benefits before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian
health service programs, Children's Health Insurance Program, and any other state-sponsored or
government health plans.
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Figure 6: Marginal Effects (with 95% Confidence Intervals) of Medicare Part D on
Polypharmacy by Educational Attainment Among U.S. Adults Aged 55-74 Without
Public Insurancea. Data Source: NHANES 1999-2012.

a

: Public insurance includes insurance programs that likely provided their beneficiaries with prescription
drug benefits before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian
health service programs, Children's Health Insurance Program, and any other state-sponsored or
government health plans.
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Figure 7: Marginal Effects (with 95% Confidence Intervals) of Medicare Part D on
Polypharmacy by Nativity/Citizenship Status Among U.S. Adults Aged 55-74
Without Public Insurancea. Data Source: NHANES 1999-2012.

a

: Public insurance includes insurance programs that likely provided their beneficiaries with prescription
drug benefits before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian
health service programs, Children's Health Insurance Program, and any other state-sponsored or
government health plans.
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Figure 8: Marginal Effects (with 95% Confidence Intervals) of Medicare Part D on
Polypharmacy by Household Poverty Thresholds Among U.S. Adults Aged 55-74
Without Public Insurancea. Data Source: NHANES 1999-2012.

a

: Public insurance includes insurance programs that likely provided their beneficiaries with prescription
drug benefits before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian
health service programs, Children's Health Insurance Program, and any other state-sponsored or
government health plans.
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Figure 9: Marginal Effects (with 95% Confidence Intervals) of Medicare Part D on
Polypharmacy by Number of Chronic Conditions Among U.S. Adults Aged 55-74
Without Public Insurancea. Data Source: NHANES 1999-2012.

a

: Public insurance includes insurance programs that likely provided their beneficiaries with prescription
drug benefits before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian
health service programs, Children's Health Insurance Program, and any other state-sponsored or
government health plans.
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Figure 10: Marginal Effects (with 95% Confidence Intervals) of Medicare Part D on
Polypharmacy by Obesity Status Among U.S. Adults Aged 55-74 Without Public
Insurancea. Data Source: NHANES 1999-2012.

a

: Public insurance includes insurance programs that likely provided their beneficiaries with prescription
drug benefits before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian
health service programs, Children's Health Insurance Program, and any other state-sponsored or
government health plans.
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Figure 11: Marginal Effects (with 95% Confidence Intervals) of Medicare Part D on
Polypharmacy by Self-Reported Health Status Among U.S. Adults Aged 55-74
Without Public Insurancea. Data Source: NHANES 1999-2012.

a

: Public insurance includes insurance programs that likely provided their beneficiaries with prescription
drug benefits before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian
health service programs, Children's Health Insurance Program, and any other state-sponsored or
government health plans.
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Table 3: Linear and Logit Regressions of The Impact of Medicare Part D on Dietary Supplement Use and PolySupplementation Among U.S. Adults Aged 55-74 Without Public Insurancea. Data Source: NHANES 1999-2012.
Model 1:
no covariates

Outcomes: Use of
supplements past
month

Model 2:
Model 1 +
demographic
covariates

Model 3:
Model 2 + health
insurance

Model 4:
Model 3 +
income

Model 5:
Model 4 + health
conditions

Used
5+

Count

Used
5+

Count

Used
5+

Count

Used
5+

Count

Used
5+

Coeff.
(SE)

OR
(SE)

Coeff.
(SE)

OR
(SE)

Coeff.
(SE)

OR
(SE)

Coeff.
(SE)

OR
(SE)

Coeff.
(SE)

OR
(SE)

Ages 65-74 (vs. 55-64)

0.173
(0.120)

1.148
(0.151)

0.048
(0.206)

0.927
(0.215)

-0.004
(0.206)

0.893
(0.209)

0.058
(0.207)

0.938
(0.221)

0.049
(0.204)

0.936
(0.219)

Post 2006

-0.146
(0.145)

0.768
(0.123)

-0.166
(0.214)

0.705
(0.185)

-0.163
(0.210)

0.703
(0.180)

-0.164
(0.207)

0.707
(0.179)

-0.148
(0.206)

0.718
(0.185)

Ages 65-74 * post 2006

0.149
(0.177)

1.325
(0.261)

0.149
(0.170)

1.364
(0.283)

0.148
(0.170)

1.369
(0.284)

0.136
(0.168)

1.337
(0.276)

0.126
(0.166)

1.338
(0.278)

Mean outcome
No. respondents

1.955
6,055

0.131
6,055

1.955
6,055

0.131
6,055

1.955
6,055

0.131
6,055

1.955
6,055

0.131
6,055

1.955
6,055

0.131
6,055
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Count

Notes: + p < 0.1, * p < 0.05, ** p < 0.01, *** p<0.001. All analyses excluded survey cycle in 2005-2006 that overlapped with the introduction
of Part D.
a: Public insurance includes insurance programs that likely provided their beneficiaries with prescription drug benefits before Medicare Part D
took effect in 2006, including Medicaid, military insurance, Indian health service programs, Children's Health Insurance Program, and any
other state-sponsored or government health plans.
Demographic covariates include age, age squared, race (non-Hispanic Whites, non-Hispanic Blacks, non-Hispanic others, and Hispanic),
gender, marital status (married or cohabiting, widowed/divorced/separated, never married), education (less than high school graduate, high
school graduate, some college, college graduate or above), and nativity/citizenship status (citizen born in the US, citizen born abroad, not a
citizen). Health insurance indicates whether a person has any type of health insurance. Income covariates include household poverty level
(less than 100%, 100-199%, 200-299%, 300-399%, 400-499%, 500% or more). Health condition covariates include the number of chronic
conditions (none, one or two, and three or more conditions), whether a person is overweight or obese (BMI of at least 25), and self-reported
health status (excellent, very good, good, fair, and poor).

Table 4: Linear and Logit Regressions of The Impact of Medicare Part D on Medication Use and Polypharmacy Among U.S.
Adults Aged 55-74 With Public Insurancea. Data Source: NHANES 1999-2012.
Model 1:
no covariates

Outcomes: Use of
prescription
medications

Model 2:
Model 1 +
demographic
covariates

Model 3:
Model 2 +
income

Model 4:
Model 3 + health
conditions

Rx
count

Used
5+ Rx

Rx
count

Used
5+ Rx

Rx
count

Used
5+ Rx

Rx
count

Used
5+ Rx

Coeff.
(SE)
0.669+
(0.386)

OR
(SE)
1.642+
(0.435)

Coeff.
(SE)
0.235
(0.550)

OR
(SE)
1.933
(0.812)

Coeff.
(SE)
0.274
(0.552)

OR
(SE)
1.851
(0.788)

Coeff.
(SE)
-0.134
(0.426)

OR
(SE)
1.693
(0.828)

Post 2006

0.254
(0.363)

1.204
(0.263)

0.250
(0.469)

1.061
(0.294)

0.243
(0.495)

1.004
(0.323)

0.571
(0.377)

1.371
(0.455)

Ages 65-74 * post 2006

0.145
(0.550)

1.007
(0.338)

0.174
(0.511)

0.974
(0.318)

0.084
(0.496)

0.971
(0.331)

0.177
(0.377)

0.986
(0.378)

Mean outcome
Number of respondents

4.087
1,190

0.398
1,190

4.087
1,190

0.398
1,190

4.087
1,190

0.398
1,190

4.087
1,190

0.398
1,190

Ages 65-74 (vs. 55-64)
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Notes: + p < 0.1, * p < 0.05, ** p < 0.01, *** p<0.001. All analyses excluded survey cycle in 2005-2006 that overlapped
with the introduction of Part D.
a:

Public insurance includes insurance programs that likely provided their beneficiaries with prescription drug benefits
before Medicare Part D took effect in 2006, including Medicaid, military insurance, Indian health service programs,
Children's Health Insurance Program, and any other state-sponsored or government health plans.
Demographic covariates include age, age squared, race (non-Hispanic Whites, non-Hispanic Blacks, non-Hispanic
others, and Hispanic), gender, marital status (married or cohabiting, widowed/divorced/separated, never married),
education (less than high school graduate, high school graduate, some college, college graduate or above), and
nativity/citizenship status (citizen born in the US, citizen born abroad, not a citizen). Health condition covariates include
the number of chronic conditions (none, one or two, and three or more conditions), whether a person is overweight or
obese (BMI of at least 25), and self-reported health status (excellent, very good, good, fair, and poor).

Table 5: Sensitivity Analyses for Linear and Logit Regressions of The Impact of Medicare Part D on Medication Use and
Polypharmacy Among U.S. Adults Aged 55-74 Without Public Insurancea. Data Source: NHANES 1999-2016.
Model 1:
no covariates

Outcomes: Use
of prescription
medications

Rx
count

Used 5+
Rx

Model 2:
Model 1 +
demographic
covariates
Rx
count

Used 5+
Rx

Model 3:
Model 2 + health
insurance

Model 4:
Model 3 + income

Model 5:
Model 4 + health
conditions

Rx
count

Rx
count

Rx
count

Used
5+ Rx

Coeff.
(SE)

OR
(SE)

-0.203
(0.171)

0.776
(0.143)

0.392*
(0.164)
0.401**
(0.137)

2.056**
(0.466)
1.506**
(0.224)

Used 5+
Rx

Used 5+
Rx

Coeff.
OR
Coeff.
OR
Coeff.
OR
Coeff.
OR
(SE)
(SE)
(SE)
(SE)
(SE)
(SE)
(SE)
(SE)
Panel A: Difference-in-differences. Sample of individuals without public insurance coveragea in all years (1999-2016)
Ages 65-74 (vs.
0.937*** 1.823***
0.014
0.995
-0.093
0.931
-0.131
0.894
55-64)
(0.123)
(0.188)
(0.208)
(0.171)
(0.211)
(0.160)
(0.211)
(0.154)
Post 2006
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Ages 65-74 *
post 2006

0.144
(0.106)
0.406*
(0.164)

1.081
(0.127)
1.301*
(0.171)

0.508***
(0.146)
0.447**
(0.162)

2.027***
(0.322)
1.328*
(0.174)

0.498***
(0.135)
0.452**
(0.162)

2.021***
(0.318)
1.334*
(0.176)

0.507***
(0.136)
0.465**
(0.158)

2.043***
(0.326)
1.357*
(0.177)

Mean outcome
2.908
0.232
2.908
0.232
2.908
0.232
2.908
0.232
2.908
0.232
No. respondents
8,158
8,158
8,158
8,158
8,158
8,158
8,158
8,158
8,158
8,158
Panel B: Difference-in-differences. Sample of individuals without public insurance coveragea, excluding the Great Recession (1999-2004 and
2011-2016)
Ages 65-74 (vs.
0.937*** 1.823***
0.107
1.110
-0.000
1.026
-0.070
0.952
-0.130
0.827
55-64)
(0.123)
(0.188)
(0.246)
(0.227)
(0.249)
(0.211)
(0.249)
(0.196)
(0.199)
(0.184)
Post 2006

0.181
(0.115)

1.116
(0.139)

0.548***
(0.152)

2.108***
(0.347)

0.534***
(0.139)

2.099***
(0.343)

0.545***
(0.142)

2.126***
(0.356)

0.404*
(0.168)

2.117**
(0.505)

Ages 65-74 *
post 2006

0.354+
(0.194)

1.271
(0.186)

0.396*
(0.190)

1.293+
(0.188)

0.402*
(0.189)

1.302+
(0.191)

0.427*
(0.181)

1.348*
(0.195)

0.388*
(0.161)

1.547*
(0.271)

Mean outcome
2.895
0.232
2.895
0.232
2.895
0.232
2.895
0.232
2.895
0.232
No. respondents
5,741
5,741
5,741
5,741
5,741
5,741
5,741
5,741
5,741
5,741
Panel C: Difference-in-differences. Sample of individuals with health insurance, excluding those with public insurance coverage a in all years
(1999-2016)
Ages 65-74 (vs.
0.802*** 1.656***
-0.136
0.904
-0.136
0.904
-0.181
0.869
-0.278
0.742
55-64)
(0.143)
(0.196)
(0.230)
(0.170)
(0.230)
(0.170)
(0.230)
(0.164)
(0.191)
(0.153)

Post 2006

0.128
(0.124)

1.037
(0.137)

0.454**
(0.152)

1.898***
(0.309)

0.454**
(0.152)

1.898***
(0.309)

0.460**
(0.152)

1.913***
(0.313)

0.298*
(0.144)

1.830**
(0.412)

Ages 65-74 *
post 2006

0.409*
(0.182)

1.341*
(0.196)

0.466**
(0.175)

1.382*
(0.199)

0.466**
(0.175)

1.382*
(0.199)

0.479**
(0.171)

1.405*
(0.200)

0.455**
(0.153)

1.614**
(0.267)

Mean outcome
3.039
0.245
3.039
0.245
3.039
0.245
3.039
0.245
3.039
0.245
No. respondents
6,836
6,836
6,836
6,836
6,836
6,836
6,836
6,836
6,836
6,836
Notes: + p < 0.1, * p < 0.05, ** p < 0.01, *** p<0.001. All analyses excluded survey cycle in 2005-2006 that overlapped with the introduction of Part D.
a: Public insurance includes insurance programs that likely provided their beneficiaries with prescription drug benefits before Medicare Part D took
effect in 2006, including Medicaid, military insurance, Indian health service programs, Children's Health Insurance Program, and any other statesponsored or government health plans.
Demographic covariates include age, age squared, race (non-Hispanic Whites, non-Hispanic Blacks, non-Hispanic others, and Hispanic), gender, marital
status (married or cohabiting, widowed/divorced/separated, never married), education (less than high school graduate, high school graduate, some
college, college graduate or above), and nativity/citizenship status (citizen born in the US, citizen born abroad, not a citizen). Health insurance indicates
whether a person has any type of health insurance. Income covariates include household poverty level (less than 100%, 100-199%, 200-299%, 300399%, 400-499%, 500% or more). Health condition covariates include the number of chronic conditions (none, one or two, and three or more
conditions), whether a person is overweight or obese (BMI of at least 25), and self-reported health status (excellent, very good, good, fair, and poor).
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Table 6: Linear and Logit Regressions of The Impact of Medicare Part D on Daily Use of Prescription Medications and
Dietary Supplements Among U.S. Adults Aged 55-74 Without Public Insurancea. Data Source: NHANES 1999-2012.
Model 1:
no covariates

Outcomes: daily use of
prescription medications
or supplements last month

Count

Model 2:
Model 1 +
demographic
covariates

Model 3:
Model 2 + health
insurance

Model 4:
Model 3 +
income

Model 5:
Model 4 + health
conditions

Used 5+

Count

Used
5+

Count

Used
5+

Count

Used
5+

Count

Used
5+

Coeff.
OR
(SE)
(SE)
Panel A: Use of prescription medications
Ages 65-74 (vs. 55-64)
0.930*** 1.826***
(0.122)
(0.200)

Coeff.
(SE)

OR
(SE)

Coeff.
(SE)

OR
(SE)

Coeff.
(SE)

OR
(SE)

Coeff.
(SE)

OR
(SE)

0.119
(0.220)

1.100
(0.209)

0.026
(0.223)

1.032
(0.198)

-0.003
(0.223)

0.992
(0.190)

-0.146
(0.180)

0.856
(0.174)
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Post 2006

0.086
(0.115)

0.979
(0.140)

0.392*
(0.159)

1.458*
(0.254)

0.398**
(0.151)

1.464*
(0.251)

0.395*
(0.154)

1.455*
(0.253)

0.322+
(0.170)

1.420
(0.319)

Ages 65-74 * post 2006

0.490*
(0.191)

1.385*
(0.216)

0.518**
(0.186)

1.409*
(0.218)

0.518**
(0.187)

1.409*
(0.219)

0.523**
(0.183)

1.432*
(0.221)

0.483**
(0.161)

1.614**
(0.271)

Mean outcome
No. respondents

2.706
6,055

0.209
6,055

2.706
6,055

0.209
6,055

2.706
6,055

0.209
6,055

2.706
6,055

0.209
6,055

2.706
6,055

0.209
6,055

1.176
(0.172)

0.077
(0.205)

1.001
(0.241)

0.026
(0.205)

0.961
(0.232)

0.089
(0.206)

1.007
(0.245)

0.080
(0.202)

1.001
(0.243)

Panel B: Use of dietary supplements
Ages 65-74 (vs. 55-64)
0.203+
(0.116)
Post 2006

-0.101
(0.143)

0.804
(0.133)

-0.116
(0.215)

0.738
(0.192)

-0.112
(0.213)

0.736
(0.188)

-0.113
(0.210)

0.741
(0.189)

-0.097
(0.210)

0.753
(0.195)

Ages 65-74 * post 2006

0.112
(0.175)

1.256
(0.260)

0.110
(0.167)

1.281
(0.277)

0.110
(0.168)

1.285
(0.279)

0.097
(0.166)

1.253
(0.270)

0.087
(0.164)

1.254
(0.269)

Mean outcome
No. respondents

2.040
6,055

0.124
6,055

2.040
6,055

0.124
6,055

2.040
6,055

0.124
6,055

2.040
6,055

0.124
6,055

2.040
6,055

0.124
6,055

Notes: + p < 0.1, * p < 0.05, ** p < 0.01, *** p<0.001. All analyses excluded survey cycle in 2005-2006 that overlapped with the introduction of Part D.
a:

Public insurance includes insurance programs that likely provided their beneficiaries with prescription drug benefits before Medicare Part D took effect
in 2006, including Medicaid, military insurance, Indian health service programs, Children's Health Insurance Program, and any other state-sponsored or
government health plans.

Demographic covariates include age, age squared, race (non-Hispanic Whites, non-Hispanic Blacks, non-Hispanic others, and Hispanic), gender, marital
status (married or cohabiting, widowed/divorced/separated, never married), education (less than high school graduate, high school graduate, some college,
college graduate or above), and nativity/citizenship status (citizen born in the US, citizen born abroad, not a citizen). Health insurance indicates whether a
person has any type of health insurance. Income covariates include household poverty level (less than 100%, 100-199%, 200-299%, 300-399%, 400499%, 500% or more). Health condition covariates include the number of chronic conditions (none, one or two, and three or more conditions), whether a
person is overweight or obese (BMI of at least 25), and self-reported health status (excellent, very good, good, fair, and poor).
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Table 7: Logit Regressions of The Impact of Medicare Part D on Polypharmacy and Poly-Supplementation Using Different
Numerical Thresholds Among U.S. Adults Aged 55-74 Without Public Insurancea. Data Source: NHANES 1999-2012.
Used
1+

Used
2+

Used
3+

Used
4+

Used
5+

Used
6+

Used
7+

Used
8+

Used
9+

Used
10+

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

0.747
(0.133)

0.822
(0.157)

0.834
(0.163)

0.986
(0.259)

0.554+
(0.167)

0.582
(0.194)

1.069
(0.491)

1.222
(0.615)

Panel A: Polypharmacy as outcomes
Ages 65-74
0.952
0.905
(vs. 55-64)
(0.170)
(0.173)
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Post 2006

1.163
(0.278)

1.424+
(0.280)

1.266
(0.230)

1.283
(0.260)

1.399
(0.308)

1.393
(0.349)

1.321
(0.388)

2.156*
(0.803)

1.969
(0.965)

2.344
(1.463)

Ages 65-74 *
post 2006

1.028
(0.182)

0.928
(0.175)

1.217
(0.193)

1.494*
(0.253)

1.572**
(0.250)

1.239
(0.265)

1.766*
(0.459)

1.924*
(0.626)

2.487*
(1.054)

2.641+
(1.388)

Mean outcome
No.
respondents

0.782
6,055

0.612
6,055

0.458
6,055

0.320
6,055

0.218
6,055

0.146
6,055

0.098
6,055

0.067
6,055

0.043
6,055

0.029
6,055

1.060
(0.212)

0.936
(0.219)

0.885
(0.293)

0.811
(0.322)

0.757
(0.328)

1.044
(0.605)

1.311
(0.867)

Panel B: Poly-supplementation as outcomes
Ages 65-74
0.895
1.141
1.022
(vs. 55-64)
(0.146)
(0.183)
(0.197)
Post 2006

0.844
(0.136)

0.786
(0.139)

0.807
(0.142)

0.736
(0.141)

0.718
(0.185)

0.688
(0.208)

0.773
(0.298)

0.947
(0.425)

1.499
(0.790)

3.075
(2.470)

Ages 65-74 *
post 2006

1.066
(0.157)

1.006
(0.137)

1.022
(0.147)

1.229
(0.205)

1.338
(0.278)

1.501
(0.407)

1.686
(0.625)

1.347
(0.588)

1.017
(0.540)

0.930
(0.570)

Mean outcome 0.714
0.485
0.315
0.202
0.131
0.083
0.051
0.036
0.025
0.019
No.
6,055
6,055
6,055
6,055
6,055
6,055
6,055
6,055
6,055
6,055
respondents
Notes: + p < 0.1, * p < 0.05, ** p < 0.01, *** p<0.001. All analyses excluded survey cycle in 2005-2006 that overlapped with the introduction of Part D.
a: Public insurance includes insurance programs that provided their beneficiaries with prescription drug benefits before Medicare Part D took effect in
2006, including Medicaid, military insurance, Indian health service programs, Children's Health Insurance Program, and any other state-sponsored or
government health plans.

Each column is a separate regression model that controls for demographic, health insurance, income, and health covariates. Demographic covariates
include age, age squared, race (non-Hispanic Whites, non-Hispanic Blacks, non-Hispanic others, and Hispanic), gender, marital status (married or
cohabiting, widowed/divorced/separated, never married), education (less than high school graduate, high school graduate, some college, college
graduate or above), and nativity/citizenship status (citizen born in the US, citizen born abroad, not a citizen). Health insurance indicates whether a
person has any type of health insurance. Income covariates include household poverty level (less than 100%, 100-199%, 200-299%, 300-399%, 400499%, 500% or more). Health condition covariates include the number of chronic conditions (none, one or two, and three or more conditions), whether a
person is overweight or obese (BMI of at least 25), and self-reported health status (excellent, very good, good, fair, and poor).
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CHAPTER 3:
Utilization of Medications with Cognitive Impairment Side Effects and The
Implications for Older Adults’ Cognitive Function

Objective: Many medications have cognitive impairment, memory loss, amnesia, or
dementia as side effects (“cognitive side effects” hereafter), but little is known about
trends in the prevalence of these medications or their implications for population-level
cognitive impairment.
Data source: I use data from the National Health and Nutrition Examination Survey
(1999-2016) to describe trends in the use of medications with cognitive side effects
among adults aged 60+ (N=16,937) and their implications for cognitive functioning
(measured using word learning and recall, animal fluency, and digit symbol substitution
assessments).
Principle findings: Between 1999-2000 and 2015-2016, the prevalence of older adults
taking one, two, and at least three medications with cognitive side effects increased by
10.2%, 57.3%, and 298.7%, respectively. Compared to non-users, respondents who
simultaneously used three or more medications with cognitive side effects scored 0.22 to
0.27 standard deviations lower in word learning and recall (p = 0.02), digit symbol
substitution (p < 0.01), and the average standardized score of the three assessments (p <
0.001).
Conclusion: Concurrent use of medications with cognitive side effects among older
adults has increased dramatically over the past two decades. The use of such medications
is associated with cognitive impairment and may explain for disparities in cognitive
function across subgroups. These findings highlight the need for cognitive screenings
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among patients who consume medications with cognitive side effects. They also highlight
the synergic effects of polypharmacy and potential drug-drug interactions that result in
cognitive deficits.
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Introduction
Adults aged 65 and older represent the fastest-growing population in the United States
and their numbers are expected to nearly double by 2060, creating urgency around the
prevention and treatment of aging-related health conditions (Federal Interagency Forum
on Aging-Related Statistics, 2016). Cognitive impairment has emerged as a significant
public health concern for older adults as it leads to a loss of independence, worsened
quality of life, and increased disability, which in turn have important implications for
individuals, families, and government programs (Hurd et al., 2013; Langa et al., 2008;
Seeher et al., 2013). In 2002, more than ten million U.S. adults aged 70 and older lived
with dementia or milder cognitive impairments without dementia, with an expected
doubling by 2050 (Brenda L Plassman et al., 2007; Brenda L Plassman et al., 2008).
Although the prevalence of cognitive impairment has declined gradually in the past
decades due to better control of some key risk factors (Langa et al., 2017; Sheffield &
Peek, 2011), substantial growth in the absolute number of older adults living with
cognitive impairment continues to expand the scope of this public health concern.

Risk factors for cognitive impairment have been well-documented in the literature,
including age, socio-demographic status, chronic conditions, and health behaviors
(Livingston et al., 2017). Despite efforts to document a wide assortment of risk factors,
little is known about the consequences of using medications with cognitive side effects
on cognitive function among community-dwelling older adults. This is a potentially
significant omission. Medications have become increasingly common among older
adults. In 2011-2012, 40% of older adults reported using five or more medications in the
past month, compared to 22% in 1999-2000. While pharmaceutical innovations are
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critical for disease management and prevention, recent research has emphasized the
adverse effects of commonly used medications on health, especially under conditions of
polypharmacy (Qato et al., 2018). Particularly, older adults taking multiple medications
simultaneously are two times more likely to experience adverse drug events and four
times more likely to be hospitalized due to adverse drug events, compared to those taking
fewer or no medications (Bourgeois et al., 2010; Marcum et al., 2012; Nguyen et al.,
2006).

Prior studies on medications with cognitive side effects have produced contradictory
results with respect to outcomes and statistical significance, potentially dampening the
relevance of cognitive side effects in particular. Studies have found that benzodiazepines,
lorazepam, and oxybutynin significantly increase the incidence of amnestic and nonamnestic cognitive impairments, while H(1)-antihistamine agents and tricyclic
antidepressants only induce non-amnestic deficits in attention and information processing
(Tannenbaum et al., 2012). Other studies have found that benzodiazepines, tricyclic
antidepressants, first-generation antihistamines, and bladder antimuscarinics are
associated with an increased risk of Alzheimer’s disease, raising concerns that the
cognitive side effects of medications are irreversible and long-lasting (de Gage et al.,
2014; Gray et al., 2015). Yet, a handful of studies have reported a trivial and potentially
non-causal increase in cognitive deficits as a result of using benzodiazepine (Gray et al.,
2016; Imfeld et al., 2015).

Further investigation of this topic is warranted, especially in the context of community
dwelling adults. It is possible that cognitive side effects of medications are much more

71

pronounced in naturalistic and population settings. Many prior studies have been clinical
in nature, exploring the effects of a single medication or a class of medication, or using
relatively small and non-representative samples. For this reason, little is known about
how frequently such medications are used in the adult population or about how the use of
such medications has changed over time. Moreover, little is known about how many
adults simultaneously consume multiple such medications and the consequences of such
combinations for cognitive health. Even if much of the evidence suggests that the risks
associated with a single medication are small or inconsistent, the total impact of
medications with cognitive side effects on population-level cognitive health could be
much larger, especially in a context of polypharmacy.

I follow the theoretical framework developed by Inouye & Charpentier (1996) to
conceptualize the adverse effects of medications with cognitive side effects on the
cognitive health of older adults. This model was originally developed to examine factors
that predicted the onset of delirium – an acute disorder of attention and cognition –
among hospitalized older adults, though the model can be extended and generalized for
the purpose of this study. Risk factors for delirium are multifactorial, but they can be
categorized into two interdependent groups factors: predisposing (baseline vulnerability)
and precipitating (acute insult) risk factors. Predisposing risk factors documented in prior
studies include demographic characteristics and pre-existing conditions (Francis, 1992;
Inouye, 1994), while precipitating factors include medication administration, intercurrent
illnesses, infections, malnutrition, and environment and psychosocial factors (Inouye &
Charpentier, 1996). These factors do not operate individually, but rather
interdependently. A patient with vulnerable baseline characteristics may develop delirium
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regardless of any precipitating factors. In contrast, patients with low-risk baseline
characteristics may require a high level of acute insult to develop delirium. Following this
theoretical framework, I hypothesize that precipitating factors such as the use of
medications with cognitive side effects is associated with an increased risk of cognitive
impairment after controlling for predisposing factors such as socio-demographic
characteristics and comorbidity.

This study improves the previous literature by using a nationally representative survey
and a comprehensive database of medications that have been previously linked to
cognitive impairment. This study has two aims:
1. What are the trends in the utilization of medications with cognitive side effects
from 1999 to 2016 among adults aged 60 and older?
2. What is the relationship between cognitive function and concurrent use of
medications with cognitive side effects for older adults?

Methods
I used the National Health and Nutrition Examination Survey (NHANES), a nationally
representative survey of the civilian noninstitutionalized U.S. population. NHANES was
obtained using a multistage probability sampling design to represent the general
population but with an oversampling of Black, Hispanic, and adults aged 60 and older.
The average non-response rate was 22%. All analyses used survey weight to produce
nationally representative estimates and to avoid non-response bias. This study first relied
on data from all nine most recent two-year cycles (1999-2000 to 2015-2016) to assess
trends in the use of medications with cognitive side effects for adults aged 60 and older
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(n=16,937). I then used data in 2011-2012 and 2013-2014 to investigate the association
between cognitive function and the use of medications with cognitive side effects
(n=2,908), after excluding 697 respondents who were not administered or did not
complete all cognitive assessments and 27 respondents who were currently taking antidementia or anti-Parkinson’s medications. Information on cognitive function was only
available in these years.

Cognitive function was measured using a series of objective assessments that remained
unchanged in both survey cycles, including word learning and recall, animal fluency, and
digit symbol substitution. Respondents who needed a proxy informant or who did not
understand any of languages offered by NHANES were not administered these
assessments. Non-response among those administered the assessments ranged from 2% to
3%. The word leaning and recall assessment has been successfully implemented in major
epidemiological studies in various ethnic and cultural contexts to investigate learning
ability for new verbal information (Fillenbaum et al., 2008; Prince et al., 2003). The
assessment was comprised of three trials and one delayed recall challenge. In each trial,
respondents were asked to read out loud ten unrelated words, one at a time, as they were
presented on a computer. Following the presentation, respondents were asked to recall as
many words as possible. The delayed word recall challenge took place after the animal
fluency and digit symbol substitution tests were completed (approximately 8-10 minutes
following the start of the trials). Each correct word was worth one point, and the
maximum score was ten.
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The animal fluency assessment examined verbal fluency independent of educational
attainment (Prince et al., 2003). The test has been proven to differentiate persons with
normal cognition from those with mild and more-severe cognitive impairment (Henry et
al., 2004). Respondents were instructed to name as many animals as they can in one
minute. Each distinct animal was worth one point. The total observed score ranged from
3 to 40.

Finally, the digit symbol substitution assessment was adopted from the Wechsler Adult
Intelligence Scale and was used to assess processing speed, sustained attention, and
working memory (Dumont & Willis, 2008). The test was conducted on a sheet of paper
that contained a key at the top with nine numbers, each paired with a symbol.
Respondents had two minutes to copy the corresponding symbols to 133 boxes
underneath adjoining numbers. Each correct symbol was worth one point, and the total
observed score ranged from 0 to 105.

Using the total scores, I constructed two sets of outcome variables for each assessment.
The first set of variables were the standardized scores for each assessment. The second
set of variables were indicators for whether a respondent’s score was more than one
standard deviation below the mean. Finally, I constructed two composite variables to
represent global cognitive function, an average standardized score of the three
assessments and a binary indicator of whether a person’s standardized scores were more
than one standard deviation below the mean for at least two assessments. Although these
measures cannot substitute for clinical diagnoses of cognitive impairment, they provided
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meaningful information to study the association between cognitive impairment and
medications with cognitive side effects.

Medications were recorded during the prescription medication interviews. Respondents
were asked to show interviewers the containers of all medications they had taken last
month. Respondents who could not show a container were asked to verbally report the
medication’s name. When interviewers entered medication names into a computer, more
than 95% of entries resulted in exact or similar matches with an existing drug. The drug
database used for the match was obtained from Lexicon Plus, a proprietary database of
Cerner Multum that provided, on an annual basis a comprehensive list of all prescription
and some non-prescription medications available in the U.S. market.

Medications with cognitive side effects were identified using Micromedex. Prior studies
have independently established the accuracy and reliability of the adverse effects listed in
Micromedex (Cheng et al., 2010). The database is based on several sources: the U.S.
Food and Drug Administration’s black box warnings, MedWatch, post-marketing
surveillance, and comprehensive literature reviews. I identified 94 medications with
cognitive side effects using a keyword search including the following words: cognitive
impairment, cognitive decline, memory loss, amnesia, and dementia. This number of
medications does not represent all medications with such side effects in the U.S market,
but rather the number of medications with cognitive side effects that were consumed by
respondents aged 60 and older in this study (see Table 1). I included all 94 medications
with cognitive side effects, irrespective of any reported frequency of those side effects as
reported in Micromedex. This decision likely underestimated the association between
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cognitive function and the use of medications with cognitive side effects, though it is
possible that small clinical trials underestimated the prevalence of side-effects among
those who took the drug. Using the reported number of medications with cognitive side
effects, I constructed a variable that indicated whether in the past 30 days a respondent
took no medications with cognitive side effects (the reference category in the analysis
model), one medication, two medications, or three or more medications with cognitive
side effects. I created a similar variable for the use of medications without known
cognitive side effects.

-Insert Table 1 About Here-

Length of time a respondent had been taking each medication was recorded during the
prescription medication interviews. All responses were converted to days. Respondents
who consumed multiple medications with cognitive side effects were assigned to a length
of time that corresponded with the length of time for the medication they had been taking
the longest. In secondary analyses, the use of medications with and without cognitive side
effects was further classified into categories of duration of use (at most one year and
more than one year).

Comorbidities that were potentially associated with cognitive health and/or the use of
medications such as depression, obesity, and other health conditions were ascertained
based on self-reports (Beydoun et al., 2008; Cherbuin et al., 2015; Livingston et al., 2017;
Luppino et al., 2010). Depression was measured using a nine-item depression-screening
instrument from the Patient Health Questionnaire (PHQ-9), which scored each of the nine
Diagnostic and Statistical Manual of Mental Disorders, 4th. Edition’s criteria
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experienced in the past two weeks from “0” (not at all) to “3” (nearly every day).
Respondents were classified as likely having depression if their total score was 10 or
higher (Kroenke et al., 2001). Obesity was defined as having a body mass index of at
least 30. Other health conditions were measured using a series of self-reported diagnoses
of asthma, arthritis, cancer, congestive health failure, coronary heart disease, heart attack,
angina, emphysema, bronchitis, stroke, hypertension, diabetes, and sleep disorder. Each
of these health conditions was introduced in the models as a binary variable.

Other covariates in this paper included socio-demographic characteristics, health
behaviors, and access to medical services such as age, gender, marital status (married or
living with a partner: reference category, widowed/divorced/separated, never married),
educational attainment (less than high school: reference category, high school graduate,
some college or two-year degree, college graduate or higher), poverty (less than 100% of
federal poverty guideline: reference category, 100-199%, 200-299%, 300-399%, 400499%, 500% or higher), citizenship, whether a person had any health insurance, whether
a person had a routine place for medical care, and smoking (never smoked: reference
category, smoked at least 100 cigarettes in the past but not a current smoker (former
smoker), smoked at least 100 cigarettes in the past and currently smoke (current
smoker)). I included a dummy variable for year to account for any trend in the outcome.
To adjust for complex sampling, weighted prevalence estimates of medications with
cognitive side effects in each year were calculated using Taylor linearization methods.
The statistical significance of trends of medications with cognitive side effects was
assessed using logistic regression. Weighted multivariate linear least-squared and logistic
regression models were used to investigate the association between cognitive function
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and the use of medications with cognitive side effects, controlling for potential
confounders. I imputed missing data for all control variables using multiple imputation
with chained equations. I generated ten imputed datasets and used them in all analyses.
Most control variables had a small number of missing cases (<1%), except for depression
and poverty status, which had up to 10% missing cases. Following conventions, I
considered a p-value of less than 0.05 as statistically significant and I did not correct for
multiple testing due to the exploratory nature of this study.

Results
Figure 1 presents the unadjusted (Panel A) and age/gender adjusted (Panel B) trends in
utilization of medications with cognitive side effects from 1999 to 2016 for adults aged
60 and older. In Panel A, about 55.3% (95% CI, 51.3%-59.3%) of older adults did not
consume any medications with cognitive side effects in 1999-2000. In 2015-2016, this
estimate declined to 37.7% (95% CI, 34.3%-41.2%). The prevalence of older adults
taking one medication with such side effects increased modestly by 3.2 percentage points
(95% CI, -1.8%-8.3%) over the same period of time. The largest increase was
concentrated among those who consumed two or more such medications. Relative to
1999-2000, the prevalence of older adults concurrently taking two or three or more
medications with cognitive side effects in 2015-2016 went up by 5.8 percentage points
(95% CI, 3.2%-8.4%) and 8.5 percentage points (95% CI, 6.5%-10.5%) respectively.
Adjusting for age and gender (Panel B) did not significantly change the interpretation of
the results. Table 2 lists 25 medications with the largest change over time in absolute
prevalence. A large proportion of the total increase in the prevalence of medications with
cognitive side effects was attributed to certain medications or classes of medication that
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treated hypercholesterolemia, cardiovascular disease, gastrointestinal disease, and the
central nervous system.

-Insert Figure 1 About Here-Insert Table 2 About Here-

Table 3 presents descriptive statistics for the use of medications with cognitive side
effects, as well as cognitive function measurements and other covariates by the number of
medications with cognitive side effects. Overall, 38.6% of respondents did not consume
any medications with cognitive side effects, while 9.4% had been taking such
medications for at most one year and 52% had been taking those medications for more
than one year. Almost 8% of respondents used at least one prescription opioid5 in the last
30 days, and such use of opioids increased as respondents consumed more medications
with cognitive side effects.6 Consistently across all cognitive measurements, those who
took more medications with cognitive side effects scored lower on cognitive assessments.
Compared to older adults who did not use any medications with cognitive side effects,
those who consumed at least three such medications scored 0.29 standard deviations (SD)
(95% CI, -0.43 to -0.14) lower in the average standardized score of the three tests, and

5

Prescription opioids include all narcotic analgesics and narcotic analgesic combinations, excluding

opioids that are often used in treatment for opioid dependence such as buprenorphine and naloxone.
6

Several studies found that the use of opioids was harmful to cognitive health (Kamboj et al., 2005;

Sjøgren et al., 2005). However, Micromedex did not classify any opioids as having cognitive side effects.
This may be due to conflicting evidence regarding whether the use of opioid is associated with cognitive
impairment (S. L. Chapman et al., 2002; Dublin et al., 2015). For information purposes, I included the
prevalence of opioid use in the descriptive statistics table.
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were 8.5 percentage points (95% CI, 3.0% to 14.0%) more likely to score more than one
standard deviation below the mean for at least two of the tests.

-Insert Table 3 About Here-

Socio-demographic characteristics, health services utilization, health behaviors, and
comorbidities also varied by the number of medications with cognitive side effects
consumed. Compared to respondents who did not consume medications with cognitive
side effects, those who consumed at least three medications with such side effects were
more likely to also consume at least three medications without cognitive side effects, to
be female, older, insured, U.S. citizens, former smokers, to have a routine place for
medical care, to be obese, to report other health conditions, and were less likely to have a
college degree or higher.

Table 4 presents results from the adjusted multivariate analyses. I found that respondents
who consumed at least three medications with cognitive side effects scored 0.22 SD (95%
CI, -0.34 to -0.10) lower in the average standardized score of the three assessments, and
that this relationship was in part driven by the association between medications with such
side effects and the word learning and recall assessment (coefficient, -0.24; 95% CI, 0.43 to -0.04) and the digit symbol substitution assessment (coefficient, -0.27; 95% CI, 0.42 to -0.12). There is no relationship between the use of medications with cognitive
side effects and the animal fluency assessment (coefficient, -0.15; 95% CI, -0.33 to 0.03).
I also found that taking numerous such medications was critical: the association between
medications with cognitive side effects and cognitive function was small and not
statistically significant for those taking fewer than three medications. Nonetheless, I
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observed a dose-response relationship such that the association between medications with
cognitive side effects and cognitive function generally increased over each category of
additional medication.

-Insert Table 4 About Here-

In Table 5, I found similar patterns between medications with cognitive side effects and
whether a respondent scored more than one standard deviation below the mean for each
assessment. Particularly, compared to the reference group, individuals consuming at least
three medications with cognitive side effects were about two times (OR, 2.10; 95% CI,
1.25 to 3.53) more likely to score more than one standard deviation below the mean for at
least two tests, and this result was also driven by the relationship between medications
with cognitive side effects and respondents’ performance on the word learning and recall
and the digit symbol substitution assessments.

-Insert Table 5 About Here-

In both Tables 4 and 5, I followed a previous study and introduced a categorical variable
for the number of medications without cognitive side effects into the models (Qato et al.,
2018). If the relationship between medications with cognitive side effects and cognitive
function was driven by unobserved heterogeneity in health, the relationship between
medications without cognitive side effects and cognitive function should be equally
significant as that between medications with cognitive side effects and cognitive function.
I found no significant relationship between medications without cognitive side effects and
cognitive function, except for the digit symbol substitution and the composite outcomes
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in Table 4, and in this case the coefficients were smaller than the coefficients for three or
more medications with side effects.

In Table 6, I further classified the use of medications with and without cognitive side
effects into categories of duration of use (at most one year and more than one year).
Consistent with previous results in Tables 4 and 5, only the use of at least three
medications with cognitive side effects was associated with cognitive deficits, and this
association was unlikely to have been driven by the duration of use. I also found that
more recent use (at most one year) of three or more medications with such side effects
was more deleterious to cognitive health compared to having used three of more such
medications for more than a year. Although the estimates were not significantly different
from one another, these results potentially suggest that the negative consequences of
medications with cognitive side effects might be short-term or reversible.

-Insert Table 6 About Here-

Finally, in Figures 2 to 6, I assessed the heterogeneous association between medications
with cognitive side effects and the global cognitive score (average standardized score of
the three assessments) by socio-demographic subgroups according to age, gender,
educational attainment, race/ethnicity, and marital status. Overall, I observed the negative
consequences of medications with cognitive side effects among all subgroups: among
younger respondents (under 75 years of age), both men and women, all education
subgroups (high school graduate or lower and college or higher), non-Hispanic whites,
non-Hispanic others, and all marital status categories (married or cohabiting and not
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married or cohabiting). The heterogeneity that exists across subgroups may be explained
by the more frequent use of medications among certain subgroups.

-Insert Figures 2 to 6 About Here-

Discussion
To my knowledge, this study was the first to assess trends in the utilization of
medications with cognitive side effects among U.S. community-dwelling older adults. I
found that between 1999-2000 and 2015-2016, the prevalence of older adults taking one,
two, or at least three medications with cognitive side effects increased by 10.2%, 57.3%,
and 298.7%, respectively. Much of the increase in utilization of medications with
cognitive side effects was attributed to an increase in consumption of medications that
treated hypercholesterolemia, the central nervous system, or cardiovascular disease.
Concurrent use of three or more such medications was associated with reductions in the
global cognitive score, performance on the word learning and recall assessment, and
performance on the digit symbol substitution assessments. These relationships persisted
even after excluding individuals who were currently taking medications for dementia or
Parkinson’s disease, and after controlling for socio-demographic characteristics, access to
health services, health behaviors, and health conditions. Medications without known
cognitive side effects were not associated with declines in the cognitive tests scores.

The summary measures of the use of medications with cognitive side effects produced
coefficients that were either similar to or smaller than those produced in studies of
specific medications or types of medication. Using a longitudinal survey that was
representative of the population aged 65 and older in England and Wales, Fox et al.
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(2011) reported that exposure to at least one anticholinergic medication7 at the baseline
was associated with a reduction of 1.27% in the Mini-Mental State Examination score,
compared to respondents who did not take any anticholinergics. Using a longitudinal
survey in France, Ancelin et al. (2006) found that consistent users of anticholinergics
scored 0.6 to 0.8 standard deviations lower in various cognitive tests. My estimates for
the use of a single medication with cognitive side effects were much smaller than those in
Ancelin et al. (2006), in part because I included in this study many medications other
than anticholinergics that had smaller incidence rates of cognitive impairment.
Nonetheless, this study contributed to the existing literature by demonstrating the
increasing trend in prevalence of concurrent use of medications with cognitive side
effects among community-dwelling older adults, and the association between the use of
such medications and cognitive health under conditions of polypharmacy. I find that the
use of three or more medications with side effects is much more consequential than the
sum of three individual medications with side effects.

The role of medications in the cognitive performance of older adults has likely been
underappreciated, especially when a decline in performance might reasonably be
attributed to a normal aging process. Although there are numerous guidelines for the
diagnosis and treatment of chronic physical diseases (Bingley et al., 2001; Chobanian et
al., 2003; Criner et al., 2015; Wender et al., 2013), there are currently no guidelines for

7

Examples include antiemetics, antispasmodics, bronchodilators, antiarrhythmic drugs, antihistamines,

analgesics, antihypertensives, antiparkinsonian agents, corticosteroids, skeletal muscle relaxants, ulcer
drugs, and psychotropic drugs
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the screening of cognitive impairment. Part of this may reflect the limited clinical
benefits of such screenings. Following a review of the literature, the U.S. Preventive
Services Task Force (2015) concluded that there was insufficient evidence on the benefits
of screening for cognitive impairment. Yet a large number of older adults report
worrisome cognitive impairments (Aigbogun et al., 2017), and, given the trends
documented here, medication use may play an increasingly important role in their
experience. In tandem with a lack of clinical guidelines for screening cognitive
impairment, the growing intensity of diagnosis and treatment for chronic and physical
diseases may contribute significantly to cognitive impairment among older adults.
Physicians could limit the risk of cognitive impairment from side effects by collecting
information on their patients’ cognitive function prior to and during drug administration
and adjust prescriptions and doses accordingly.

The results also highlight the impact of polypharmacy. The most significant side effects
documented in this study were limited to those taking three of more medications.
Although most people who take medications with such side effects take only one or two,
polypharmacy is increasingly common. In this study, about 9% of older adults took three
or more medications with cognitive side effects in the past 30 days. Although the
prevalence of older adults taking at least five medications increased by 81.8% from 19992000 to 2011-2012 (Kantor et al., 2015), the present study found that the prevalence of
older adults taking at least three medications with cognitive side effects has increased
considerably more over this baseline increase in polypharmacy, by almost 300% between
1999-2000 and 2015-2016. Polypharmacy may present unique risks for side effects,
amplifying the effects of each of the medications in a set. Further, polypharmacy also
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increases the risk of drug-drug interactions that may lead to negative cognitive outcomes.
Prior research has shown that taking multiple medications is a risk factor for dementia
and delirium, as well as other adverse events (Jyrkkä et al., 2011; Martin et al., 2000).
Research on the reasons for an increase in polypharmacy is limited, though prior studies
points to the growing presence of comorbidity (Slabaugh et al., 2010), the failure to
consider comorbidity in clinical practice guidelines (Tinetti et al., 2004), visiting multiple
providers (Col et al., 1990), and marked variation in patterns of medical practice of
individual providers (Hovstadius & Petersson, 2012). Since exposure to adverse side
effects is positively correlated with the number of medications taken (Marcum et al.,
2012), efforts to reduce polypharmacy might also lessen exposure to multiple drugs with
similar side effects. As the pharmaceutical treatment of chronic disease is increasingly
common, future research should further investigate its spillover effects to other illnesses
and symptoms.

To help guide clinical decisions, Table 7 provides the most common combinations of
medications with cognitive side effects among respondents who consumed at least three
such medications. Such combinations of medications in part reflect the common chronic
conditions triad for U.S. older adults (Ward & Schiller, 2013). All combinations, for
instance, include either antihyperlipidemic agents or proton pump inhibitors. While prior
studies found no association between cognitive function and the use of
antihyperlipidemic agents (Bitzur, 2016) or conflicting evidence in the case of proton
pump inhibitors (Gomm et al., 2016; Kuller, 2016), most studies have only examined
these medications individually. It is possible that the association between these
medications and cognitive impairment is larger under conditions of polypharmacy,
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especially when antihyperlipidemic agents or proton pump inhibitors are combined with
other medications that have cognitive side effects. Although the clinical benefits of
antihyperlipidemic agents and proton pump inhibitors might outweigh the risks of
cognitive side effects, clinicians might want to be cautious when prescribing these
medications in combination with others that also have cognitive side effects.

-Insert Table 7 About Here-

Some medications in Appendix Table 1 are available over the counter (OTC). An
increase in the consumption of medications with cognitive side effect may be in part due
to the rapidly growing availability of OTC medications (S.-A. Francis et al., 2005). Many
Americans are either unaware of the side effects of OTC medications or incorrectly
believe that such medications do not have significant side effects (Wilcox et al., 2005).
Almost 60% of patients used OTC medications in the past month, but only 58% of those
who used such medications informed their physician about it and, for their part,
physicians only asked about OTC medications during 37% of visits (Sleath et al., 2001).
The lack of communication between physicians and patients and the growing availability
of OTC medications may result in duplicate prescribing of medications with cognitive
side effects. Carefully monitoring patients’ use of OTC medications can prevent the risk
of combining OTC and prescription medications that both have cognitive side effects.

Finally, I found that medications with cognitive side effects were more debilitating to
cognitive health among younger adults than among older adults (Figure 2). This finding
suggests that the association between medications with cognitive side effect and
cognitive function was not mainly driven by poor health in old ages. The finding also
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implies that the selection into consuming these medications at young ages due to the early
onset of chronic conditions and comorbidity can be more debilitating to cognitive health
than those that occur at older ages (Huang et al., 2010). In addition, young adults
generally have more cognitive abilities than older adults, as many cognitive abilities –
such as conceptual reasoning, memory, and processing speed – gradually diminish over
time (Harada et al., 2013). The low stock of cognitive abilities among older adults may in
part explain why medications with cognitive side effects play a less important role in
their cognitive health compared to that of younger adults.

While this study improved the previous literature by using nationally representative data
and including a comprehensive list of all medications with cognitive side effects, it faced
several limitations. First, I was not able to establish a causal relationship between
cognitive function and medications with cognitive side effects. Due to the cross-sectional
nature of the NHANES, it was challenging to determine whether medications with
cognitive side effects caused cognitive impairment or if cognitive impairment led to the
onset of other health conditions that required pharmaceutical treatment involving
additional cognitive side effects. Second, the medications in this study not only involved
cognitive side effects but also other side effects that might indirectly influence cognitive
function. I addressed both issues by controlling for a comprehensive list of health
conditions, including conditions that might influence a respondent’s cognitive function,
but there were likely other unobserved conditions that are influential. Third, although
Micromedex is a reliable source of information on adverse side effects, it is possible that
there were medications with cognitive side effects that were not included in the database.
Fourth, since NHANES only collected data on outpatient and over-the-counter
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medications, I lacked information on medications administered to inpatients at hospitals.
To address some forms of unobserved heterogeneity, I followed another similar study and
included in all analysis models the number of medications without any known cognitive
side effects (Qato et al., 2018). I found that there was almost no association between
medications without such side effects and cognitive function. This suggests both that
unobserved heterogeneity with respect to health is unlikely to explain the results and that
there were few medications with cognitive side effects that have not been correctly
identified by Micromedex. Finally, the data lacked information on dosage of medications
associated with cognitive side effects. This is an important omission because the
association between medications with cognitive side effects and cognitive health may
depend on the treatment intensity. I did, however, attempt to test the effects of treatment
intensity in other ways. In a secondary analysis presented in Table 4, I further classified
the use of medications with and without cognitive side effects into categories of duration
of use (at most one year and more than one year). I found that the association between
medications with cognitive side effects and cognitive function was unlikely to have been
driven by differences in the duration of use. I also found that more recent use (at most
one year) of three or more medications with such side effects was more deleterious to
cognitive health compared to having used three or more medications for more than a
year, a result consistent with the fact that side-effects occur as a consequence of the
recent use of medication. While the duration of medications cannot perfectly substitute
for information on dosage, duration of use does reflect the long-run amount of medication
that a person has been consuming prior to the interview.
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Conclusion
This study demonstrated a strong relationship between taking multiple medications with
cognitive side effects and cognitive functioning. Almost 9% of older adults take three or
more such medications, and this percentage is likely to increase more in the future. The
investigation of cognitive side effects is an important frontier for future research and
could help to explain important trends and disparities. Research on the population-level
implications of medication use could help to explain, among other things, the decline in
intelligence test scores beginning in the 21st century (Flynn & Shayer, 2018), as well as
some of the apparent sociodemographic variation in cognitive function among older
adults (Zaninotto et al., 2018).
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Table 1. Medications with Cognitive Side Effects Consumed by U.S. Adults Aged 60+ in NHANES from 1999-2000 to 20152016

101

Acamprosate
Alprazolam
Amitriptyline
Amitriptyline Hydrochloride/Perphenazine
Atorvastatin
Baclofen
Bendroflumethiazide/Nadolol
Benztropine
Ciprofloxacin
Clomipramine
Clonazepam
Conjugated Estrogens
Cyclopentolate
Cyclophosphamide
Cyclosporine
Cyproheptadine
Dexlansoprazole
Diazepam
Diltiazem
Dorzolamide
Dronabinol
Enzalutamide
Esomeprazole
Estazolam
Esterified Estrogens

Fluorouracil
Fluoxetine
Fluvastatin
Heparin
Hydrochlorothiazide/Propranolol
Ibuprofen
Interferon Alfa-2A
Isoniazid
Ketoprofen
Lamotrigine
Leuprolide
Levetiracetam
Levofloxacin
Lorazepam
Lovastatin
Meclizine
Mefloquine
Methocarbamol
Methotrexate
Methyldopa
Montelukast
Moxifloxacin
Naproxen
Niacin/Simvastatin
Nifedipine

Pantoprazole
Phenobarbital
Phenytoin
Pitavastatin
Pravastatin
Prednisolone
Pregabalin
Progesterone
Promethazine
Propafenone
Propranolol
Pyridoxine
Quinidine
Rabeprazole
Ramelteon
Ribavirin
Rosuvastatin
Scopolamine
Simvastatin
Tamsulosin
Temazepam
Testosterone
Tolterodine
Topiramate
Trazodone

Estradiol
Estradiol/Norethindrone
Estradiol/Norgestimate
Conjugated Estrogens/Medroxyprogesterone
Acetate
Estrogens/Methyltestosterone
Estropipate
Etidronate

Nortriptyline
Ofloxacin
Omeprazole
Omeprazole/Sodium
Bicarbonate
Oxcarbazepine
Oxybutynin

Tretinoin
Triazolam
Valproic Acid
Zaleplon
Zolmitriptan
Zolpidem
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Figure 1. Unadjusted and Adjusted Weighted Prevalence of U.S. Adults Aged 60+ Taking Medications with Cognitive Side
Effects, with 95% Confidence Intervals. Data Source: NHANES 1999-2000 to 2015-2016.
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Table 2. Top 25 Medications with the Largest Change in Utilization Among U.S. Adults Aged 60+ from 1999-2000 to 20152016. Data Source: NHANES 1999-2000 to 2015-2016.
Medications

Difference Between 20152016 and 1999-2000 (%)

Weighted Prevalence of Utilization Among U.S. Adults Aged 60+ (%)
20012002
7.20
10.67
10.35
4.48
2.56
0.00
1.98
1.24
0.00
2.52
1.32
0.94
1.60
1.17
4.78
0.00
0.75
1.31
1.34
1.04
1.34
0.25
0.57
1.47
0.00

20032004
8.09
13.38
3.18
2.44
3.46
0.51
2.18
2.54
3.56
2.22
2.96
1.57
1.73
1.57
4.23
0.00
1.65
1.20
1.28
1.04
2.36
0.05
0.63
1.54
0.10

20052006
10.74
16.06
1.60
4.34
1.60
0.87
1.84
2.61
4.53
1.90
2.25
1.50
3.60
2.19
3.92
0.16
1.84
1.34
0.53
0.96
2.08
0.36
0.42
1.55
0.12

20072008
13.45
14.44
2.12
7.23
2.46
2.47
2.79
2.56
4.75
1.27
2.04
1.90
3.16
1.45
2.86
0.27
1.65
2.01
1.11
0.41
2.63
0.21
0.81
1.70
0.10

20092010
18.94
9.40
1.33
9.29
2.74
3.24
3.12
3.03
3.96
1.86
2.02
2.43
4.04
0.62
2.13
1.11
1.88
1.69
0.76
0.02
1.02
0.44
1.06
1.15
0.48

20112012
18.68
9.63
1.07
9.95
4.82
3.37
3.60
3.53
2.81
1.18
1.60
1.27
3.25
1.03
1.77
0.34
1.39
0.81
0.88
0.00
1.88
0.28
1.78
1.68
0.24

20132014
14.97
15.05
0.83
12.44
5.60
6.77
4.67
4.34
2.94
0.85
3.69
1.91
3.15
0.78
1.95
0.99
3.02
2.70
0.63
0.00
3.30
0.72
0.77
1.41
0.35

20152016
14.35
14.99
0.60
10.43
7.12
4.54
4.34
4.43
3.28
0.83
2.58
2.97
2.90
0.43
2.07
1.70
2.47
2.29
0.44
0.00
2.89
1.23
1.44
0.92
0.90

1834
1872
No. observations
a: P-value is obtained from logistic regression.

1901

1570

2154

2073

1791

1841

1901

Survey cycles:
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Simvastatin
Atorvastatin
Conjugated estrogens
Omeprazole
Pravastatin
Rosuvastatin
Gabapentin
Tamsulosin
Esomeprazole
Nifedipine
Pantoprazole
Montelukast
Lovastatin
Propranolol
Diltiazem
Pregabalin
Zolpidem
Fluoxetine
Meclizine
Fluvastatin
Alprazolam
Cyclosporine
Clonazepam
Naproxen
Baclofen

19992000
5.81
7.36
7.08
4.48
2.45
0.00
0.55
0.76
0.00
3.38
0.05
0.44
0.98
2.30
3.89
0.00
1.01
0.86
1.87
1.33
1.63
0.00
0.30
1.96
0.02

8.54
7.63
-6.48
5.94
4.67
4.54
3.79
3.67
3.28
-2.55
2.53
2.53
1.92
-1.86
-1.82
1.70
1.47
1.44
-1.43
-1.33
1.26
1.23
1.14
-1.04
0.87

P-value for
Trend a

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.11
<0.001
<0.001
0.001
<0.001
0.001
<0.001
<0.001
0.003
0.01
0.05
0.01
0.02
0.02
0.001
0.83
0.003

Table 3. Descriptive Statistics of Cognitive Function Measurements and Covariates Among U.S. Adults Aged 60+. Data
Source: NHANES 2011-2012 and 2013-2014.
All
respondents

Number of medications with cognitive side effects taken
by respondents
None

1
medication
N=941

2
medications
N=526
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N=2,908
N=1,180
Cognitive assessment score, meanc (SD)c
Word learning and recall
6.3 (2.3)
6.4 (2.3)
6.2 (2.2)
6.1 (2.4)
Animal fluency
18.2 (5.7)
18.7 (6.0)
18.0 (5.1)
17.9 (5.8)
Digit symbol substitution
52.3 (16.8)
54.3 (17.0) 52.2 (16.0) 50.3 (17.0)
Whether score was more than 1 standard deviation (SD) below the mean, Nb (%)c
Word learning and recall
432 (11.4)
148 (9.3)
142 (12.1)
97 (14.0)
Animal fluency
691 (15.9)
266 (14.8) 210 (14.1) 138 (17.3)
Digit symbol substitution
846 (16.9)
323 (14.0) 250 (16.0) 179 (20.0)
Composite global cognitive function
Average standardized score
-0.0 (1.00)
0.1 (1.03) -0.0 (0.93) -0.1 (1.02)
of 3 tests, meanc (SD)c
Whether 2+ test scores were more than
543 (11.4)
200 (9.7)
155 (9.6)
128 (15.3)
one SD below the mean, Nb (%)c
Whether used medications WITH cognitive side effects last 30 days, N b (%)c
None
1180 (38.6)
1 medication
941 (34.7)
2 medications
526 (17.7)
3+ medications
261 (9.0)
Whether used medications WITHOUT cognitive side effects last 30 days, N b (%)c
None
557 (18.5)
430 (34.2)
95 (11.8)
23 (5.2)
1 medication
490 (17.8)
275 (25.8) 136 (15.4)
65 (11.5)
2 medications
470 (17.6)
179 (16.5) 175 (19.9)
96 (21.0)
3+ medications
1391 (46.1)
296 (23.5) 535 (52.9) 342 (62.4)
Whether used medications WITH cognitive side effects last 30 days and duration of use, N b (%)c
None
1180 (38.6)
N/A
N/A
N/A
Used 1+ medication, at most 1 year
298 (9.4)
N/A
218 (21.4)
63 (8.8)
Used 1+ medication, > 1 year
1430 (52.0)
N/A
723 (78.6) 463 (91.2)

P-value
a

3+
medications
N=261
6.0
17.3
47.5

(2.3)
(6.0)
(16.7)

0.04
0.03
< 0.001

45
77
94

(12.9)
(24.8)
(26.9)

0.08
0.02
< 0.001

-0.2

(1.00)

< 0.001

60

(18.2)

< 0.001

9
14
20
218

(3.1)
(5.3)
(6.4)
(85.2)

< 0.001
< 0.001
< 0.001
< 0.001

17
244

N/A
(4.5)
(95.5)

< 0.001
< 0.001
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Whether used medications WITHOUT cognitive side effects last 30 days and duration of use, N b (%)c
None
557 (18.5)
430 (34.2)
95 (11.8)
23 (5.2)
Used 1+ medication, at most 1 year
261 (8.2)
128 (11.6)
79 (7.3)
35 (4.1)
Used 1+ medication, > 1 year
2090 (73.3)
622 (54.2) 767 (80.9) 468 (90.7)
Whether used any prescription opioid last 30 days, Nb (%)c
254 (7.9)
39 (3.3)
78 (6.2)
63 (11.3)
Race & ethnicity, Nb (%)c
Non-Hispanic White
1380 (79.5)
494 (77.0) 468 (80.7) 271 (80.3)
Hispanic
550 (7.0)
266 (8.7)
150 (5.6)
91 (6.7)
Non-Hispanic Black
697 (8.4)
288 (8.7)
230 (8.6)
123 (8.2)
Non-Hispanic others
281 (5.0)
132 (5.6)
93 (5.1)
41 (4.8)
Gender, Nb (%)c
Women
1493 (54.1)
597 (53.7) 471 (50.6) 275 (56.8)
Men
1415 (45.9)
583 (46.3) 470 (49.4) 251 (43.2)
Age groups, Nb (%)c
60-69
1581 (56.8)
736 (62.0) 463 (53.4) 243 (50.6)
70-79
855 (29.3)
293 (26.6) 317 (32.1) 175 (32.2)
80+
472 (13.9)
151 (11.4) 161 (14.5) 108 (17.2)
Marital status, Nb (%)c
Married or partnered
1676 (65.1)
669 (62.7) 553 (67.3) 306 (65.7)
Widowed/divorced/separated
1063 (30.5)
426 (31.6) 337 (28.8) 198 (31.6)
Never married
165 (4.3)
83 (5.7)
49 (3.9)
22 (2.7)
Education, Nb (%)c
Less than high school
741 (15.7)
290 (13.0) 223 (15.5) 156 (20.1)
High school graduate
680 (22.1)
268 (20.5) 228 (23.9) 124 (22.5)
Some college
816 (31.6)
323 (31.9) 275 (31.5) 133 (29.5)
College graduate or above
668 (30.6)
297 (34.6) 215 (29.1) 112 (28.0)
Poverty, Nb (%)c
<100% poverty threshold
455 (9.4)
182 (9.4)
136 (8.7)
81 (9.3)
100-199%
794 (23.6)
319 (24.0) 247 (22.7) 159 (25.6)
200-299%
376 (15.3)
155 (14.2) 121 (14.5)
63 (17.2)
300-399%
323 (13.4)
115 (12.2) 121 (14.1)
58 (14.1)
400-499%
207 (10.5)
80 (10.1)
72 (10.9)
40 (10.3)
500%+
505 (27.8)
217 (30.1) 173 (29.0)
83 (23.5)
U.S. citizenship, Nb (%)c
Not U.S. citizen
198 (2.6)
134 (4.7)
41 (1.6)
15 (1.0)
U.S. citizen
2707 (97.4)
1044 (95.3) 899 (98.4) 511 (99.0)

9
19
233

(3.1)
(5.2)
(91.8)

< 0.001
< 0.001
< 0.001

74

(27.9)

< 0.001

147
43
56
15

(83.7)
(5.8)
(7.3)
(3.1)

0.09
0.03
0.76
0.22
0.03

150
111

(64.1)
(35.9)

139
70
52

(59.7)
(24.7)
(15.6)

0.004
0.03
0.04

148
102
11

(66.2)
(30.5)
(3.4)

0.22
0.71
0.12

72
60
85
44

(19.4)
(20.9)
(34.6)
(25.1)

0.05
0.41
0.71
0.03

56
69
37
29
15
32

(12.0)
(21.7)
(19.7)
(14.7)
(10.5)
(21.4)

0.18
0.55
0.41
0.63
0.98
0.13
< 0.001

8
253

(1.0)
(99.0)
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Had any health insurance, Nb (%)c
Yes
2666 (94.5)
1005 (90.5) 903 (97.0) 505 (97.7) 253 (96.0)
No
238 (5.5)
173 (9.5)
37 (3.0)
20 (2.3)
8 (4.0)
Had routine place for medical care, Nb (%)c
Yes
2739 (95.7)
1032 (91.0) 925 (98.3) 523 (99.6) 259 (98.7)
No
169 (4.3)
148 (9.0)
16 (1.7)
3 (0.4)
2 (1.3)
Smoking status, Nb (%)c
Never smoked
1432 (49.6)
633 (53.9) 454 (49.3) 242 (47.1) 103 (37.8)
Former smoker
1106 (39.3)
376 (34.4) 385 (40.9) 221 (40.8) 124 (51.8)
Current smoker
368 (11.0)
170 (11.8) 101 (9.9)
63 (12.1)
34 (10.4)
Health conditions, Nb (%)c
Asthma
401 (13.9)
124 (11.7) 122 (11.0)
80 (15.4)
75 (31.7)
Arthritis
1417 (49.9)
428 (37.9) 468 (48.1) 326 (65.2) 195 (78.1)
Cancer
589 (24.0)
203 (22.5) 209 (25.2) 116 (23.5)
61 (27.4)
Congestive heart failure
202 (6.7)
41 (3.5)
67 (6.5)
60 (12.4)
34 (10.0)
Coronary heart disease
261 (9.4)
35 (2.6)
100 (11.4)
84 (17.4)
42 (15.4)
Heart attack
244 (8.5)
45 (3.1)
88 (9.7)
83 (16.3)
28 (11.5)
Angina
157 (5.8)
26 (1.6)
57 (5.9)
45 (11.2)
29 (13.0)
Emphysema
106 (4.6)
23 (2.7)
34 (3.8)
26 (7.3)
23 (10.8)
Bronchitis
207 (7.7)
71 (6.7)
61 (6.6)
44 (11.0)
31 (9.4)
Stroke
200 (6.3)
53 (4.6)
69 (6.4)
50 (8.2)
28 (9.7)
Hypertension
1257 (39.4)
507 (39.6) 398 (39.7) 237 (37.7) 115 (40.5)
Diabetes
678 (20.4)
155 (10.2) 272 (25.5) 159 (28.1)
92 (28.7)
Sleep disorder
946 (34.5)
261 (23.1) 301 (33.3) 226 (44.8) 158 (67.9)
Depression (PHQ-9), Nb (%)c
Yes (score >= 10)
258 (7.2)
73 (4.5)
68 (5.9)
67 (10.4)
50 (17.7)
No (score < 10)
2602 (92.8)
1085 (95.5) 857 (94.1) 452 (89.6) 208 (82.3)
Obese, Nb (%)c
Yes (BMI >= 30)
1081 (37.7)
380 (32.9) 371 (37.1) 207 (42.4) 123 (51.8)
No (BMI < 30)
1778 (62.3)
779 (67.1) 560 (62.9) 307 (57.6) 132 (48.2)
a
: P-value indicates if means are significantly different across respondents who took none, one, two, or at least three medications with
cognitive side effects, based on logistics regression, survey weights, and 10 imputed datasets.
b
: Unweighted and non-imputed raw frequency. The numbers may not add up to the total due to missing data.
c

: Weighted estimates.

< 0.001

< 0.001

0.004
0.002
0.79
< 0.001
< 0.001
0.51
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
0.15
0.07
0.90
< 0.001
< 0.001
< 0.001

0.003

Table 4. Adjusted Linear Least-Squared Regressions of Standardized Cognitive Test Scores on Utilization of Medications with
Cognitive Side Effects for Adults Aged 60+. Data Source: NHANES 2011-2012 and 2013-2014.

Animal
Fluency

Digit Symbol
Substitution

Coef. (SE)

Coef. (SE)

Composite
measure
Average
standardized score
of three tests
Coef. (SE)

-0.04 (0.06)
0.01 (0.08)
-0.15 (0.09)

0.00 (0.06)
-0.03 (0.07)
-0.27** (0.07)

-0.02 (0.05)
-0.04 (0.05)
-0.22*** (0.06)

-0.10 (0.08)
-0.05 (0.08)
-0.07 (0.08)

-0.11 (0.08)
-0.07 (0.07)
-0.17* (0.06)

-0.07 (0.05)
-0.07 (0.05)
-0.10* (0.05)

-0.23*** (0.06)
-0.49*** (0.05)
-0.46*** (0.10)
0.00 (0.05)
-0.04*** (0.00)

-0.58*** (0.05)
-0.65*** (0.05)
-0.09 (0.07)
0.34*** (0.03)
-0.05*** (0.00)

-0.34*** (0.05)
-0.43*** (0.04)
-0.15* (0.05)
0.23*** (0.03)
-0.05*** (0.00)

0.02 (0.05)
-0.04 (0.13)

-0.02 (0.04)
-0.02 (0.10)

-0.02 (0.03)
-0.03 (0.09)

0.13* (0.05)
0.42*** (0.05)
0.72*** (0.08)

0.39*** (0.04)
0.61*** (0.04)
0.77*** (0.05)

0.19*** (0.04)
0.42*** (0.03)
0.59*** (0.06)

Standardized scores
Outcome:

Word learning
and recalls
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Coef. (SE)
Whether taking medications WITH cognitive side effects
None (reference)
1 medication
-0.02 (0.06)
2 medications
-0.10 (0.06)
3+ medications
-0.24* (0.09)
Whether taking medications WITHOUT cognitive side effects
None (reference)
1 medication
0.00 (0.07)
2 medications
-0.10 (0.06)
3+ medications
-0.07 (0.05)
Race & ethnicity
Non-Hispanic White (reference)
Hispanic
-0.20** (0.06)
Non-Hispanic Black
-0.15* (0.06)
Non-Hispanic others
0.11 (0.08)
Female
0.36*** (0.04)
Age (in years)
-0.05*** (0.00)
Marital status
Married or living with partner (reference)
Widowed, divorced, separated
-0.05 (0.04)
Never married
-0.02 (0.11)
Educational attainment
Less than high school (reference)
High school graduate
0.05 (0.07)
Some college or AA degree
0.23*** (0.06)
College graduate or above
0.26* (0.10)
Poverty
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<100% federal guideline (reference)
100-199%
200-299%
300-399%
400-499%
500%+
Not U.S. citizen
Has any health insurance
Has routine place for medical care
Smoking
Never smoked (reference)
Smoked 100+ cigarettes, not current smoker
Smoked 100+ cigarettes, current smoker
Depression (PHQ-9 >= 10)
Obese (BMI >= 30)
Year fixed effect (2013-2014 vs. 2011-2012)
Health conditions a
No. observations

-0.01 (0.06)
0.14 (0.08)
0.18* (0.08)
0.05 (0.09)
0.17 (0.09)
-0.21** (0.07)
0.09 (0.07)
0.17* (0.07)

0.05 (0.06)
0.05 (0.09)
0.08 (0.09)
0.13 (0.08)
0.13 (0.08)
-0.26* (0.11)
0.10 (0.12)
-0.01 (0.12)

0.10 (0.06)
0.24** (0.06)
0.41*** (0.07)
0.44*** (0.08)
0.38*** (0.08)
-0.46*** (0.07)
0.14 (0.08)
0.07 (0.08)

0.05 (0.05)
0.14* (0.05)
0.22*** (0.05)
0.21** (0.06)
0.23** (0.07)
-0.31*** (0.07)
0.11 (0.06)
0.08 (0.07)

0.05 (0.06)
-0.00 (0.07)
-0.10 (0.07)
0.09 (0.05)
0.33*** (0.06)
Yes
2,908

0.02 (0.05)
0.01 (0.09)
-0.25** (0.07)
0.07 (0.05)
-0.03 (0.05)
Yes
2,908

0.02 (0.05)
-0.15* (0.06)
-0.17 (0.09)
0.06 (0.04)
-0.04 (0.04)
Yes
2,908

0.03 (0.04)
-0.04 (0.05)
-0.17** (0.05)
0.07 (0.04)
0.09* (0.03)
Yes
2,908

Notes: a Health conditions include a set of binary indicators for whether a person has ever been told by a health professional
that they have asthma, arthritis, cancer, congestive health failure, coronary heart disease, heart attack, angina, emphysema,
bronchitis, stroke, diabetes, hypertension, and sleep disorder.
* p<0.05, ** p<0.01, *** p<0.001. Standard errors are in parentheses. All analyses were weighted using survey weights.

Table 5. Adjusted Logistic Regressions of Whether Cognitive Assessment Scores Are More Than One Standard Deviation
Below the Mean on Utilization of Medications with Cognitive Side Effects for Adults Aged 60+. Data Source: NHANES 20112012 and 2013-2014.
Whether scores are one standard deviation below the mean
Word learning
and recalls

Animal
Fluency

Digit Symbol
Substitution

OR (SE)
Whether taking medications WITH cognitive side effects
None (reference)
1 medication
1.38* (0.22)
2 medications
1.55* (0.28)
3+ medications
2.04* (0.64)
Whether taking medications WITHOUT cognitive side effects
None (reference)
1 medication
0.68 (0.15)
2 medications
1.08 (0.25)
3+ medications
0.83 (0.18)
Race & ethnicity
Non-Hispanic White (reference)
Hispanic
1.60* (0.35)
Non-Hispanic Black
1.39 (0.30)
Non-Hispanic others
0.69 (0.18)
Female
0.60* (0.11)
Age (in years)
1.13*** (0.02)
Marital status
Married or living with partner (reference)
Widowed, divorced, separated
0.93 (0.17)
Never married
1.20 (0.45)
Educational attainment
Less than high school (reference)

OR (SE)

OR (SE)

Composite
measure
Whether 2+ test
scores are more
than one standard
deviation below
the mean
OR (SE)

0.77 (0.12)
0.85 (0.13)
1.59 (0.39)

1.20 (0.18)
1.34 (0.29)
2.82*** (0.67)

0.88 (0.15)
1.38 (0.23)
2.10** (0.54)

1.10 (0.27)
0.98 (0.25)
1.41 (0.33)

0.98 (0.24)
0.61* (0.14)
1.22 (0.28)

0.92 (0.23)
0.82 (0.21)
1.28 (0.27)

1.62* (0.34)
3.23*** (0.55)
2.46*** (0.53)
0.88 (0.15)
1.09*** (0.01)

4.54*** (0.77)
5.18*** (0.83)
0.99 (0.19)
0.51*** (0.09)
1.15*** (0.01)

2.28** (0.56)
3.25*** (0.82)
1.18 (0.32)
0.70* (0.12)
1.14*** (0.02)

1.12 (0.18)
1.18 (0.34)

1.21 (0.22)
1.61 (0.51)

1.14 (0.14)
1.66 (0.60)

Outcome:

110

111

High school graduate
Some college or AA degree
College graduate or above
Poverty
<100% federal guideline (reference)
100-199%
200-299%
300-399%
400-499%
500%+
Not U.S. citizen
Has any health insurance
Has routine place for medical care
Smoking
Never smoked (reference)
Smoked 100+ cigarettes, not current smoker
Smoked 100+ cigarettes, current smoker
Depression (PHQ-9 >= 10)
Obese (BMI >= 30)
Year fixed effect (2013-2014 vs. 2011-2012)
Health conditions a
Number of observations

1.06 (0.21)
0.74 (0.13)
0.51** (0.12)

0.75 (0.12)
0.41*** (0.07)
0.34*** (0.07)

0.37*** (0.05)
0.20*** (0.03)
0.15*** (0.03)

0.61* (0.12)
0.29*** (0.06)
0.21*** (0.04)

0.88 (0.17)
0.73 (0.21)
0.51* (0.14)
0.58 (0.19)
0.65 (0.23)
1.37 (0.37)
0.90 (0.25)
0.55 (0.23)

0.93 (0.17)
0.91 (0.23)
0.67 (0.14)
0.65 (0.23)
0.60 (0.18)
1.82 (0.76)
1.07 (0.27)
0.70 (0.22)

0.91 (0.17)
0.58** (0.11)
0.25*** (0.06)
0.30*** (0.09)
0.39** (0.12)
3.75*** (0.89)
0.76 (0.19)
0.43* (0.13)

1.01 (0.21)
0.64 (0.18)
0.44* (0.13)
0.47* (0.17)
0.51 (0.23)
2.07* (0.55)
0.79 (0.20)
0.42* (0.14)

0.61* (0.11)
0.85 (0.22)
1.48 (0.34)
0.79 (0.13)
0.55*** (0.09)
Yes
2,908

1.00 (0.14)
1.11 (0.22)
1.87*** (0.29)
0.80 (0.12)
0.89 (0.09)
Yes
2,908

0.85 (0.12)
1.42 (0.38)
1.69* (0.42)
0.74 (0.14)
1.00 (0.14)
Yes
2,908

0.72* (0.11)
1.19 (0.25)
2.18*** (0.40)
0.72 (0.12)
0.81 (0.13)
Yes
2,908

Notes: a Health conditions include a set of binary indicators for whether a person has ever been told by a health professional
that they have asthma, arthritis, cancer, congestive health failure, coronary heart disease, heart attack, angina, emphysema,
bronchitis, stroke, diabetes, hypertension, and sleep disorder.
* p<0.05, ** p<0.01, *** p<0.001. Standard errors are in parentheses. All analyses were weighted using survey weights.

Table 6. Adjusted Linear and Logistic Regressions of Composite Cognitive Measures on Utilization of Medications with
Cognitive Side Effects and Duration of Using These Medications for Adults Aged 60+. Data Source: NHANES 2011-2012 and
2013-2014.
Global cognitive measures
Average standardized
Whether 2+ test
score of the 3 tests
scores are more than
one standard
deviation below the
mean
Coef. (SE)
OR (SE)
Whether taking medications WITH cognitive side effects and duration of using such medications
None (reference)
1 medication
At most one year
-0.00 (0.07)
0.81 (0.21)
Outcome:
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More than one year
2 medications
At most one year
More than one year
3+ medications
At most one year
More than one year

-0.01 (0.05)

0.87 (0.14)

-0.08 (0.09)

1.02 (0.38)

-0.02 (0.05)

1.35 (0.22)

-0.69** (0.25)

14.80** (11.38)

-0.19** (0.06)

1.79* (0.48)

Whether taking medications WITHOUT cognitive side effects and duration of using such medications
None (reference)
1 medication
At most one year
-0.07 (0.06)
0.98 (0.42)
More than one year
2 medications

-0.04 (0.06)

0.76 (0.20)

At most one year
More than one year
3+ medications
At most one year
More than one year

0.01 (0.08)

0.48 (0.25)

-0.06 (0.06)

0.79 (0.22)

0.04 (0.15)

1.37 (0.59)

-0.09 (0.04)

1.12 (0.24)

Number of observations
2,908
2,908
Notes: All analyses controlled for race, age, gender, marital status, educational attainment, poverty,
citizenship, health insurance coverage, whether the person has a routine place for medical care, smoking
status, binary indicator for each self-reported health condition (asthma, arthritis, cancer, congestive health
failure, coronary heart disease, heart attack, angina, emphysema, bronchitis, stroke, diabetes, hypertension,
and sleep disorder), depression (PHQ-9 scale), obesity (BMI of at least 30), and time trends.
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* p<0.05, ** p<0.01, *** p<0.001. Standard errors are in parentheses. All analyses were weighted using
survey weights.

Figure 2: Marginal Effects (with 95% Confidence Intervals) of Medications
With/Without Cognitive Side Effects on Global Cognitive Score by Age Among
Adults Aged 60+. Data Source: NHANES 2011-2012 and 2013-2014.

Notes: The marginal effects were calculated from the linear regression of the global cognitive score
(average of the three standardized cognitive assessment scores) on the interactions between medications
with/without cognitive side effects and age groups (60-64, 65-74, and 75+), while controlling for other
covariates such as race, gender, marital status, educational attainment, poverty, citizenship, health
insurance coverage, whether the person has a routine place for medical care, smoking status, binary
indicator for each self-reported health condition (asthma, arthritis, cancer, congestive health failure,
coronary heart disease, heart attack, angina, emphysema, bronchitis, stroke, diabetes, hypertension, and
sleep disorder), depression (PHQ-9 scale), obesity (BMI of at least 30), and time trends.
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Figure 3: Marginal Effects (with 95% Confidence Intervals) of Medications
With/Without Cognitive Side Effects on Global Cognitive Score by Gender Among
Adults Aged 60+. Data Source: NHANES 2011-2012 and 2013-2014.

Notes: The marginal effects were calculated from the linear regression of the global cognitive score
(average of the three standardized cognitive assessment scores) on the interactions between medications
with/without cognitive side effects and gender, while controlling for other covariates such as race, age,
marital status, educational attainment, poverty, citizenship, health insurance coverage, whether the person
has a routine place for medical care, smoking status, binary indicator for each self-reported health condition
(asthma, arthritis, cancer, congestive health failure, coronary heart disease, heart attack, angina,
emphysema, bronchitis, stroke, diabetes, hypertension, and sleep disorder), depression (PHQ-9 scale),
obesity (BMI of at least 30), and time trends.
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Figure 4: Marginal Effects (with 95% Confidence Intervals) of Medications
With/Without Cognitive Side Effects on Global Cognitive Score by Educational
Attainment Among Adults Aged 60+. Data Source: NHANES 2011-2012 and 20132014.

Notes: The marginal effects were calculated from the linear regression of the global cognitive score
(average of the three standardized cognitive assessment scores) on the interactions between medications
with/without cognitive side effects and educational attainment (high school graduate or lower and college
or higher), while controlling for other covariates such as race, gender, age, marital status, poverty,
citizenship, health insurance coverage, whether the person has a routine place for medical care, smoking
status, binary indicator for each self-reported health condition (asthma, arthritis, cancer, congestive health
failure, coronary heart disease, heart attack, angina, emphysema, bronchitis, stroke, diabetes, hypertension,
and sleep disorder), depression (PHQ-9 scale), obesity (BMI of at least 30), and time trends.
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Figure 5: Marginal Effects (with 95% Confidence Intervals) of Medications
With/Without Cognitive Side Effects on Global Cognitive Score by Race/Ethnicity
Among Adults Aged 60+. Data Source: NHANES 2011-2012 and 2013-2014.

Notes: The marginal effects were calculated from the linear regression of the global cognitive score
(average of the three standardized cognitive assessment scores) on the interactions between medications
with/without cognitive side effects and race/ethnicity (non-Hispanic whites, Hispanic, non-Hispanic blacks,
and non-Hispanic others), while controlling for other covariates such as age, gender, marital status,
educational attainment, poverty, citizenship, health insurance coverage, whether the person has a routine
place for medical care, smoking status, binary indicator for each self-reported health condition (asthma,
arthritis, cancer, congestive health failure, coronary heart disease, heart attack, angina, emphysema,
bronchitis, stroke, diabetes, hypertension, and sleep disorder), depression (PHQ-9 scale), obesity (BMI of at
least 30), and time trends.
NH: non-Hispanic.
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Figure 6: Marginal Effects (with 95% Confidence Intervals) of Medications
With/Without Cognitive Side Effects on Global Cognitive Score by Marital Status
Among Adults Aged 60+. Data Source: NHANES 2011-2012 and 2013-2014.

Notes: The marginal effects were calculated from the linear regression of the global cognitive score
(average of the three standardized cognitive assessment scores) on the interactions between medications
with/without cognitive side effects and marital status (married or cohabiting and not married or cohabiting),
while controlling for other covariates such as race, age, gender, educational attainment, poverty,
citizenship, health insurance coverage, whether the person has a routine place for medical care, smoking
status, binary indicator for each self-reported health condition (asthma, arthritis, cancer, congestive health
failure, coronary heart disease, heart attack, angina, emphysema, bronchitis, stroke, diabetes, hypertension,
and sleep disorder), depression (PHQ-9 scale), obesity (BMI of at least 30), and time trends.
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Table 7. Most Common Combinations of Medications with Cognitive Side Effects Among Adults Aged 60+ Who Consumed At
Least Three Medications with Cognitive Side Effects. Data Source: NHANES 1999-2000 to 2015-2016.
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Combinations of medications with cognitive side effects
Anticonvulsants - antihyperlipidemic agents - proton pump inhibitors
Omeprazole-gabapentin-simvastatin
Omeprazole-atorvastatin-gabapentin
Omeprazole-gabapentin-pravastatin
Pantoprazole-gabapentin-simvastatin
Pantoprazole-atorvastatin-gabapentin
Omeprazole-pregabalin-atorvastatin
Esomeprazole-gabapentin-simvastatin
Rabeprazole-atorvastatin-gabapentin
Antiadrenergic agents - antihyperlipidemic agents - proton pump inhibitors
Omeprazole-tamsulosin-simvastatin
Omeprazole-tamsulosin-atorvastatin
Pantoprazole-tamsulosin-simvastatin
Pantoprazole-tamsulosin-atorvastatin
Omeprazole-tamsulosin-pravastatin
Esomeprazole-tamsulosin-simvastatin
Esomeprazole-tamsulosin-rosuvastatin
Sex hormones - antihyperlipidemic agents - proton pump inhibitors
Conjugated estrogens-omeprazole-atorvastatin
Omeprazole-simvastatin-testosterone
Esomeprazole-estrogens methyltestosterone-atorvastatin
Conjugated estrogens-omeprazole-simvastatin
Conjugated estrogens-esomeprazole-atorvastatin
Anxiolytics, sedatives, and hypnotics - antihyperlipidemic agents - proton pump inhibitors
Alprazolam-omeprazole-simvastatin
Alprazolam-esomeprazole-atorvastatin
Esomeprazole-atorvastatin-zolpidem
Alprazolam-omeprazole-lovastatin
Alprazolam-omeprazole-atorvastatin
Antidepressants - antihyperlipidemic agents - proton pump inhibitors
Omeprazole-trazodone-simvastatin
Omeprazole-fluoxetine-simvastatin
Pantoprazole-fluoxetine-simvastatin

N
66

%
5.31

37

3.2

23

3.02

33

2.91

26

2.86
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Pantoprazole-amitriptyline-simvastatin
Pantoprazole-amitriptyline-fluoxetine-lovastatin
Anticonvulsants - antidepressants - antihyperlipidemic agents
26
2.02
Amitriptyline-diazepam-simvastatin
Amitriptyline-atorvastatin-gabapentin
Trazodone-gabapentin-simvastatin
Trazodone-diazepam-simvastatin
Clonazepam-fluoxetine-simvastatin
Antiarrhythmic agents - antihyperlipidemic agents - proton pump inhibitors
27
1.87
Diltiazem-omeprazole-simvastatin
Diltiazem-omeprazole-atorvastatin
Diltiazem-esomeprazole-simvastatin
Omeprazole-propranolol-simvastatin
Omeprazole-phenytoin-simvastatin
Leukotriene modifiers - antihyperlipidemic agents - proton pump inhibitors
16
1.59
Montelukast-omeprazole-atorvastatin
Montelukast-pantoprazole-simvastatin
Montelukast-omeprazole-simvastatin
Montelukast-omeprazole-rosuvastatin
Montelukast-rabeprazole-simvastatin
Antidepressants - antihyperlipidemic agents - anxiolytics, sedatives, and hypnotics
12
1.5
Alprazolam-amitriptyline-atorvastatin
Fluoxetine-rosuvastatin-zolpidem
Atorvastatin-fluoxetine-zolpidem
Amitriptyline-simvastatin-zaleplon
Amitriptyline-rosuvastatin-zolpidem
Analgesics - antihyperlipidemic agents - proton pump inhibitors
19
1.27
Omeprazole-ibuprofen-simvastatin
Esomeprazole-naproxen-atorvastatin
Pantoprazole-ibuprofen-simvastatin
Omeprazole-ibuprofen-pravastatin
Naproxen-omeprazole-rosuvastatin
Notes: Estimates were based on 1,153 adults aged 60+ who consumed at least three medications with cognitive side effects in the past 30 days using the
pooled NHANES data from 1999-2000 to 2015-2016. Frequency was unweighted while percentage was weighted using survey weights.

CHAPTER 4:
The Consequences of Medications with Insomnia, Depression, Anxiety, and Suicidal
Side Effects on U.S. Adults’ Mental Health and Use/Cost of Mental Health Services.

Objective: To document the trends in using medications with insomnia, depression,
anxiety, and suicidal side effects (“mental health side effect” hereafter) among U.S.
adults from 1996 to 2016, and to investigate the association between the use of these
medications and psychiatric distress and the use of mental health services.
Data source: Nationally representative sample of adults aged 25-84 from the Medical
Expenditure Panel Survey (MEPS) in 1996-2016 (N = 211,551). Psychological distress is
measured using the Kessler-6 scale.
Principal findings: In 2016, 50% U.S. adults used medications with mental health side
effects, an increase from 45% in 1996. Much of the growth was driven by increasing use
of medications with insomnia (relative increase of 66.8% between 1996 and 2016),
anxiety (relative increase of 80.7%), and suicidal (relative increase of 77.3%) side effects.
Compared to respondents who did not consume medications with mental health side
effects at the baseline, individuals who used three or more of these medications
simultaneously had higher odds of reporting psychological distress (OR = 1.859, p <
0.001), new mental disorders at follow-up (OR = 1.986, p < 0.001), having more visits
for mental disorders at follow-up (coefficient = 0.153, p < 0.001), having higher total
charges for mental disorders at follow-up (coefficient = 103.2, p < 0.001), and using
more psychotropic medications for treatments of mental disorders at follow-up (OR =
2.273, p < 0.001). In contrast, the use of medications without known mental health side
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effects was not associated with psychological distress or the use of mental health
services.
Conclusion: Concurrent use of medications with mental health side effects has increased
significantly since 1996. The use of these medications was associated with an increase in
psychological distress and the use/costs of mental health services. Since many
medications with mental health side effects are intended for treatments of physical
disease, these findings suggest that physicians may have neglected the role of mental
health when proving care to patients, and that any mental health side effects may be
subsequently treated by prescribing psychotropic medications. These findings also
suggest an important role of polypharmacy in amplifying the side effects of medications.
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Introduction
Mental disorders refers to a wide range of conditions that influence one’s mood, thinking,
and behaviors (Mental Health: A Report of the Surgeon General, 1999). It has been
estimated that more than one-fourth of American adults currently have at least one mental
disorder, and half will develop a mental disorder in their lifetime (Kessler, Berglund, et
al., 2005; Kessler, Chiu, et al., 2005). The most common mental disorders are anxiety
disorders (lifetime prevalence of 31.5%), mood disorders (28%), and impulse-control
disorders (25.4%) (Kessler, Berglund, et al., 2005). Although many U.S. adults have at
least one mental disorder, only 15.5% of them receive treatment (Thorpe et al., 2017).
While mental illness is a significant public health concern itself, its association with other
chronic and physical conditions has important implications for morbidity and mortality
(Chapman et al., 2005; Evans et al., 2005). In 2010, mental and substance disorders
accounted for 183.9 million disability-adjusted life years worldwide, 8.6 million years of
life lost, and 175.3 million years lost due to disability, and these burdens have increase by
37.6% since 1990 (Whiteford et al., 2013). Having a mental disorder is also associated
with increased health care utilization and costs. In 2013, mental disorders collectively
represented the costliest conditions in the United States, which totaled $201 billion in
health care expenditures (Roehrig, 2016). The total cost would be even higher when
adding lost earnings wages and disability benefits, which were estimated to be $193
billion and $24 billion in 2002, respectively (Insel, 2008).

Not only is the prevalence of mental disorders high and their consequences on morbidity
and mortality are alarming, the age of onset and cohort-differences in mental disorders
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are also of important concerns to policy makers. While the age of onset varies
significantly, many disorders first occur in young ages, from 11 years old for anxiety and
impulse-control disorders to 30 years old for mood disorders (Kessler, Berglund, et al.,
2005). In addition, adolescents and young adults are much more likely to experience
mood and anxiety disorders than older adults (Kessler et al., 2012). Since the early onset
of mental disorders is a significant predictor for late-life mental and cognitive illnesses
(Kraaij et al., 2002; Schoevers et al., 2005), a large number of young adults reporting
worrisome mental illness today implies that the future aging population may be mentally
sicker and require more health care resources than the current one.

Given the adverse health consequences and financial burdens of mental disorders on
individuals, families, and society, prior studies have investigated risk factors of mental
disorders to provide recommendations for public health interventions. Well-documented
risk factors include dietary factors, drugs and substance abuse, family background,
socioeconomic status, lifestyle, medical history and comorbidity, and trauma (Köhler et
al., 2018). However, little is known about the role of medications in mental health,
despite the growing popularity of medication use. In 2011-2012, almost 60% of
American adults used at least one prescription medication and 15% used at least five, an
increase from 51% and 8.2% in 1999-2000 respectively (Kantor et al., 2015). While
medication use is important and critical for disease management, a growing literature
suggests that many commonly used medications have adverse effects on mental disorders
(Gorton et al., 2016; Lavigne, 2016; Qato et al., 2018). For example, Qato et al. (2018)
used a nationally representative sample of U.S. adult from the National Health and
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Nutrition Examination Survey (NHANES) and found that the prevalence of using at least
one medication with depression as a potential side effect increased from 35% in 20052006 to 38.4% in 2013-2014. The prevalence of using at least three of such medications
increased even more: from 6.9% to 9.5% during the same period, or a relative increase of
almost 38%. The authors also found that respondents who consumed at least three
medications with depression side effects were 10.7 percentage points more likely to
report depressive symptoms, compared to nonusers.

Despite previous evidence on the adverse consequences of medications on mental health,
more research on this topic is warranted. Many prior studies only focused on a single
medication or a class of medication, and/or used a non-representative sample (Gorton et
al., 2016). As such, little is known about the adverse consequences of medications on
mental health at the population level and how the use of these medications has changed
over time. Qato et al. (2018) was the first to investigate trends in the prevalence of
medications with depression as a potential side effect at the population level and how the
use of these medications influenced depression among community-dwelling adults. While
the authors improved the existing literature by using a nationally representative sample of
U.S. adults and examining more than 200 medications that had depression as a potential
side effect, their study faced several limitations. First, their definition of medications with
depression side effect only included medications with depression, depressive disorder,
suicide, suicidal thoughts, suicidal ideation, or suicidal behavior listed as common or
serious adverse effects. There are medications with other potential side effects that may
also influence mental health, such as anxiety or insomnia (Baglioni et al., 2011). Second,
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the authors only investigated depression as an outcome without considering other
interrelated mental disorders such as anxiety or impulse-control disorders. Third, their
study used a cross-sectional survey, which might limit their ability to address reverse
causation and unobservable heterogeneity. Fourth, little is known about how the use of
these medications influenced respondents’ subsequent use of mental health services and
the costs associated with those services. Finally, although Qato et al. (2018) significantly
improved the previous literature by including in their study both younger adults and older
adults, they did not investigate whether the association between medications with
depression side effect and concurrent depression differed by age. There are conflicting
theories and evidence on whether such association is larger among older adults or among
young adults. On the one hand, older adults are expected to experience more adverse drug
reactions due to decreasing hepatic metabolism and renal clearance (Leon, 2011; Shi &
Klotz, 2011), having more chronic conditions (Ward & Schiller, 2013), and consuming
multiple medications simultaneously (Kantor et al., 2015). On the other hand, the
selection of young and healthy adults into taking multiple medications with depression as
a potential side effect may signal an early onset of chronic conditions that can be more
debilitating to health than those that occur at older ages (Huang et al., 2010). The extent
to which theory dominates the other explains for the age-differences in adverse drug
reactions.

The present study seeks to improve the existing literature by using a longitudinal national
representative survey from 1996 to 2016 and examining a comprehensive list of
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medications on the U.S. market that have mental health side effects. The study has four
aims:
1. What is the trend in the prevalence of using medications with insomnia,
depression, anxiety, or suicidal side effects (“mental health side effects”)
among community-dwelling adults aged 25-84 from 1996 to 2016?
2. What is the association between the use of medications with mental health
side effects and subsequent nonspecific psychological distress and mental
disorders?
3. What is the association between medications with mental health side effects
and subsequent use of mental health services and total costs associated with
these services?
4. How does the relationship differ by age?

Methods
Data comes from the 2004-2015 Medical Expenditure Panel Survey (MEPS). Although
the MEPS has been fielded every single year from 1996 to 2016, I selected the 2004-2015
surveys because nonspecific psychological distress was not collected until 2004.
Moreover, data on utilization and cost of mental health services in 2016 are not yet
available due to the replacement of the International Classification of Diseases (ICD)-9
with the ICD-10. However, when assessing trends in the use of medications with mental
health side effects, I used the full sample from 1996 to 2016.
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The MEPS is a nationally representative and longitudinal survey of the civilian noninstitutionalized U.S. population, drawn from a subsample of households that participated
in the prior year’s National Health Interview Survey (NHIS). Both MEPS and NHIS
oversample Black, Hispanic, Asian, and low-income respondents to improve the
precision of estimates for these subgroups. The overall MEPS response rate, after
accounting for nonresponse rate from the NHIS, ranges from 46% to 71%.

MEPS respondents enter the survey annually as members of a unique survey panel. For a
graphical illustration of the MEPS study design, please refer to the IPUMS-MEPS’s user
guideline: https://meps.ipums.org/meps/userNotes_MEPS_panel_design.shtml. MEPS
then interviews participants of each panel five times over two calendar years. During
each interview, one informant who is most knowledgeable about health and health care
use in the household will typically report for all household members. The average recall
period for each interview round is five months. For each calendar year, data from
interview rounds 1, 2, and 3 are included for individuals in the first year of their panel,
and data from interview rounds 3, 4, and 5 are included for individuals in the second year
of their panel. Collectively, respondents from two overlapping panels in each calendar
year provide nationally representative estimates of their health status, socio-demographic
characteristics, chronic conditions, and medication use. Note that MEPS data in most
years are not independent of one another because most respondents are in the survey for
two consecutive years. However, it is still valid to pool data from multiple calendar years
despite this lack of independence because MEPS was designed to be nationally
representative in each calendar year, provided that the survey weight and the variance
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structure are properly specified in all analyses (Agency for Healthcare Research and
Quality, 2019).

Following the completion of the household interview, MEPS interviewers asked
respondents for permission to contact their medical providers (i.e. physicians, hospitals,
home health agencies, and pharmacies) to confirm information that the respondents
reported8. Collected information included the date of visits, diagnoses and procedures,
charges, payments, detailed information on medications, dates when prescriptions were
filled, sources and amounts of payments. Collected information was only used to impute
missing data and improve the precision of estimates. Response rates vary by the types of
medical providers, but typically range from 75% to 85%. For this reason, MEPS is one of
the most comprehensive data sources on national-level medical utilization and
expenditures, as well as individual characteristics such as socio-demographic
characteristics, health behaviors, and health conditions.

This study used a merged sample of respondents from 2004 to 2015, which combined the
full year consolidated files with the medical condition files, the event files, and the
prescribed medicine files. Information on end-of-the-year socio-demographic

8

Note that MEPS only contacted medical providers to confirm information reported by respondents, and in

many cases, asked for more information about an event reported by a respondent (i.e. cost or diagnosis for a
reported doctor visit). Additional events reported by medical providers but not by the respondents were not
included in the data to avoid the discrepancy in the number of events between respondents who gave
permission to contact their medical providers and those who did not.
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characteristics was obtained from the full year consolidated files, while round-specific
information on the use of medications, self-reported chronic conditions, and the use and
costs of health services came from the remaining files. I first selected respondents aged
25 to 84 (N = 248,741). Respondents aged 85 and older were dropped because MEPS
censored age at 85, and unobservable characteristics of the oldest population might be
systematically different from those of the general population. I excluded respondents who
were under 25 years of age because all analysis models controlled for educational
attainment. Restricting the sample to those aged 25 and older allowed respondents to
complete their educational attainment. After excluding 33,886 respondents without
mental health assessment9, 3,304 respondents with missing information on any of the
covariates described shortly below, the final sample included 211,551 respondents. In a
sensitivity analysis not reported here, I used multiple imputation with chained equations
to handle missing data, but the interpretation of the results did not change because only
1.5% of the sample had missing data on covariates. The results in this paper come from
the analytic sample without missing data.

Nonspecific psychological distress. MEPS measures nonspecific psychological distress
over a 30-day recall period using a five point Likert-type scale developed by Ronald C.
Kessler and is widely known as the Kessler 6 Scale (K6) (Kessler et al., 2002, 2003). The
K6 scale has been successfully implemented in major epidemiological studies in various

9

Respondents were not eligible for the mental health assessment if there was no record of the person in the

interview round, if they were deceased or institutionalized, if they had moved out of the U.S. or to a
military facility, if their disposition status was inapplicable.
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ethnic and cultural contexts to investigate six manifestations of nonspecific psychological
distress (Furukawa et al., 2003; Kessler et al., 2003, 2010). Interviewers asked
respondents for the frequency with which, in the past four weeks, they felt so sad that
nothing could cheer them up, felt nervous, felt restless or fidgety, felt hopeless, felt that
everything was an effort, and felt worthless. Acceptable responses for all six questions
fell into five categories, ranging from “none of the time,” “a little of the time,” “some of
the time,” “most of the time,” to “all of the time,” and were assigned a corresponding
value from 0 to 4. The summed responses of the K6 scale therefore ranges from 0 to 24,
where 0 represents the lowest level of nonspecific psychological distress, and 24
indicates the highest level of nonspecific psychological distress.

I classified respondents as likely having major nonspecific psychological distress if their
score was 13 or higher. This cutoff point has been proven to have a classification
accuracy of 0.92 for serious mental illness, as defined by the Diagnostic and Statistical
Manual of Mental Disorders 4th Edition (Kessler et al., 2003). I also used each individual
K6 question as an outcome variable to investigate which aspect of nonspecific
psychological distress was driving the result observed in the composite K6 score. For
each question, I created a binary variable that took a value of 1 if a person reported the
frequency of “most of the time” or “all of the time.” (scores 3 and 4).

Self-reported mental disorders. To supplement the analysis using the K6 scale, I used
self-reported information on whether a respondent had any mental disorders as a
secondary outcome. These self-reported measures have been previously used to study the
prevalence of mental disorders and health seeking behaviors (Olfson et al., 2016; Thorpe
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et al., 2017). Medical condition data were collected from household respondents during
each round. However, only conditions indicated as being “current” were included in the
medical condition files. MEPS defines a condition as being “current” if the person was
currently experiencing the condition or if the condition was associated with a specific
event that occurred during the reference period of the interview round (i.e. outpatient
visit, inpatient visit, emergency department visit, office-based visit, prescription
medication). Each medical condition was recorded as verbatim text, which was then
coded to fully specified ICD-9 by professional coders. All ICD-9 codes were verified,
and the error rates did not exceed 2.5% for any coders. ICD-9 condition codes were
further aggregated into mutually-exclusive clinical classification codes (Elixhauser et al.,
1998). Most ICD-9 conditions within each clinical classification code are clinically
homogenous. Mental disorders in MEPS are coded from 650 to 67010. Using these
clinical classification codes, I created an indicator for whether a person experienced any
new mental disorders, either treated or untreated, in each interview round relative to the
previous round.

Use and costs of mental health services were measured by linking the medical condition
files to the event files. Most conditions recorded in the medical condition files
corresponded to at least one event (i.e. outpatient visit, inpatient visit, emergency
department visit, office-based visit, prescription medications used) in the event files.
Each event included the following information: date of the visit, whether the respondent

10

See a list of all clinical classification codes here:

https://meps.ahrq.gov/data_stats/download_data/pufs/h154/h154app3.html
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saw a doctor, type of care received, type of services received, whether medications were
prescribed during the visit, flat fee charges, imputed sources of payments, total payments
and total charges. Using detailed information at the visit-level, I calculated the total
number of visits in each round regardless of the place of service (outpatient, inpatient,
emergency department, office-based), and the total charges (including charges for visits
and prescription medications) for all mental disorders that a respondent reported in the
medical condition files. I adjusted all charges to reflect 2016 dollars.

Previous studies have assessed the validity of events reported in MEPS. While inpatient
stays and the number of inpatient hospital nights were accurately reported in MEPS
compared to the linked Medicare data (Zuvekas & Olin, 2009b), office visits, emergency
department visits, and Medicare expenditure are underreported by 12% to 34% (Zuvekas
& Olin, 2009a). Regardless, underreporting of utilization and costs for certain events was
unlikely to affect behavioral analyses because the magnitude of the misreport was not
different across subgroups (Zuvekas & Olin, 2009a).

Medications. MEPS documents the use of prescription medications, nonprescription
medications, and dietary supplements for each interview round. The prescription
medication files contain information11 on the name and national drug code of each
medication; quantity, form, strength, and the number of days supplied; Multum
therapeutic drug classes; the condition(s) that each medication was intended for, the date
when respondents started using each medication; and the total cost of each medication.

11

Information was either self-reported or imputed after MEPS contacted the respondents’ pharmacy.
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Interviewers asked respondents to report all medications, including all refills, that they
consumed since the last interview round. Interviewers then entered the complete
medication names into a computer, which were automatically matched with an existing
drug in the database. The drug database used for the match was obtained from Lexicon
Plus, a proprietary database of Cerner Multum that provided, on an annual basis, a
comprehensive list of all prescription and some non-prescription medications available in
the U.S. market.

The quality of prescription medication data has been independently assessed in prior
studies. Hill, Zuvekas, & Zodet (2011) linked MEPS prescription drug database to
Medicare Part D claim data and found that while the number of medications and total
expenditures were generally in accordance with those in claim data, respondents had the
tendency of underreporting different types of medication consumed and overreporting the
number of refills for each medication. Despite such discrepancy, these authors suggested
that behavioral analyses were unlikely to be affected because misreport did not vary
across socio-demographic subgroups. In this study, I removed all medication refills due
to overreporting, and treat each distinct reported medication in each interview round as a
course of treatment. I also created a series of binary variables that indicated whether
respondents used any antidepressants; anxiolytics, sedatives, hypnotics; anticonvulsants;
and antipsychotics for treatment of any mental disorders (clinical classification codes
650-670).

Medications with potential mental health side effects. Medications with depression or
suicide as potential side effects were obtained from Qato et al. (2018). Similar to Qato et
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al. (2018), I used the Micromedex database to identify medications with insomnia and
anxiety side effects. Prior studies have independently established the accuracy and
reliability of adverse effects listed in Micromedex (Cheng et al., 2010). The database is
based on several sources: the U.S. Food and Drug Administration’s black box warnings,
MedWatch, post-marketing surveillance, clinical trials, and comprehensive literature
reviews. In this study, medications with insomnia side effects were identified using a
keyword search including the following words: insomnia and sleep disorder; medications
with anxiety side effects were detected using the following search words: anxiety,
anxious, and nervous. Consistent with the study by Qato et al. (2018), I classified
medications as having insomnia and anxiety as potential side effects if their adverse
effects are listed as common or serious in Micromedex. Note that the lists of medications
with different mental health side effects are not mutually exclusive. A medication with
insomnia as a side effect may also have depression as a potential side effect.

I identified 98 medications with insomnia side effect, 124 medications with depression
side effect, 41 medications with anxiety side effect, and 107 medications with suicidal
side effect (Tables 1-4). It is important to note that these numbers do not represent the
full set of medications with mental health side effects in the U.S market, but rather the
number of medications with mental health side effects consumed by respondents aged 2584 in the analytic sample from 1996 to 2016. Using the reported number of medications
with mental health side effects, I constructed a variable that indicated whether during the
recall period of an interview round (usually five months on average), a respondent took
no medications with any mental health side effects (the reference category in the
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regression models), one medication, two medications, or at least three medications with
any mental health side effects.

-Insert Tables 1 to 4 About Here-

Chronic conditions. Many medications with mental health side effects are intended for
treatment of chronic conditions that have been found to be correlated with the onset of
depression (Köhler et al., 2018). I controlled in all analysis models the number of selfreported chronic conditions that the person was currently experiencing during interview
round, either treated or untreated. Using the definition of chronic conditions from
Goodman et al. (2013), I classified the following conditions as being chronic:
hypertension, congestive heart failure, coronary artery disease, cardiac arrhythmias,
hyperlipidemia, stroke, arthritis, asthma, cancer, chronic kidney disease, chronic
obstructive pulmonary disease, dementia (Alzheimer’s, and other senile dementias),
diabetes, hepatitis, human immunodeficiency virus (HIV), and osteoporosis. Using the
number of self-reported chronic conditions, I created a variable that represented whether
a respondent had no chronic conditions (the reference category), one conditions, two
conditions, or at least three conditions during a round of interview. Controlling for each
individual chronic condition as a binary variable did not alter the interpretation of the
results.

Pain. A growing number of studies has found that pain and depressive symptoms usually
coexist and share similar biological pathways and neurotransmitters (Bair et al., 2003).
65% of depressive patients experience some type of pain, and up to 85% of patients with
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pain also report depressive symptoms (Bair et al., 2003). In addition, pain is one of the
leading reasons for seeking medical care (Komaroff, 1990; Kroenke, 2001), which may
increase patients’ exposure to medication use. MEPS respondents reported the frequency
that pain interfered with their work in the last four weeks, including both work outside of
the home and housework. Possible responses included “none of the time,” “a little of the
time,” “some of the time,” “most of the time,” and “all of the time.” I created a binary
variable that indicated whether the person experienced any pain, regardless of the
reported frequency.

Other covariates. In all models, I controlled for socio-demographic variables that were
potentially associated with one’s depression and the use of medications such as race
(non-Hispanic white: reference category, non-Hispanic black, Hispanic, or others); age
and age squared; gender; marital status (married or living with a partner: reference
category, widowed/divorced/separated, or never married); educational attainment (less
than high school: reference category, high school graduate, college or higher); whether
the person’s household income was under the federal poverty threshold; whether the
person has private insurance, public insurance (i.e. Medicaid or State Children's Health
Insurance Program), Medicare, and/or any other insurance; and whether the person is
obese (BMI is at least 30). I also included a dummy variable for each year and each
region (Northeast, Midwest, South, West) to account for any secular trends in the
outcomes.
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To adjust for complex and multistage sampling, I calculated weighted prevalence
estimate of medications with mental health side effects in each year using Taylor
linearization methods. I used logistic regression to assess the statistical significance of
trends of medications with mental health side effects. In each calendar year, I used
information on the reported use of medications with mental health side effects in round 1
(or 3) to predict subsequent mental health and use/costs of mental health services in
round 2 (or 4) for respondents in the first (or second) year of their panel. Rounds 1 and 3
will be referred to as the baseline, while rounds 2 and 4 will be referred to as the followup hereafter. Weighted multivariate linear least-squared and logistic regression models
were used to investigate the association between the use of medications with mental
health side effects at baseline and mental distress (K6) at follow-up, whether a respondent
reported any new mental disorders at follow-up, whether a respondent had more visits for
mental health disorders at follow-up compared to baseline, and whether a respondents
used more psychotropic medications for treatment of mental disorders at follow-up
compared to baseline. Weighted two-part model was used to estimate the relationship
between the use of medications with mental health side effects at the baseline and
changes in the number of visits and total charges for mental disorders between the
baseline and follow-up due to their zero-heavy count data. The first part of the model
estimated the probability of having a non-zero and non-negative12 value using a logit
regression. The second part estimated changes in the number of visits/charges associated

12

Some respondents had a negative value because they had fewer visits or charges at the follow-up

compared to at the baseline.
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with mental disorders conditional on having any using a Gamma generalized linear model
with log link.

For analysis of the K6 and each element in the K6 scale, I controlled for whether a person
had any mental disorders at the baseline to avoid reverse causation and reduce the threat
of spuriousness, using an indicator for whether a person reported having any mental
disorders (treated or untreated) or used any psychotropic medications for treatment of
mental disorders such as antidepressants, anxiolytics, sedatives, hypnotics,
anticonvulsants, and antipsychotics. This is because the K6 was only collected in rounds
2 and 4 for each respondent; therefore, no information was available at the baseline
(rounds 1 and 3). Regardless, self-reported mental disorders and the use of medications
for treatment of mental disorders are relatively reasonable indicators for psychological
distress at the baseline. I also controlled for changes in the number of medications with
mental health side effects between the baseline and follow-up (decline in the number of
medications with such side effects or no changes: reference category, an increase of one,
two, or three of such medications). As a test for sensitivity, I included in all models the
use of medications without any of known mental health side effects and changes in the
reported number of these medications between the baseline and follow-up. If the
association between medications with mental health side effects and the outcome was
driven by any unobservable heterogeneity in health, the relationship between medications
without mental health side effects and the outcome should be equally significant as that
between medications with mental health side effects and the outcome. Lastly, all models
controlled for socio-economic characteristics, chronic conditions, pain, and health
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insurance status as described above, as well as a series of dummy variables for year and
region fixed effects.

To assess whether the association between medications with mental health side effects
and mental health outcomes varied by age, I included in the analytic models an
interaction term between the categories of medications with/without mental health side
effects and a categorical variable for age (25-44, 45-64, and 65-84). I then computed the
marginal effects of medications with and without mental health side effects on the
outcomes for each age group, while holding all other covariates constant.

In several sensitivity analyses, I repeated the main analyses for three sub-samples:
respondents with at most one self-reported chronic condition at the baseline, respondents
without any self-reported mental disorders (either treated or untreated) at baseline, and
respondents with at least one self-reported mental disorder at baseline. The first subsample included relatively healthy respondents without comorbidity, while the second
sub-sample consisted of respondents without any existing mental disorders at baseline. If
the association between medications with mental health side effects and mental health
was not mainly driven by comorbidity and existing mental disorders, I expect to observe
similar results in the first and second sub-samples compared to those in the main analysis.
I repeated the same analyses for the third sub-sample of respondents with pre-existing
mental disorders in order to investigate whether the use of medications with mental
health side effects worsened mental health for these respondents (i.e. developing new
mental disorders or having more office visits at the follow-up).
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Results
Figure 1 presents unadjusted (Panel A) and age/sex adjusted (Panel B) trends in the use
of medications with any mental health side effects from 1996 to 2016 for U.S. adults
aged 25-84. In Panel A, 55% of U.S. adults aged 25-84 in 1996 did not use medications
with any mental health side effects. In 2016, this prevalence dropped to 49.5% (p <
0.001). Further investigation suggests that while the prevalence of using one or two of
these medications has been relatively stable or even slightly declining over the same
period, the reported use of three or more medications with mental health side effects has
increased from 21.9% to 29.8% (p < 0.001, or a relative increase of 36.2%). The increase
in concurrent use of at least three of these medications could be in part due to factors
such as the introduction of new medications on the market, the increase in chronic
conditions and comorbidity in the population (Ward & Schiller, 2013), or the growing
availability of over-the-counter medications with mental health side effects (Qato et al.,
2018).

-Insert Figure 1 About Here-

Figure 2 examines the unadjusted and age/sex adjusted prevalence of U.S. adults aged
25-84 who used at least one medication with insomnia, depression, anxiety, and suicidal
side effects, respectively. Although more adults who used medications with depression as
a potential side effect than medications with any other side effects in every single year,
the prevalence of using medications with depression side effect was relatively stagnant
between 1996 and 2016 (37.3% in 2016 vs. 36.5% in 1996, p = 0.40). In contrast, the use
of at least one medication with insomnia, anxiety, and suicidal side effects has been
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increasing between 1996 and 2016 by 11.3 percentage points (p < 0.001, relative increase
of 66.8%), 6.3 percentage points (p < 0.01, relative increase of 80.7%), and 11.2
percentage points (p < 0.001, relative increase of 77.3%), respectively.

-Insert Figure 2 About Here-

Table 5 presents descriptive statistics of the outcomes and the control variables for the
full analytic sample, and by the number of medications with potential mental health side
effects. Overall, 68.6% of respondents reported not using medications with mental health
side effects, while 17.7%, 7.5%, and 6.3% reported using one, two, and at least three of
those medications. Between the baseline and follow-up, 77.3% of respondents consumed
at most the same number of medications with mental health side effects, while 14.4%,
5.1%, and 3.2% increased their consumption by one, two, or three of such medications,
respectively.

-Insert Table 5 About Here-

Respondents who used at least three medications with mental health side effects were
much more likely to report psychological distress (K6), mental disorders, having at least
one visit associated with such mental disorder(s), and more visits and higher costs
associated with mental disorders between the baseline and follow-up. For example,
among respondents who reported using at least three medications with mental health side
effects at the baseline, 19.6% likely had mental distress at follow-up, 9.8% had at least
one new mental disorder at follow-up, 18.7% had more visits for mental disorders at
follow-up compared to at the baseline, and 12.5% used more psychotropic medications at
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follow-up compared to at the baseline, compared to 3.3%, 4.0%, 2.2%, and 3.6% among
respondents who did not use such medications, respectively (p-value < 0.001 for all
comparisons). Additionally, individuals who reported using at least three medications
with mental health side effects on average had an increase of 0.63 visits and $242 in total
charges for mental disorders between the baseline and follow-up (p-value < 0.001 for
both comparisons) compared to individuals who did not use these medications. Note that
there is a dose-response relationship, such that the prevalence of psychological distress
and the use/costs of mental health services increased for every additional medication
consumed that have mental health side effects.

I also found that respondents who used more medications with mental health side effects
tended to be white; aged 65 to 84; married or cohabiting with a partner; divorced,
widowed, or separated; high school graduated; low-income; publicly insured; obese; had
any pain that interfered with work or housework; and were more chronically ill (p <
0.001 for all variables). Respondents who used more medications with mental health side
effects were systematically sicker than non-users. Some of the most common chronic
conditions among individuals who consumed at least three medications with mental
health side effects were hypertension (56.4%), hyperlipidemia (46.5%), arthritis (25.2%),
chronic obstructive pulmonary disease (17.9%), and diabetes (23.8%).

Table 6 presents evidence for the association between the use of medications with mental
health side effects and psychological distress (K6), each individual question in the K6
scale, and whether a respondent reported any new mental disorder at follow-up relative to
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the baseline. In column (1), compared to non-users, those who used one, two, or at least
three of those medications with mental health side effects at the baseline reported a
higher K6 score by 0.113 (p < 0.001), 0.224 (p < 0.001), and 1.318 (p < 0.001) points,
respectively. A similar pattern was observed when investigating psychological distress
(K6 score of at least 13) in column (2). Consuming at least three medications with mental
health side effects was associated with an increase in the odds of psychological distress
by 1.859 times (p < 0.001). Further investigation into each individual question in the K6
scale in columns (3) to (8) revealed that using these medications was associated with all
aspects of psychological distress. Finally, medications with mental health side effect are
also significantly associated with the likelihood of reporting a new mental disorder during
follow-up (column 9). The odds of reporting a new mental disorder increased by almost
two times when using three or more of these medications when compared to not using
any (p < 0.001). In all analyses, I observed a dose-response such that the incidence of
psychological distress or self-reported mental disorder increased with every additional
medication with mental health side effects.

-Insert Table 6 About Here-

If the association between medications with mental health side effects and mental health
was driven by unobserved heterogeneity in health, then one should expect to observe
similar results for medications without these side effects. I found that the use of
medications without known mental health side effects was generally not associated with
worsened mental health, and in a few cases, such use was even beneficial to mental
health. There was an exception for the outcome of whether the respondent felt that
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everything was an effort (column 3 of Table 6). Using at least three medications without
known mental health side effects was associated with an increase in the odds of feeling
that everything was an effort by 1.132 times (p < 0.05). However, the magnitude of the
coefficient for medications without known mental health side effects was significantly
smaller than that for medications with these side effects. These findings suggest that the
use of medications with mental health side effects at the baseline was associated with
worsened mental health at follow-up. These associations, however, were unlikely to have
been driven by unobservable heterogeneity in health.

In Table 7, I demonstrate the association between the use of medications with mental
health side effects at the baseline and changes in use and costs of mental health services
between the baseline and follow-up. In columns (1) to (3), compared to nonusers, those
who used at least three medications with mental health side effects reported higher odds
(OR = 2.346, p < 0.001) of having at least one additional visit for mental disorders at
follow-up relative to baseline, 0.152 more visits between the baseline and follow-up for
mental disorders (p < 0.001), and an increase of more than $100 in total charges between
baseline and follow-up for visits with mental health diagnoses (p < 0.001). I also found
that respondents used more psychotropic medications for treatment of mental disorders at
follow-up compared to at the baseline as a result of consuming medications with mental
health side effects. For example, the odds of using at least one additional antidepressant;
anxiolytics, sedatives, or hypnotics; anticonvulsants; and antipsychotics at follow-up
relative to baseline increased by more than two times for individuals consuming at least
three medications with mental health side effects compared to nonusers (columns 4 to 8
of Table 7). The dose-response was observed for all outcomes. Similar to results in Table
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6, I found that the associations between medications without known mental health side
effects and the use/costs of mental health services were generally trivial and, in many
cases, they were associated with a decline in utilization and costs.

-Insert Table 7 About Here-

To ensure that the associations between medications with mental health side effects and
mental health outcomes were not driven by comorbidity or individuals who already had
mental disorders at the baseline, I repeated all analyses for three sub-samples:
respondents with at most one chronic condition at baseline, respondents without any
preexisting mental disorders at baseline, and respondents with at least one pre-existing
mental disorder at baseline.

I observed similar results among respondents with at most one chronic condition at the
baseline in Tables 8 and 9. In some cases, the associations between medications with
mental health side effects and mental health outcomes were even slightly larger than
those of the full analytic sample in Tables 6 and 7. This implies that the results were
applicable to relatively more-healthy respondents and were not driven by comorbidity. I
also found similar patterns among respondents with and without any preexisting mental
disorders at the baseline (Tables 10 to 13). However, the associations between
medications with mental health side effects and mental health outcomes were much larger
among respondents with preexisting mental disorders at the baseline compared to those
without these preexisting conditions. As such, the results observed in the full analytic
sample were likely driven by those with preexisting mental disorders. Regardless, mental
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health side effects were likely associated with an onset of mental disorders among those
without these disorders at the baseline and worsened mental health among those who
already had these disorders.

-Insert Tables 8 to 13 About Here-

In Figures 3 to 9, I present the marginal effect of medications with mental health side
effects on mental health and use/costs of mental health services by age groups (25-44, 4564, and 65-84). Figures 3 and 4 demonstrate the age-profile of the association between
medications with mental health side effects and nonspecific psychological distress (K6
score and whether the K6 score is at least 13). Among respondents aged 25-44,
medications with mental health side effects had significantly negative consequences on
mental health, regardless of the number of doses taken. For middle-aged and older adults,
the association between medications with mental health side effects and nonspecific
psychological distress did not become statistically significant until the respondent
consumed at least three of those medications. A similar finding has been documented in
Huang et al. (2010). The declining association between medications with mental health
side effects and mental health across age groups is worth noting. Among respondents
who consumed two or at least three medications with mental health side effects, young
adults aged 25-44 were more likely to experience psychological distress than middleaged and older adults.

-Insert Figures 3 and 4 About Here-
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In Figures 5 to 7, I present the association between medications with mental health side
effects and whether a respondent developed at least one new mental disorder at followup, whether a respondent had more visits for mental disorders at follow-up, and whether a
respondent used more psychotropic medications13 for treatments of mental disorders at
follow-up compared to at the baseline. Across all age groups, respondents were much
more likely to develop a new mental disorder, had more visits, and used more
psychotropic medications for mental disorders when taking at least one medication with
side effect, relative to nonusers. The association increased with every additional
medication taken. The age differences in such associations were less significant than
those in Figures 3 and 4. Medications with mental health side effects seemed to have
relatively equal impacts on respondents regardless of their age.

-Insert Figures 5 to 7 About Here-

Finally, Figures 8 and 9 illustrate the marginal effects of medications with mental health
side effects on changes in the number of visits and total costs for visits with mental
disorder diagnoses between follow-up and baseline. Using medications with mental
health side effects at the baseline was associated with an increase in the number of visits
or total costs for mental disorders across all age groups. However, the association did not
become statistically significant until a person consumed at least three of these
medications. Moreover, the increase in visits and totals costs was larger for adults aged

13

Medications used for treatment of mental disorders include antidepressant; anxiolytics, sedatives, or

hypnotics; anticonvulsants; and antipsychotics.
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25-44 compared to adults aged 65-84, although the estimates were not significantly
different from one another.

-Insert Figures 8 and 9 About Here-

Discussion
This chapter investigated the trends in using medications with mental health side effects
among community-dwelling adults from 1996 to 2016. It then examined the extent to
which the use of these medications was associated with worsened mental health, as well
as increased utilization and costs of mental health services.

The findings are six-fold. First, I found that the use of medications with mental health
side effects has increased significantly since 1996, and much of the increase was
attributed to the use of medications with insomnia, anxiety, and suicidal side effects,
rather than medications with depression as a potential side effect. Second, I found that the
use of medications with any mental health side effects was detrimental to mental health
and was associated with an increase in the onset of new mental disorders, especially
under conditions of polypharmacy. Third, concurrent use of medications with mental
health side effects was associated with an increase in the number of visits and costs for
mental disorders, as well as the subsequent use of psychotropic medications for
treatments of mental disorders. Fourth, while medications with mental health side effects
had negative consequences on health and health care use/costs, I found that medications
without any known mental health side effects were not associated with worsened mental
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health or increased use/cost of mental health services. In some cases, taking medications
without mental health side effects was even beneficial to mental health and reduced the
use and costs for mental health services. Fifth, medications with mental health side
effects were more detrimental to mental health among respondents who already had
mental disorders at the baseline compared to those without these preexisting disorders.
Finally, I found that young adults were equally impacted, or in some cases, they were
more likely to be impacted by medications with mental health side effects compared to
middle-aged and older adults. While the association between medications with mental
health side effects and nonspecific psychological distress (K6) declined over age (Figures
3 and 4), such age discrepancy was less significant for other outcomes (Figures 5 to 9).
This may be due to underreporting or recall bias of psychological symptoms in the K6
scale among older adults (Lyness et al., 1995). Underreporting or recall bias were
alleviated for other outcomes (i.e. self-reported mental disorders, visits and costs
associated with mental disorders, and the use of psychotropic medications for treatments
of mental disorders) because MEPS contacted respondents’ medical providers to correct
and impute missing information. Moreover, the large and significant association between
the use of medications with mental health side effects and several outcomes for young
adults may also be attributed to the selection to using multiple of these medications as a
result of an early onset of chronic conditions that can be more detrimental to health than
those that occur at older ages (Huang et al., 2010)

These findings imply that physicians are likely to have neglected the important role of
mental health when proving care to patients. Many of medications that have mental
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health side effects in this study are intended for the treatments of chronic and physical
diseases such as antihypertensives, proton pump inhibitors, respiratory agents, and
hormonal modifiers. While these medications may be beneficial for controlling and
treating disease for which they are intended, many of them may induce psychological
distress and the use/costs of mental health services. The decision to prescribe these
medications may in part reflect physicians’ belief that physical health should be
prioritized over mental health, and that any mental health side effects can be treated later
by prescribing more psychotropic medications after physical conditions are under control
(Tamblyn, 1996). In this study, I found that the use of medications with mental health
side effects indeed induced the use of additional psychotropic medications for treatments
of mental disorders at the follow-up. To avoid adverse consequences of medications on
mental health, physicians may want to conduct mental health screenings before and
during administration of medications with potential mental health side effects, especially
when patients consume multiple of these medications simultaneously, in order to adjust
medication doses.

While many medications with mental health side effects are harmful to mental health, I
found that medications without these known side effects did not have any adverse
consequences, even when used in a set. This finding aligns with prior studies by Qato et
al. (2018) and Do and Schnittker (2020). In many cases, the use of medications without
known mental health side effects was even beneficial to mental health and reduced
subsequent use and costs of mental health services. The results hold even after controlling
for socio-demographic and preexisting medical conditions, as well as excluding
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respondents with any existing mental disorders or respondents with multiple chronic
conditions. It is possible that the use of medications without known mental health side
effects helps manage chronic and physical conditions that have been found to have a
detrimental effects on mental health (Köhler et al., 2018). These findings bridge the gap
between the literature on polypharmacy and the literature on medication side effects.
Much of the adverse consequences of polypharmacy on health may be mainly due to
consuming multiple medications with certain side effects. As such, any policies that aim
to address polypharmacy should focus on reducing the inappropriate use of medications
with adverse side effects instead of medications without known side effects.

Finally, the literature on polypharmacy typically focuses on older adults because they are
at higher risks of experiencing adverse drug reactions due to biological and medical
reasons. As such, little is known about the role of polypharmacy or medications with side
effects in mental health of younger adults. In this study, I found that medications with
mental health side effects were as harmful to the mental health of younger adults as they
were to older adults. For self-reported nonspecific psychological distress (K6 scale), I
found that the bar was even lower for young adults. Using one, two, or at least three
medications with mental health side effects had adverse effects on psychological distress
for young adults, while the association was not observed among older adults until they
consumed at least three medications with these side effects. This finding has been
previously observed in a study by Huang et al. (2010) that investigated the association
between polypharmacy and the risk of falls among diabetic patients. The authors found
that using four to five medications simultaneously increased the risk of falls among
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young adults compared to those using one or no medications. For older diabetic adults,
the authors did not observe a significant relationship between polypharmacy and falls
until patients consumed six to seven medications. In addition, I found that using at least
three medications with mental health side effects was much more harmful to young
adults’ psychological distress than it was for older adults (Figure 4). It is possible that for
young and healthy adults, the selection into concurrently using at least three medications
with mental health side effects may be attributed to the early onset of chronic conditions
that can be more debilitating to health than those that occur in older ages. For other
outcomes such as the development of new mental disorders, the use of psychotropic
medications, and use/costs of mental health services, I found that the associations
between these outcomes and the use of medications with mental health side effects did
not significantly vary by age groups. Future studies should investigate the consequences
of polypharmacy and medications with side effects among the young adult population.

Conclusion
This study presents a significant increase in the use of medications with insomnia,
depression, anxiety, or suicidal side effects among community-dwelling U.S. adults in the
past two decades. Exposure to these medications was associated with psychological
distress, the development of new mental disorders, and the use/costs of mental health
services across all age groups, especially under the condition of polypharmacy. These
results highlight the needs for mental health screenings among patients who consume
medications with mental health side effects. They also highlight the synergic effects of
polypharmacy and potential drug-drug interactions that result in mental disorders.
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Figure 1: Unadjusted and Adjusted Weighted Prevalence of U.S. Adults Aged 25-84
Taking Medications with Any Insomnia, Depression, Anxiety, or Suicidal Side
Effects. Data Source: MEPS 1996-2016.
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Figure 2: Unadjusted and Adjusted Weighted Prevalence of U.S. Adults Aged 25-84
Taking Medications with Individual Side Effect of Insomnia, Depression, Anxiety,
or Suicide. Data Source: MEPS 1996-2016.
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Table 1: Medications with Insomnia Side Effect Consumed by U.S. Adults Aged 25-84 in MEPS 1996-2016.
Abacavir
Abacavir-Lamivudine

Emtricitabine
Emtricitabine-RilpivirineTenofovir
Emtricitabine-Tenofovir
Escitalopram
Exemestane

Phentermine
Pindolol

Amantadine
AmphetamineDextroamphetamine
Amphotericin B
Anastrozole
Aripiprazole
Armodafinil
Asenapine
Atomoxetine
Benzphetamine
Boceprevir
Buprenorphine-Naloxone
Bupropion
Butorphanol
Carteolol
Cetirizine-Pseudoephedrine

Felbamate
Fentanyl

Propranolol
Pseudoephedrine

Fexofenadine-Pseudoephedrine
Fluoxetine
Fluvoxamine
Formoterol
Guanfacine
Interferon Beta-1B
Lamivudine-Zidovudine
Lamotrigine
Letrozole
Leuprolide
Levofloxacin
Levothyroxine
Lindane

Quetiapine
Raltegravir
Ramelteon
Ribavirin
Rimantadine
Roflumilast
Selegiline
Sertraline
Sibutramine
Sildenafil
Tacrolimus
Tamsulosin
Tenofovir

Ciprofloxacin
Citalopram
Clomipramine
Dalfampridine
Daptomycin
Desloratadine-Pseudoephedrine
Desvenlafaxine
Dexmethylphenidate

Lisdexamfetamine
Loratadine-Pseudoephedrine
Mefloquine
Megestrol
Methylphenidate
Milnacipran
Modafinil
Mycophenolate Mofetil

Theophylline
Thyroid
Tiagabine
Tramadol
Tranylcypromine
Trazodone
Valproic Acid
Varenicline

Acamprosate
Acetaminophen
Acetaminophen-Tramadol

Piperacillin-Tazobactam
Pramipexole
Progesterone
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Diflunisal
Divalproex
Donepezil
Duloxetine
Efavirenz

Mycophenolic Acid
Nabumetone
Ofloxacin
Paroxetine
Peginterferon Alfa-2A

Venlafaxine
Vilazodone
Zileuton
Zoledronic Acid
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Table 2: Medications with Depression Side Effect Consumed by U.S. Adults Aged 25-84 in MEPS 1996-2016.
Abacavir-Lamivudine
Acebutolol
Acetaminophen-Hydrocodone
Acetaminophen-Oxycodone
Acitretin
Acyclovir
Albuterol
Amiodarone
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AmphetamineDextroamphetamine
Anastrozole
Aspirin
Atenolol
Atenolol-Chlorthalidone
Atropine-Diphenoxylate
Azathioprine
Baclofen
Bendroflumethiazide-Nadolol
Benzphetamine
Betamethasone
Betaxolol
Bicalutamide
Brimonidine
Brimonidine-Timolol
Cabergoline
Cetirizine
Cimetidine
Clonidine
Conjugated Estrogens

Drospirenone-Estradiol
Drospirenone-EstradiolLevomefolate
Emtricitabine
Enalapril
Enalapril-Hydrochlorothiazide
Esomeprazole
Esterified Estrogens
Esterified EstrogensMethyltestosterone
Estradiol

Magnesium Gluconate
Medroxyprogesterone

Estradiol-Levonorgestrel
Estradiol-Norethindrone
Estradiol-Norgestimate
Estropipate
Estradiol
Estradiol-Ethynodiol
Estradiol-Etonogestrel
Estradiol-Levonorgestrel
Estradiol-Norethindrone
Estradiol-Norgestimate
Estradiol-Norgestrel
Etonogestrel
Exemestane
Famotidine
Fentanyl
Flecainide
Fluphenazine
Galantamine
Goserelin

Metolazone
Metoprolol
Metronidazole
Montelukast
Morphine
Nabumetone
Nisoldipine
Norethindrone
Omeprazole
Oxybutynin
Oxycodone
Pantoprazole
Phentermine
Pimozide
Prazosin
Prednisolone
Prednisone
Propafenone
Propranolol

Megestrol
Metaproterenol
Metaxalone
Methocarbamol
Methotrexate
Methyldopa
Methylprednisolone
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Conjugated EstrogensMedroxyprogesterone
Cortisone
Cyclobenzaprine
Cyclosporine
Dantrolene
Desogestrel-Estradiol
Dexamethasone
Dexlansoprazole
Dexmethylphenidate
Dienogest-Estradiol
Donepezil
Dorzolamide-Timolol
Dronabinol
Drospirenone-Estradiol

Guaifenesin-Hydrocodone

Quinapril

Haloperidol
Homatropine-Hydrocodone
Hydrochlorothiazide-Metoprolol
Hydrocodone
Hydrocodone-Ibuprofen
Hydrocortisone
Hydroxyprogesterone
Hydroxyzine
Ibuprofen
Indomethacin
Lansoprazole
Losartan

Rabeprazole
Ranitidine
Rasagiline
Risedronate
Tamoxifen
Telmisartan
Testosterone
Theophylline
Timolol
Tizanidine
Trandolapril
Triamcinolone

Table 3: Medications with Suicidal Side Effect Consumed by U.S. Adults Aged 25-84 in MEPS 1996-2016.
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Acamprosate
Acetaminophen
Acetaminophen-Hydrocodone
Acetaminophen-Tramadol
Alprazolam
Amantadine
Amitriptyline
Amitriptyline-Chlordiazepoxide
Amitriptyline-Perphenazine
Amoxicillin-Clavulanate
Aripiprazole
Armodafinil
Asenapine
Aspirin
Atomoxetine
Bupropion
Butabarbital
Carbamazepine
Carbidopa-Entacapone-Levodopa
Carbidopa-Levodopa
Chlordiazepoxide
Chlorzoxazone
Ciprofloxacin
Citalopram
Clomipramine
Clonazepam
Clorazepate
Dapsone
Desipramine
Desvenlafaxine
Diazepam

Escitalopram
Esomeprazole
Eszopiclone
Ferrous Sulfate
Finasteride
Fluoxetine
Fluoxetine-Olanzapine
Flurazepam
Fluticasone
Fluvoxamine
Gabapentin
Haloperidol
Hydrocortisone
Iloperidone
Imipramine
Interferon Beta-1A
Interferon Beta-1B
Isotretinoin
Lamotrigine
Leuprolide
Levetiracetam
Levonorgestrel
Lorazepam
Lurasidone
Mefloquine
Memantine
Methylphenidate
Metoclopramide
Milnacipran
Mirtazapine
Modafinil

Olanzapine
Oxandrolone
Oxcarbazepine
Paroxetine
Peginterferon Alfa-2A
Phenelzine
Phenytoin
Prednisone
Pregabalin
Progesterone
Protriptyline
Quetiapine
Raltegravir
Ramelteon
Ranitidine
Ribavirin
Risperidone
Rivastigmine
Roflumilast
Selegiline
Sertraline
Sibutramine
Tapentadol
Topiramate
Tramadol
Trazodone
Triazolam
Valproic Acid
Varenicline
Venlafaxine
Vilazodone

Didanosine
Doxepin

Montelukast
Moxifloxacin

Zafirlukast
Zaleplon

Duloxetine
Efavirenz
Efavirenz-Emtricitabine-Tenofovir

Nefazodone
Nortriptyline
Ofloxacin

Zolpidem
Zonisamide
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Table 4: Medications with Anxiety Side Effect Consumed by U.S. Adults Aged 25-84 in MEPS 1996-2016.
Acamprosate
Amantadine
Aripiprazole
Armodafinil
Carbidopa-Levodopa
Cetirizine-Pseudoephedrine
Chlorpheniramine-Hydrocodone
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Codeine-PhenylephrinePromethazine
Dalfampridine
Desvenlafaxine
Dexmethylphenidate
Dronabinol
Efavirenz-Emtricitabine-Tenofovir
Epinephrine

Estazolam
Exemestane
Fentanyl
Fluoxetine
Fluvoxamine
Glatiramer
Guaifenesin-HydrocodonePseudoephedrine
Hydrocodone

Modafinil
Mycophenolate Mofetil
Paliperidone
Peginterferon Alfa-2A
Propafenone
Pseudoephedrine
Risperidone

Hydrocodone-Pseudoephedrine
Levothyroxine
Lindane
Lisdexamfetamine
Mefloquine
Methylphenidate

Tretinoin
Triazolam
Valproic Acid
Venlafaxine
Ziprasidone

Topiramate

Table 5. Descriptive Statistics for Mental Health, Medication Use, and Control Variables for U.S. Adults Aged 25-84. Data
Source: MEPS 2004-2015.
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Binary outcomes at follow-upc, Nd (%)e
Mental distress (K6 >= 13)
Felt everything an effort most/all of the time
Felt hopeless most/all of the time
Felt nervous most/all of the time
Felt restless most/all of the time
Felt sad most/all of the time
Felt worthless most/all of the time
Any new mental disorders at follow-up
Whether had more outpatient, inpatient, officebased, emergency visits for mental disorders at
follow-up
Used more of any four medications below for
treatment of mental disorders at follow-up
Used more antidepressants
Used more anxiolytics, sedatives, or
hypnotics
Used more anticonvulsants
Used more antipsychotics

Number of medications with any insomnia, depression, suicide, or
anxiety side effectsa

N = 211,551

None
N = 151,337

1 medication
N = 33,883

12390
17896
9076
11801
13902
7393
8055
9775
8712

(5.0)
(7.5)
(3.6)
(4.9)
(5.8)
(2.8)
(3.3)
(5.0)
(4.5)

5924
9469
4627
5821
7238
3712
3962
5621
3137

(3.3)
(5.4)
(2.5)
(3.3)
(4.2)
(2.0)
(2.2)
(4.0)
(2.2)

2187
3095
1567
2112
2480
1274
1394
1921
1851

(5.2)
(7.6)
(3.5)
(5.1)
(6.1)
(2.7)
(3.3)
(5.8)
(5.6)

1527
1967
1034
1409
1624
865
960
1057
1423

(8.7)
(11.7)
(5.7)
(8.2)
(9.3)
(4.6)
(5.4)
(7.4)
(10.2)

2752
3365
1848
2459
2560
1542
1739
1176
2301

(19.6)
(25.5)
(13.0)
(17.6)
(18.1)
(10.5)
(12.5)
(9.8)
(18.7)

p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001

9434

(5.0)

4748

(3.6)

1978

(6.1)

1195

(8.4)

1513

(12.5)

p < 0.001

7371
4157

(4.0)
(2.2)

3788
1617

(3.0)
(1.2)

1475
862

(4.6)
(2.6)

887
656

(6.3)
(4.7)

1221
1022

(10.1)
(8.6)

p < 0.001
p < 0.001

3173
2417

(1.7)
(1.2)

1095
822

(0.8)
(0.6)

623
427

(1.9)
(1.3)

537
402

(3.8)
(2.9)

918
766

(7.7)
(6.4)

p < 0.001
p < 0.001

2.81
0.09

(0.02)
(0.01)

3.57
0.19

(0.03)
(0.02)

4.59
0.33

(0.06)
(0.03)

6.97
0.63

(0.08)
(0.05)

p < 0.001
p < 0.001

46.01

(4.14)

97.60

(10.99)

(87.75)

p < 0.001

Continuous outcomes at follow-upc, meand (standard error)
3.34 (0.02)
K6 total score
Changes in number of outpatient, inpatient,
0.16 (0.01)
office-based, emergency visits for mental
disorders between baseline and follow-up
Changes in total costs for mental disorders
between baseline and follow-upf

P-valueb

All
respondents

76.46

(7.02)

2 medications
N = 14,225

166.97

(29.80)

3+ medications
N = 12,106

241.50
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Independent variablesa, Nd (%)e
Number of medications WITH insomnia, depression, suicidal, and anxiety side effects
151337 (68.6)
None
33883 (17.7)
1 medication
14225 (7.5)
2 medications
12106 (6.3)
3+ medications
Number of medications WITHOUT insomnia, depression, suicidal, and anxiety side
effects
134356 (61.1)
None
31552 (16.2)
1 medication
17849 (9.1)
2 medications
27794 (13.6)
3+ medications
Changes in number of medications WITH insomnia, depression, suicidal, and anxiety side effects between baseline and subsequent
round
166584 (77.3)
120437 (77.7) 26061 (76.6)
10891 (76.4)
9195 (76.0)
Decline or no changes
28681 (14.4)
19915 (14.2)
4932 (14.9)
2071 (14.7)
1763 (14.8)
Increase of 1 medication
9971 (5.1)
6753 (5.0)
1737 (5.1)
759 (5.4)
722 (5.9)
Increase of 2 medications
6315 (3.2)
4232 (3.1)
1153 (3.4)
504 (3.4)
426 (3.3)
Increase of 3+ medications
Changes in number of medications WITHOUT insomnia, depression, suicidal, and anxiety side effects between baseline and subsequent round
151197 (70.1)
111886 (72.2) 22636 (67.0)
9143 (64.6)
7532 (62.4)
Decline or no changes
30248 (15.1)
19689 (14.0)
5754 (16.8)
2523 (17.8)
2282 (19.1)
Increase of 1 medication
13902 (6.9)
9035 (6.3)
2613 (7.8)
1214 (8.4)
1040 (8.6)
Increase of 2 medications
16204 (7.9)
10727 (7.5)
2880 (8.4)
1345 (9.3)
1252 (9.9)
Increase of 3+ medications
Race
104477 (69.1)
67230 (64.9) 20005 (76.4)
9050 (79.6)
8192 (82.0)
Non-Hispanic White
37145 (10.8)
27582 (11.9)
5547 (8.9)
2304 (8.7)
1712 (7.4)
Non-Hispanic Black
51583 (13.1)
42009 (15.4)
5863 (9.1)
2095 (7.6)
1616 (6.9)
Hispanic
18346 (6.9)
14516 (7.9)
2468 (5.6)
776 (4.1)
586 (3.7)
Others
115305 (52.2)
76418 (47.2) 21345 (61.2)
9256 (63.4)
8286 (67.1)
Female
Age groups
93171 (41.9)
75536 (47.5) 11498 (34.3)
3710 (26.3)
2427 (19.6)
25-44
83370 (40.1)
56939 (38.7) 14221 (41.6)
6260 (43.3)
5950 (48.5)
45-64
35010 (18.0)
18862 (13.8)
8164 (24.1)
4255 (30.3)
3729 (31.9)
65-84
Marital status
123510 (60.8)
89678 (61.3) 20088 (62.5)
7770 (58.4)
5974 (53.9)
Married or cohabiting

p < 0.001
p = 0.065
p = 0.001
p = 0.048
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
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Divorced, widowed, or separated
Never married
Educational attainment
Less than high school
High school graduate
College or above
Household income <100% federal poverty
guideline
Has private insurance
Has public insurance, Medicaid, or SCHIP
Has Medicare insurance
Has any other health insurance
Whether obese (BMI >= 30)
Any pain that interfered with work/housework
Number of reported/treated chronic conditions
None
1 condition
2 conditions
3+ conditions
Specific types of reported/treated chronic
conditions
Hypertension
Congestive heart failure
Coronary artery disease
Cardiac arrhythmias
Hyperlipidemia
Stroke
Arthritis
Asthma
Cancer
Chronic kidney disease
Chronic obstructive pulmonary disease
Dementia, Alzheimer’s, and other senile
dementias)
Diabetes
Hepatitis

47033
41008

(21.4)
(17.8)

29467
32192

(19.0)
(19.7)

8640
5155

(23.2)
(14.3)

4433
2022

(28.4)
(13.1)

4493
1639

(34.0)
(12.1)

p < 0.001
p < 0.001

43595
64726
103230
32849

(12.9)
(29.7)
(57.4)
(9.9)

32157
45998
73182
22817

(13.1)
(29.5)
(57.4)
(9.5)

5950
10241
17692
4800

(10.9)
(29.0)
(60.1)
(9.0)

2841
4457
6927
2485

(13.1)
(30.7)
(56.3)
(11.1)

2647
4030
5429
2747

(15.2)
(33.0)
(51.7)
(15.7)

p < 0.001
p < 0.001
p < 0.001
p < 0.001

126526
30997
41688
2487
68727
100490

(69.3)
(9.6)
(20.7)
(1.2)
(30.8)
(47.2)

90449
18804
21121
1486
45705
61739

(69.5)
(8.0)
(15.0)
(5.9)
(28.3)
(40.5)

21970
5426
9467
507
11907
18973

(73.6)
(9.8)
(27.0)
(1.4)
(32.7)
(53.3)

8257
3054
5312
246
5698
9861

(67.0)
(13.9)
(36.0)
(1.7)
(38.4)
(66.4)

5850
3713
5788
248
5417
9917

(57.6)
(21.6)
(46.9)
(2.1)
(43.1)
(80.1)

p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001

125484
39398
22825
23844

(57.5)
(19.5)
(11.2)
(11.7)

105590
24686
11912
9149

(68.2)
(17.3)
(8.2)
(6.3)

13645
8577
5661
6000

(41.8)
(25.1)
(16.2)
(16.9)

4001
3574
2832
3818

(29.3)
(25.1)
(20.0)
(25.6)

2248
2561
2420
4877

(19.2)
(21.4)
(20.0)
(39.4)

p < 0.001
p < 0.001
p < 0.001
p < 0.001

58607
1629
9746
5681
43545
3381
14210
12041
10795
169
11438
1185

(27.7)
(0.8)
(5.0)
(3.2)
(22.2)
(1.6)
(7.4)
(5.8)
(6.3)
(0.07)
(6.1)
(0.5)

30198
612
3679
2296
22124
1389
5725
5638
5179
57
5319
419

(20.0)
(0.4)
(2.7)
(1.8)
(16.0)
(0.9)
(4.3)
(3.8)
(4.4)
(0.03)
(4.0)
(0.2)

14065
378
2531
1468
10385
753
3295
2587
2696
41
2468
261

(38.6)
(1.0)
(7.5)
(4.8)
(30.6)
(2.0)
(9.8)
(7.4)
(9.2)
(0.10)
(7.6)
(0.6)

7260
273
1565
927
5436
538
2162
1614
1458
21
1505
211

(48.6)
(1.7)
(10.8)
(7.0)
(38.4)
(3.4)
(15.5)
(10.6)
(11.2)
(0.1)
(10.8)
(1.4)

7084
366
1971
990
5600
701
3028
2202
1462
50
2146
294

(56.4)
(2.9)
(16.0)
(8.8)
(46.5)
(5.8)
(25.2)
(17.3)
(13.1)
(0.4)
(17.9)
(2.2)

p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001

24671
738

(10.6)
(0.3)

13065
346

(7.9)
(0.2)

5456
155

(13.7)
(0.4)

2963
98

(18.1)
(0.6)

3187
139

(23.8)
(1.0)

p < 0.001
p < 0.001

493 (0.2)
202 (0.1)
Human immunodeficiency virus (HIV)
3443 (1.8)
1586 (1.2)
Osteoporosis
Region of residence
32740 (18.0)
23027 (18.0)
Northeast
41728 (22.1)
28170 (21.3)
Midwest
81078 (37.1)
57684 (36.8)
South
56005 (22.8)
42456 (24.0)
West
a
: Measured in rounds 1/3 (baseline)
b
: p-value for differences in the variable across categories of medications with side
effects.
c
: Measured in rounds 2/4.

102
864

(0.2)
(2.6)

67
468

5596 (19.1)
2309
7463 (23.6)
3236
12835 (36.6)
5609
7989 (20.8)
3071
d
: unweighted frequency.
e
f

(0.4)
(3.3)

122
525

(0.8)
(4.2)

(18.2)
(23.9)
(38.2)
(19.7)

1808
2859
4950
2489

(15.4)
(25.2)
(39.8)
(19.5)

: weighted prevalence or mean.

: adjusted to 2016 dollars

p < 0.001
p < 0.001
p = 0.006
p < 0.001
p = 0.001
p < 0.001
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Table 6. Adjusted Linear Least-Squared and Logit Regressions of Mental Health on Medication Use for Adults Aged 25-84.
Data Source: MEPS 2004-2015.
(1)
(2)
Overall K6 scale a
Outcome:

(3)

(4)
(5)
(6)
(7)
Individual questions of the K6 scale (score >=3) a

(9)
Mental
disorders a

Raw
score

Whether
score
>=13

Felt
everything
an effort

Felt
hopeless

Felt
nervous

Felt
restless

Felt
sad

Felt
worthless

Any new
mental
disorders at
follow-up

OLS

Logit

Logit

Logit

Logit

Logit

Logit

Logit

Logit

Coeff.
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)
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Number of medications WITH any insomnia, depression, suicidal, or anxiety side effects at baseline
None (reference)
1 medication

(8)

b

0.113***
(0.030)

1.085
(0.046)

1.057
(0.033)

1.021
(0.049)

1.076
(0.043)

1.151***
(0.047)

0.990
(0.053)

1.007
(0.053)

1.334***
(0.052)

2 medications

0.224***
(0.048)

1.214***
(0.060)

1.155**
(0.051)

1.107
(0.064)

1.169**
(0.064)

1.266***
(0.068)

1.112
(0.075)

1.086
(0.069)

1.598***
(0.083)

3+ medications

1.318***
(0.077)

1.859***
(0.113)

1.936***
(0.098)

1.634***
(0.102)

1.696***
(0.098)

1.736***
(0.110)

1.623***
(0.123)

1.597***
(0.108)

1.987***
(0.121)

Number of medications WITHOUT any insomnia, depression, suicidal, or anxiety side effects at baseline
None (reference)
1 medication

b

0.043
(0.031)

0.959
(0.038)

1.039
(0.035)

0.996
(0.043)

1.037
(0.044)

1.014
(0.038)

0.908*
(0.043)

1.000
(0.048)

1.043
(0.042)

2 medications

0.026
(0.043)

0.955
(0.045)

1.022
(0.042)

0.946
(0.053)

0.989
(0.050)

0.983
(0.049)

0.996
(0.056)

0.948
(0.054)

1.058
(0.051)

3+ medications

0.059
(0.050)

0.939
(0.048)

1.132**
(0.049)

0.908
(0.052)

0.923
(0.047)

0.988
(0.049)

0.867*
(0.051)

1.001
(0.063)

0.935
(0.049)

Mean outcome

3.301

0.049

0.074

0.035

0.048

0.057

0.028

0.032

0.050

No. of persons

211,551

211,551

211,551

211,551

211,551

211,551

211,551

211,551

211,551

Note: * p<0.05, ** p<0.01, *** p<0.001
All analyses control for changes in the number of medications with and without side effects consumed between round 1 and round 2 (for those in the
first year of their panel) and between round 3 and round 4 (for those in the second year of their panel), race/ethnicity, gender, age and age squared,
marital status, education, poverty, health insurance coverage, obesity, number of chronic conditions, whether had any pain that interfered with normal
work outside the house or housework in the past 4 weeks, year and region fixed-effects.
a: Measured in round 2 for those in the 1st year of their panel, and round 4 for those in the 2nd year.
b: Measured in round 1 for those in the 1st year of their panel, and round 3 for those in the 2nd year.
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Table 7. Adjusted Logit and Two-Part Model Regressions of Utilization/Cost of Mental Health Services on Medication Use for
Adults Aged 25-84. Data Source: MEPS 2004-2015.

Outcome:

(1)

(2)

Whether
had more
visits for
mental
disorders
at followup

Changes
in number
of visits
for mental
disorders
between
baseline
and
follow-up
Two-part
model
Marginal
effect
(SE)

Logit
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OR
(SE)

(3)

(4)
(5)
Health services utilization a
Changes in
Whether
Whether
cost for
used more
used more
mental
psychotropic antidepresdisorders
medications
sants for
between
for mental
mental
baseline
disorders at
disorders
and followfollow-up
at followup
up

(6)

(7)

(8)

Whether
used more
anticonvulsants for
mental
disorders
at followup

Whether
used more
antipsychotics for
mental
disorders
at followup

Logit

Logit

OR
(SE)

OR
(SE)

Two-part
model

Logit

Logit

Whether
used more
anxiolytics,
sedatives,
or
hypnotics
for mental
disorders at
follow-up
Logit

Marginal
effect (SE)

OR
(SE)

OR
(SE)

OR
(SE)

Number of medications WITH any insomnia, depression, suicidal, or anxiety side effects at baseline
None (reference)
1 medication

b

1.359***
(0.071)

0.030*
(0.013)

11.103
(9.684)

1.415***
(0.067)

1.274***
(0.068)

1.410***
(0.096)

1.276**
(0.102)

0.955
(0.100)

2 medications

1.715***
(0.114)

0.047*
(0.018)

31.411*
(15.642)

1.737***
(0.104)

1.538***
(0.106)

1.856***
(0.141)

1.735***
(0.156)

1.309*
(0.159)

3+ medications

2.346***
(0.167)

0.152***
(0.026)

103.274***
(23.050)

2.272***
(0.190)

2.224***
(0.179)

2.519***
(0.250)

2.543***
(0.277)

1.909***
(0.241)

Number of medications WITHOUT any insomnia, depression, suicidal, or anxiety side effects at baseline
None (reference)
1 medication
2 medications

b

1.000
(0.047)

0.005
(0.015)

-1.817
(9.432)

0.967
(0.041)

0.971
(0.043)

0.954
(0.062)

0.940
(0.066)

1.033
(0.082)

0.965
(0.057)

-0.012
(0.017)

4.367
(11.136)

0.976
(0.056)

0.878*
(0.057)

1.059
(0.084)

1.055
(0.103)

1.039
(0.106)

3+ medications

0.818***
(0.046)

-0.027
(0.015)

-1.608
(10.842)

0.785***
(0.045)

0.790***
(0.052)

0.969
(0.068)

0.896
(0.078)

0.936
(0.095)

Mean outcome

0.045

0.158

76.465

0.050

0.040

0.022

0.017

0.012

No. of persons

211,551

211,551

211,551

211,551

211,551

211,551

211,551

211,551

Note: * p<0.05, ** p<0.01, *** p<0.001
All analyses control for changes in the number of medications with and without side effects consumed between round 1 and round 2 (for those
in the first year of their panel) and between round 3 and round 4 (for those in the second year of their panel), race/ethnicity, gender, age and age
squared, marital status, education, poverty, health insurance coverage, obesity, number of chronic conditions, whether had any pain that
interfered with normal work outside the house or housework in the past 4 weeks, year and region fixed-effects.
a: Measured in round 2 for those in the 1st year of their panel, and round 4 for those in the 2nd year.
b: Measured in round 1 for those in the 1st year of their panel, and round 3 for those in the 2nd year.
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Table 8. Adjusted Linear Least-Squared and Logit Regressions of Mental Health on Medication Use for Adults Aged 25-84
With at Most One Chronic Condition. Data Source: MEPS 2004-2015.
(1)
(2)
Overall K6 scale a
Outcome:

(3)

(4)
(5)
(6)
(7)
Individual questions of the K6 scale (score >=3) a

(9)
Mental
disorders a
Any new
mental
disorders at
follow-up

Raw
score

Whether
score
>=13

Felt
everything
an effort

Felt
hopeless

Felt
nervous

Felt
restless

Felt
sad

Felt
worthless

OLS

Logit

Logit

Logit

Logit

Logit

Logit

Logit

Logit

Coeff.
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

Number of medications WITH any insomnia, depression, suicidal, or anxiety side effects at baseline
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None (reference)
1 medication

(8)

b

0.118***
(0.033)

1.117*
(0.057)

1.032
(0.044)

1.005
(0.059)

1.062
(0.053)

1.214***
(0.061)

0.982
(0.068)

1.008
(0.065)

1.392***
(0.069)

2 medications

0.244***
(0.060)

1.225**
(0.084)

1.142*
(0.067)

1.021
(0.082)

1.112
(0.079)

1.277***
(0.085)

1.136
(0.105)

1.095
(0.095)

1.745***
(0.118)

3+ medications

1.268***
(0.099)

1.975***
(0.162)

1.842***
(0.145)

1.719***
(0.143)

1.696***
(0.129)

1.826***
(0.151)

1.589***
(0.159)

1.559***
(0.145)

2.249***
(0.184)

Number of medications WITHOUT any insomnia, depression, suicidal, or anxiety side effects at baseline
None (reference)
1 medication

b

0.065
(0.034)

0.960
(0.044)

1.061
(0.044)

1.013
(0.053)

1.092
(0.057)

1.018
(0.044)

0.941
(0.055)

1.004
(0.056)

1.072
(0.051)

2 medications

0.095
(0.050)

1.011
(0.059)

1.105
(0.057)

1.064
(0.071)

1.073
(0.064)

1.035
(0.057)

1.117
(0.077)

1.045
(0.078)

1.055
(0.061)

3+ medications

0.170*
(0.069)

0.987
(0.070)

1.270***
(0.083)

0.969
(0.084)

0.966
(0.065)

1.073
(0.068)

0.890
(0.082)

1.123
(0.102)

0.968
(0.072)

Mean outcome

3.003

0.038

0.059

0.028

0.039

0.048

0.022

0.026

0.044

No. of persons

164,882

164,882

164,882

164,882

164,882

164,882

164,882

164,882

164,882

Note: * p<0.05, ** p<0.01, *** p<0.001
All analyses control for changes in the number of medications with and without side effects consumed between round 1 and round 2 (for those in the
first year of their panel) and between round 3 and round 4 (for those in the second year of their panel), race/ethnicity, gender, age and age squared,
marital status, education, poverty, health insurance coverage, obesity, number of chronic conditions, whether had any pain that interfered with normal
work outside the house or housework in the past 4 weeks, year and region fixed-effects.
a: Measured in round 2 for those in the 1st year of their panel, and round 4 for those in the 2nd year.
b: Measured in round 1 for those in the 1st year of their panel, and round 3 for those in the 2nd year.
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Table 9. Adjusted Logit and Two-Part Model Regressions of Utilization/Cost of Mental Health Services on Medication Use for
Adults Aged 25-84 With at Most One Chronic Condition. Data Source: MEPS 2004-2015.

Outcome:

(1)

(2)

(3)

Whether
had more
visits for
mental
disorders
at followup

Changes
in number
of visits
for
mental
disorders
between
baseline
and
follow-up
Two-part
model
Marginal
effect
(SE)

Changes in
cost for
mental
disorders
between
baseline
and followup

Whether
used more
medications
for mental
disorders at
follow-up

Two-part
model
Marginal
effect (SE)
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Logit
OR
(SE)

(4)
(5)
Health services utilization a

(6)

(7)

(8)

Whether
used more
antidepressants for
mental
disorders
at followup

Whether
used more
anxiolytics,
sedatives,
or
hypnotics
for mental
disorders at
follow-up

Whether
used more
anticonvulsants for
mental
disorders
at followup

Whether
used more
antipsychotics for
mental
disorders
at followup

Logit

Logit

Logit

Logit

Logit

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

Number of medications WITH any insomnia, depression, suicidal, or anxiety side effects at baseline
None (reference)
1 medication

b

1.447***
(0.091)

0.021
(0.014)

11.398
(8.728)

1.558***
(0.098)

1.392***
(0.096)

1.507***
(0.148)

1.235
(0.139)

0.925
(0.125)

2 medications

1.994***
(0.162)

0.070**
(0.023)

38.634*
(15.156)

2.128***
(0.181)

1.921***
(0.184)

2.201***
(0.254)

1.939***
(0.261)

1.489**
(0.227)

3+ medications

2.730***
(0.262)

0.158***
(0.034)

102.222***
(24.579)

2.989***
(0.363)

3.092***
(0.396)

3.049***
(0.429)

3.019***
(0.450)

2.129***
(0.376)

Number of medications WITHOUT any insomnia, depression, suicidal, or anxiety side effects at baseline
None (reference)
1 medication

0.990
(0.055)

0.013
(0.014)

4.757
(8.268)

0.987
(0.050)

0.988
(0.050)

0.986
(0.077)

0.946
(0.076)

b

0.999
(0.091)

2 medications

0.914
(0.063)

-0.007
(0.017)

14.572
(12.903)

0.969
(0.074)

0.896
(0.080)

1.051
(0.107)

1.067
(0.131)

1.044
(0.153)

3+ medications

0.936
(0.073)

0.008
(0.022)

2.130
(13.366)

0.816*
(0.074)

0.831
(0.080)

0.985
(0.109)

0.853
(0.115)

0.943
(0.155)

Mean outcome

0.038

0.137

59.606

0.039

0.031

0.016

0.012

0.009

No. of persons

164,882

164,882

164,882

164,882

164,882

164,882

164,882

164,882

Note: * p<0.05, ** p<0.01, *** p<0.001
All analyses control for changes in the number of medications with and without side effects consumed between round 1 and round 2 (for those
in the first year of their panel) and between round 3 and round 4 (for those in the second year of their panel), race/ethnicity, gender, age and
age squared, marital status, education, poverty, health insurance coverage, obesity, number of chronic conditions, whether had any pain that
interfered with normal work outside the house or housework in the past 4 weeks, year and region fixed-effects.
a: Measured in round 2 for those in the 1st year of their panel, and round 4 for those in the 2nd year.
b: Measured in round 1 for those in the 1st year of their panel, and round 3 for those in the 2nd year.
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Table 10. Adjusted Linear Least-Squared and Logit Regressions of Mental Health on Medication Use for Adults Aged 25-84
Without Mental Disorders at Baseline. Data Source: MEPS 2004-2015.
(1)
(2)
Overall K6 scale a
Outcome:

(3)

(4)
(5)
(6)
(7)
(8)
Individual questions of the K6 scale (score >=3) a

Raw
score

Whether
score
>=13

Felt
everything
an effort

Felt
hopeless

Felt
nervous

Felt
restless

Felt
sad

Felt
worthless

OLS

Logit

Logit

Logit

Logit

Logit

Logit

Logit

Logit

Coeff.
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

Number of medications WITH any insomnia, depression, suicidal, or anxiety side effects at baseline
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None (reference)
1 medication

(9)
Mental
disorders a
Any new
mental
disorders at
follow-up

b

0.159***
(0.030)

1.060
(0.054)

1.068
(0.039)

1.043
(0.060)

1.119*
(0.051)

1.123*
(0.051)

1.012
(0.065)

0.975
(0.063)

1.341***
(0.057)

2 medications

0.194***
(0.050)

1.157*
(0.072)

1.130*
(0.066)

1.051
(0.085)

1.118
(0.080)

1.173*
(0.075)

1.069
(0.089)

1.048
(0.091)

1.614***
(0.099)

3+ medications

0.776***
(0.086)

1.550***
(0.120)

1.842***
(0.132)

1.277**
(0.120)

1.516***
(0.129)

1.664***
(0.136)

1.318*
(0.144)

1.257*
(0.122)

2.024***
(0.161)

Number of medications WITHOUT any insomnia, depression, suicidal, or anxiety side effects at baseline
None (reference)
1 medication

b

0.054
(0.032)

0.959
(0.053)

1.030
(0.045)

1.008
(0.056)

1.059
(0.058)

1.006
(0.045)

0.896
(0.061)

1.031
(0.069)

1.015
(0.045)

2 medications

0.082
(0.043)

1.027
(0.064)

1.077
(0.056)

0.977
(0.070)

1.021
(0.066)

1.020
(0.061)

1.108
(0.089)

1.008
(0.080)

1.049
(0.059)

3+ medications

0.144**
(0.046)

1.017
(0.063)

1.204**
(0.068)

0.981
(0.069)

1.012
(0.065)

1.080
(0.066)

1.039
(0.077)

1.193*
(0.099)

0.897
(0.058)

Mean outcome

3.301

0.049

0.074

0.035

0.048

0.057

0.028

0.032

0.050

No. of persons

176,362

176,362

176,362

176,362

176,362

176,362

176,362

176,362

176,362

Note: * p<0.05, ** p<0.01, *** p<0.001
All analyses control for changes in the number of medications with and without side effects consumed between round 1 and round 2 (for those in the
first year of their panel) and between round 3 and round 4 (for those in the second year of their panel), race/ethnicity, gender, age and age squared,
marital status, education, poverty, health insurance coverage, obesity, number of chronic conditions, whether had any pain that interfered with normal
work outside the house or housework in the past 4 weeks, year and region fixed-effects.
a
: Measured in round 2 for those in the 1st year of their panel, and round 4 for those in the 2nd year.
b: Measured in round 1 for those in the 1st year of their panel, and round 3 for those in the 2nd year.
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Table 11. Adjusted Logit and Two-Part Model Regressions of Utilization/Cost of Mental Health Services on Medication Use
for Adults Aged 25-84 Without Mental Disorders at Baseline. Data Source: MEPS 2004-2015.

Outcome:
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(1)

(2)

(3)

Whether
had more
visits for
mental
disorders
at followup

Changes
in
number
of visits
for
mental
disorders
between
baseline
and
follow-up
Two-part
model
Marginal
effect
(SE)

Changes
in cost for
mental
disorders
between
baseline
and
follow-up

Logit
OR
(SE)

Two-part
model
Marginal
effect
(SE)

(4)
(5)
(6)
Health services utilization a
Whether
Whether
Whether
used more
used more used more
medications antidepres- anxiolytics,
for mental
sants for
sedatives,
disorders at
mental
or
follow-up
disorders
hypnotics
at followfor mental
up
disorders at
follow-up

(7)

(8)

Whether
used more
anticonvulsants for
mental
disorders
at followup

Whether
used more
antipsychotics for
mental
disorders
at followup

Logit

Logit

Logit

Logit

Logit

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

Number of medications WITH any insomnia, depression, suicidal, or anxiety side effects at baseline
None (reference)
1 medication

b

1.565***
(0.110)

0.017**
(0.006)

4.430
(3.384)

1.545***
(0.104)

1.425***
(0.106)

1.584***
(0.168)

1.270
(0.174)

0.914
(0.165)

2 medications

2.056***
(0.232)

0.032**
(0.010)

18.500*
(7.229)

2.121***
(0.189)

1.949***
(0.202)

2.152***
(0.322)

1.864***
(0.330)

1.082
(0.302)

3+ medications

1.857***
(0.275)

0.043*
(0.019)

17.742
(9.680)

3.143***
(0.360)

2.935***
(0.400)

3.042***
(0.489)

2.544***
(0.531)

1.548
(0.507)

Number of medications WITHOUT any insomnia, depression, suicidal, or anxiety side effects at baseline
None (reference)
1 medication

0.959
(0.077)

0.006
(0.006)

-3.324
(3.258)

1.041
(0.063)

1.021
(0.066)

1.020
(0.112)

0.976
(0.133)

b

1.180
(0.214)

2 medications

0.983
(0.098)

-0.002
(0.006)

2.231
(5.504)

1.028
(0.082)

0.923
(0.089)

1.220
(0.155)

1.326
(0.217)

1.226
(0.262)

3+ medications

0.886
(0.097)

-0.004
(0.007)

-6.508
(4.688)

0.792**
(0.068)

0.773**
(0.072)

0.961
(0.127)

0.936
(0.163)

1.138
(0.289)

Mean outcome

0.045

0.158

76.465

0.050

0.040

0.022

0.017

0.012

No. of persons

176,362

176,362

176,362

176,362

176,362

176,362

176,362

176,362

Note: * p<0.05, ** p<0.01, *** p<0.001
All analyses control for changes in the number of medications with and without side effects consumed between round 1 and round 2 (for
those in the first year of their panel) and between round 3 and round 4 (for those in the second year of their panel), race/ethnicity, gender,
age and age squared, marital status, education, poverty, health insurance coverage, obesity, number of chronic conditions, whether had any
pain that interfered with normal work outside the house or housework in the past 4 weeks, year and region fixed-effects.
a: Measured in round 2 for those in the 1st year of their panel, and round 4 for those in the 2nd year.
b: Measured in round 1 for those in the 1st year of their panel, and round 3 for those in the 2nd year.
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Table 12. Adjusted Linear Least-Squared and Logit Regressions of Mental Health on Medication Use for Adults Aged 25-84
With Mental Disorders at Baseline. Data Source: MEPS 2004-2015.
(1)
(2)
Overall K6 scale a
Outcome:

(3)

(4)
(5)
(6)
(7)
Individual questions of the K6 scale (score >=3) a

(9)
Mental
disorders a

Raw
score

Whether
score
>=13

Felt
everything
an effort

Felt
hopeless

Felt
nervous

Felt
restless

Felt
sad

Felt
worthless

Any new
mental
disorders at
follow-up

OLS

Logit

Logit

Logit

Logit

Logit

Logit

Logit

Logit

Coeff.
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)
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Number of medications WITH any insomnia, depression, suicidal, or anxiety side effects at baseline
None (reference)
1 medication

(8)

b

0.100
(0.121)

1.056
(0.079)

1.000
(0.072)

0.963
(0.078)

0.916
(0.068)

1.171
(0.095)

0.913
(0.084)

0.985
(0.081)

1.164
(0.121)

2 medications

0.552***
(0.148)

1.240*
(0.110)

1.149
(0.091)

1.149
(0.108)

1.091
(0.094)

1.369***
(0.120)

1.101
(0.123)

1.099
(0.106)

1.422**
(0.173)

3+ medications

1.837***
(0.169)

2.078***
(0.196)

1.983***
(0.175)

1.859***
(0.179)

1.650***
(0.146)

1.912***
(0.188)

1.742***
(0.198)

1.814***
(0.176)

1.837***
(0.249)

Number of medications WITHOUT any insomnia, depression, suicidal, or anxiety side effects at baseline
None (reference)
1 medication

b

-0.108
(0.110)

0.940
(0.058)

1.052
(0.064)

0.966
(0.066)

0.989
(0.067)

1.012
(0.066)

0.909
(0.067)

0.946
(0.069)

1.077
(0.092)

2 medications

-0.305*
(0.131)

0.866*
(0.060)

0.937
(0.062)

0.894
(0.078)

0.934
(0.069)

0.923
(0.067)

0.886
(0.079)

0.866
(0.074)

1.032
(0.104)

3+ medications

-0.364**
(0.139)

0.864*
(0.064)

1.037
(0.067)

0.837*
(0.071)

0.838*
(0.060)

0.884
(0.062)

0.738***
(0.062)

0.844
(0.074)

1.016
(0.098)

Mean outcome

6.656

0.170

0.199

0.116

0.158

0.163

0.094

0.109

0.075

No. of persons

35,189

35,189

35,189

35,189

35,189

35,189

35,189

35,189

35,189

Note: * p<0.05, ** p<0.01, *** p<0.001
All analyses control for changes in the number of medications with and without side effects consumed between round 1 and round 2 (for those in the
first year of their panel) and between round 3 and round 4 (for those in the second year of their panel), race/ethnicity, gender, age and age squared,
marital status, education, poverty, health insurance coverage, obesity, number of chronic conditions, whether had any pain that interfered with normal
work outside the house or housework in the past 4 weeks, year and region fixed-effects.
a: Measured in round 2 for those in the 1st year of their panel, and round 4 for those in the 2nd year.
b: Measured in round 1 for those in the 1st year of their panel, and round 3 for those in the 2nd year.
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Table 13. Adjusted Logit and Two-Part Model Regressions of Utilization/Cost of Mental Health Services on Medication Use
for Adults Aged 25-84 With Mental Disorders at Baseline. Data Source: MEPS 2004-2015.

Outcome:
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(1)

(2)

Whether
had more
visits for
mental
disorders
at followup

Changes
in
number
of visits
for
mental
disorders
between
baseline
and
follow-up
Two-part
model
Marginal
effect
(SE)

Logit
OR
(SE)

(3)

(4)
(5)
(6)
Health services utilization a
Changes in
Whether
Whether
Whether
cost for
used more
used more used more
mental
medications antidepres- anxiolytics,
disorders
for mental
sants for
sedatives,
between
disorders at
mental
or
baseline
follow-up
disorders
hypnotics
and followat followfor mental
up
up
disorders at
follow-up

(7)

(8)

Whether
used more
anticonvulsants for
mental
disorders
at followup

Whether
used more
antipsychotics for
mental
disorders
at followup

Two-part
model

Logit

Logit

Logit

Logit

Logit

Marginal
effect (SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

OR
(SE)

Number of medications WITH any insomnia, depression, suicidal, or anxiety side effects at baseline
None (reference)
1 medication

b

1.184*
(0.084)

0.069
(0.085)

68.206
(60.799)

1.165*
(0.087)

1.047
(0.081)

1.169
(0.108)

1.180
(0.123)

0.952
(0.116)

2 medications

1.489***
(0.122)

0.119
(0.110)

152.039
(90.350)

1.368***
(0.116)

1.210*
(0.117)

1.533***
(0.154)

1.580***
(0.182)

1.349*
(0.181)

3+ medications

2.101***
(0.192)

0.660***
(0.125)

534.938***
(126.322)

1.927***
(0.209)

1.873***
(0.199)

2.126***
(0.245)

2.386***
(0.321)

2.014***
(0.282)

Number of medications WITHOUT any insomnia, depression, suicidal, or anxiety side effects at baseline
None (reference)

b

1 medication

0.980
(0.049)

-0.014
(0.084)

29.979
(60.331)

0.878*
(0.053)

0.911
(0.058)

0.901
(0.063)

0.906
(0.067)

0.968
(0.077)

2 medications

0.938
(0.058)

-0.097
(0.103)

6.955
(63.331)

0.883
(0.074)

0.805*
(0.071)

0.950
(0.079)

0.929
(0.094)

0.965
(0.104)

3+ medications

0.777***
(0.046)

-0.184
(0.098)

40.054
(65.025)

0.714***
(0.053)

0.748***
(0.062)

0.946
(0.070)

0.873
(0.073)

0.875
(0.080)

Mean outcome

0.232

0.810

360.470

0.206

0.167

0.101

0.084

0.069

No. of persons

35,189

35,189

35,189

35,189

35,189

35,189

35,189

35,189
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Note: * p<0.05, ** p<0.01, *** p<0.001
All analyses control for changes in the number of medications with and without side effects consumed between round 1 and round 2 (for
those in the first year of their panel) and between round 3 and round 4 (for those in the second year of their panel), race/ethnicity, gender, age
and age squared, marital status, education, poverty, health insurance coverage, obesity, number of chronic conditions, whether had any pain
that interfered with normal work outside the house or housework in the past 4 weeks, year and region fixed-effects.
a: Measured in round 2 for those in the 1st year of their panel, and round 4 for those in the 2nd year.
b: Measured in round 1 for those in the 1st year of their panel, and round 3 for those in the 2nd year.

Figure 3: Association Between Baseline Medications with Side Effects and K6 Score
by Age Groups
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Figure 4: Association Between Baseline Medications with Side Effects and Mental
Distress (K6 >= 13) by Age Groups
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Figure 5: Association Between Baseline Medications with Side Effects and Whether
Having a New Mental Disorder at Follow-up by Age Groups
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Figure 6: Association Between Baseline Medications with Side Effects and Whether
Have More Visits for Mental Disorders at Follow-up by Age Groups
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Figure 7: Association Between Baseline Medications with Side Effects and Whether
Used More Psychotropic Medications for Treatment of Mental Disorders at Followup by Age Groups
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Figure 8: Association Between Baseline Medications with Side Effects and Changes
in Number of Visits for Mental Disorders Between Baseline and Follow-up by Age
Groups
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Figure 9: Association Between Baseline Medications with Side Effects and Changes
in Costs for Mental Disorders Between Baseline and Follow-up by Age Groups
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CHAPTER 5:
Discussion
Summary
This dissertation investigated the causes and health consequences of polypharmacy. In
the first chapter, I provided strong evidence that while the expansion of Medicare Part D
increased access to affordable and life-saving medications for older adults, it had a
substantial impact on polypharmacy. An increase at this margin introduced a potential
moral hazard, given that the additional research conducted in my dissertation showed
significant adverse effects for emotional and cognitive well-being associated with
polypharmacy. To the extent that these results are generalizable to other health insurance
programs, expanding Medicaid under the Affordable Care Act in 2014 or implementing a
Medicare-for-All program might produce similar effects on polypharmacy. Therefore,
policies that reduce polypharmacy by promoting proper prescribing practices following
an insurance expansion program can potentially alleviate adverse medical outcomes
associated with polypharmacy. In the second chapter, I showed that the concurrent use of
three or more medications with cognitive impairment side effects among U.S. older
adults increased three-fold in the past two decades. Further, I found that concurrent use of
three or more of these medications was associated with reductions in the global cognitive
score, performance on the word learning and recall assessment, and performance on the
digit symbol substitution assessments. In contrast, medications without known cognitive
side effects were not associated with a decline in cognitive function. Finally, in my third
chapter, I assessed trends in the use of medications with mental health side effects and
their consequences for mental health and the use/costs of mental health services. My
results showed a growth of 36% in the concurrent use of three of more of these
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medications among U.S. adults in the past two decades. I also found that the concurrent
use of mediations with mental health side effects was associated with an increase in
psychiatric symptoms and the use/costs of mental health services. Patterns in medication
use observed in the second and third chapters were potentially due to overconfidence in
medicine as a solution to disease, a focus on single disease outcomes rather than
comorbidity, and the spillover effect of treating chronic physical disease to mental
disease. The results also highlighted the impact of polypharmacy. The most significant
side effects documented in this dissertation were limited to individuals taking three or
more medications with cognitive or mental health side effects. Polypharmacy may
present unique risks for side effects, amplifying the effects of each of the medications in a
set. Further, polypharmacy also increases the risk of drug-drug interactions that may lead
to adverse cognitive and psychiatric disorders.

Given the growing prevalence of polypharmacy and its adverse consequences on
population health, it is important to understand how people are initially exposed to
medication use and polypharmacy, and how the overuse of medications can potentially
lead to larger social problems. In this chapter, I use the theoretical frameworks of
medicalization and pharmaceuticalization to better understand the potential causes of
polypharmacy and the increasing use of medications with cognitive and mental health
side effects. Medicalization is a process in which previously non-medical problems are
defined as illnesses or disorders, and are treated using medical interventions (Conrad,
1992). Pharmaceuticalization is defined as “the process by which social, behavioural or
bodily conditions are treated or deemed to be in need of treatment, with medical drugs by
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doctors or patients” (Abraham, 2010b). Despite the overlap, there are marked differences
between two theories (Abraham, 2010b). Although medicalization increases patients’
exposure to medical interventions, the treatment does not necessarily involve the use of
prescription medications. Moreover, some medications can be used to treat established
medical conditions, without transforming a non-medical problem to a medical one. In
addition, whereas studies on medicalization focus on the interactions between physicians
and patients when defining an illness, they pay less attention to the increasingly important
role of the pharmaceutical industry in shaping and influencing medical treatments
(Conrad & Leiter, 2004). Although these agents remain unchanged under both theoretical
frameworks (i.e. physicians, patients, and the pharmaceutical industry), the key player is
different. Guided by these two interrelated theories, I first demonstrate the extent to
which physicians, the pharmaceutical industry, and patients contribute to the rise in
medication use. I then examine how the processes of medicalization and
pharmaceuticalization vary across subgroups in the population, resulting in disparities in
medication use. Finally, I discuss the implication of disparities in medication usage
across subgroups for population-level health disparities.

The roles of medicalization and pharmaceuticalization in increased medication use
Physicians. Prior studies have emphasized the ways that medical professionals organized
to create demand in order to generate new markets for their services (Larson & Larson,
1979). In order to achieve professional dominance, it was crucial for medical
professionals to become major players in the social construction of disease, including
controlling the meanings, interpretations, and diagnoses of illnesses. These efforts can be
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traced back to the medicalization of menopause in the 1930s and 1940s (Bell, 1987). A
small number of elite physicians created a medical vocabulary for menopause and used it
to define menopause as a deficiency disease instead of a normal process of aging
(Moynihan, 2002). As a result, it was recommended that all menopausal women, not just
some women, should consult physicians for appropriate treatment, making menopause a
medical problem. The medicalization of menopause was successful in part due to the
approval and availability of a new estrogen medication in 1938 (Bell, 1987). As a result,
estrogen sales doubled and tripled in the mid-1960s and 1970s (Stefanick, 2005). By
2000, approximately 25% of women aged 40 and older were current estrogen therapy
users (Brett & Reuben, 2003). While estrogen therapy can resolve symptoms of
menopause and lower the risk of osteoporosis, they can also increase the risks of
depression, suicide, and anxiety, as demonstrated in the third chapter of this dissertation.
In fact, almost half of prescription medications with depression as a common or serious
side effect are hormone/estrogen therapies (Qato et al., 2018). In some additional
analyses not presented in this dissertation, I found that women were more likely to use
medications with depression or suicide as potential side effects and were more likely to
experience polypharmacy than men, in part due to their frequent consumption of
hormone/estrogen medications. The dominant role of medical professionals in defining
disease has also been documented in other historical examples of mental illness,
alcoholism, opiate addiction, homosexuality, hyperactivity, delinquency, and crime
(Conrad, 2005; Conrad & Schneider, 2010; Moynihan, 2002). Although advances in
medicine allow physicians to improve the standards of medical care deliveries, they also
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preserve the central role of physicians in pushing the boundaries of disease as wide as
possible to expand markets for their services.

Pharmaceutical industry. Although previous analyses of medicalization designated
physicians as the key drivers of the social construction of disease, recent studies of
pharmaceuticalization have increasingly focused on the pharmaceutical industry
(Abraham, 2010a; Conrad, 2005). Part of this shift was due to recent changes in the
organization of medical care – including the introduction of managed care, the emphasis
on consumer advocacy and accountability, and the advancement of pharmaceutical
innovations (Abraham, 2010a; Conrad, 2005). Studies found that the pharmaceutical
industry drove the process of pharmaceuticalization mainly through three channels,
including (1) pharmaceutical detailing, (2) direct-to-consumer advertising, and (3)
marketing diseases (Conrad, 2005; Conrad & Leiter, 2004; Williams et al., 2011). First,
while pharmaceutical marketing varies widely in types, more than half of marketing
expenditure directly targets physicians through detailing (Campbell, 2009). Aggressive
detailing efforts from pharmaceutical representatives have resulted in almost 94% of
physicians having some type of financial ties to the industry, most of which are by ways
of free meals or gifts at the workplace (Campbell et al., 2007). Using various sources of
exogenous shocks such as detailing regulations, drug patent expirations, or the migration
of patients, prior studies have established a robust and positive association between
receiving detailing payments and the quantity of drugs prescribed (Carey et al., 2017;
Grennan et al., 2018; Manchanda & Honka, 2005; Spurling et al., 2010). Physicians with
greater contact with drug sales representatives are also more likely to prescribe brand200

name medications that are clinically equivalent to other more-affordable or generic
substitutes (Greenway & Ross, 2017). Second, the rise in direct-to-consumer advertising
(DTCA) of prescription medications in the U.S. has generated a controversial debate on
the extent to which DTCA has substantial effects on consumer behavior. Following a
policy change that relaxed restrictions on DTCA in 1997, spending on DTCA has
increased from $150 million in 1993 to $6 billion in 2016 (Dave, 2013; Schwartz &
Woloshin, 2019). While DTCA may drive demand for expensive pharmaceutical
treatments despite the clinical effectiveness of other existing alternatives (market
stealing), it can also increase pharmaceutical usage and spending by getting undiagnosed
individuals to doctor’s office (market expansion). A handful of studies supported the
effects of DTCA on market expansion (Bradford et al., 2006; Iizuka & Jin, 2005;
Rosenthal et al., 2003) rather than market stealing (Dave, 2013; Wosinska, 2002),
implying that DTCA tends to increase individuals’ exposure to pharmaceutical therapies.
Third, pharmaceutical companies are not just advertising medication, but are also selling
sickness by reframing disease as having a pharmaceutical solution and by promoting the
use of medication for non-medical purposes. Using a case study of erectile dysfunction,
Lexchin (2006) demonstrated how Pfizer – one of the world’s largest pharmaceutical
companies – turned Viagra from an effective product for erectile dysfunction due to
organic causes, such as diabetes or prostate surgery, to a legitimate lifestyle medication14
for almost all men. Pfizer redefined the prevalence and psychological effects of erectile
dysfunction by extrapolating results from a non-nationally-representative study to argue
that more than half of men aged 40 and older experienced erectile dysfunction and that

14

Medications that treat non–life-threatening or non-painful conditions.
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erectile dysfunction led to psychological distress (Lexchin, 2006). By convincing men
that Viagra should be the first choice of therapy for any degree of erectile dysfunction,
regardless of the patient’s age or the sources of the problem, Pfizer pharmaceuticalized a
normal process of aging and turned it to a medical condition that required pharmaceutical
interventions. Prior studies have also documented similar marketing strategies for the
cases of restless leg syndrome (Woloshin & Schwartz, 2006), excessive sleepiness
(Kroll‐Smith, 2003), or male pattern baldness (Moynihan, Heath, & Henry, 2002). Taken
together, aggressive marketing strategies employed by the pharmaceutical industry –
either through detailing physicians, direct-to-consumer marketing, or redefining disease –
can potentially contribute to patients’ reliance on medications and increase the risk of
polypharmacy. While the pharmaceutical industry has increasingly become an important
player in the social construction of illness, it is important to not deemphasize the role of
physicians. In fact, physicians remain as gatekeepers to most medical resources in the
U.S., including prescription medications. The growth of the pharmaceutical industry, if
any, may just help physicians reinforce their ability to transform non-medical problems to
ones that have a pharmaceutical solution.

Patients. While physicians and pharmaceutical companies define or broaden the
boundaries of illnesses to increase the demand for their services, these agents also
respond to the markets that patients create (Conrad, 2005; Riessman, 1983). Barsky and
Borus (1995) noted that the public’s tolerance for mild symptoms and the threshold at
which patients seek medical interventions have lowered in recent decades.
Approximately 25 to 50% of patients in primary care complain about symptoms that have
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no pathophysiological explanation or organic causes (Burton, 2003; Escobar et al., 2010;
olde Hartman et al., 2009). These patients tend to overuse medical care, have higher
medical expenditures, and undergo unnecessary procedures (Barsky et al., 2005). Using
an example of sleeplessness, Moloney et al. (2011) reported that the number of office
visits that involved complains for sleeplessness had more than doubled between 1993 and
2007 from 2.7 million to 5.7 million. In response, the diagnosis of sleeplessness and the
prescription of nonbenzodiazepine sedative hypnotics increased by 7.6-fold and 30-fold,
respectively (Moloney et al., 2011). As such, complains about mild symptoms in part
contribute to the medicalization of physical distress in which uncomfortable bodily states
are considered disease that require medical or pharmaceutical interventions.

The roles of medicalization and pharmaceuticalization in medication use disparities
Although the processes of medicalization and pharmaceuticalization might have
significantly contributed to the rise in medication use and polypharmacy, these processes
did not affect every individual equally. For instance, women’s bodies were more
vulnerable to medicalization and pharmaceuticalization than men’s bodies due to normal
bodily conditions such as childbirth, premenstrual syndrome, and menopause (Bell, 1987;
Riessman, 1983). As a result, women are more likely to consume prescription
medications and are at a higher risk of polypharmacy than men (Kantor et al., 2015). In
the second and third chapters of this dissertation, I found that women were more likely
than men to use medications that have cognitive impairment and mental health side
effects. Many medications with these side effects were estrogen or hormone therapies,
which was partly a result of the medicalization of menopause in the 1930s and 1940s
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(Bell, 1987). In addition, there are substantial racial/ethnic disparities in the use of
prescription medications and polypharmacy (Han & Liu, 2005; Kantor et al., 2015; Wang
et al., 2007). While a majority of studies attributed the racial/ethnic gap in medication use
to unequal access to health care and socioeconomic status (Wang et al., 2007), a growing
literature focuses on minority patients’ reluctance to medicalization and
pharmaceuticalization as a reason for racial/ethnic disparities in medication use (Adams
et al., 2018; Gaskin et al., 2006; Schnittker, 2003). One study has shown that minority
patients are more likely than non-Hispanic White patients to have concerns about the side
effects of diabetes-related medications and the potential reliance on medication, and are
more reluctant to adding more medications to their treatment plans (Huang et al., 2009).
Similarly, the use of clozapine – the first-choice medication for refractory illness – is
significantly lower among Hispanic and non-Hispanic Black patients, compared to nonHispanic Whites, in part due to concerns about serious side effects of the medication such
as loss of white blood cells or instabilities of serum glucose levels (Copeland et al.,
2003). Schnittker (2003) found that neither socioeconomic status, knowledge, religion,
nor trust in medicine explained black patients’ reluctance against the use of psychiatric
medications, but rather their concerns towards serious side effects and efficacy of these
medications. Minorities who are resistant to pharmaceuticals tend to adopt
complementary and alternative medicine or healthy lifestyle changes, especially among
less acculturated minorities (Adams et al., 2018). Therefore, even though medicalization
and pharmaceuticalization might have increased the dependence on pharmaceutical
treatments, they affected some groups more than others.
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Implications for population-level health disparities
Disparities in medication use – either due to the heterogeneous effects of medicalization
and pharmaceuticalization or other factors such as disparities in access to health care or
socio-demographic status – can have substantial implications for population-level health
disparities. On the one hand, medication underuse may lead to medical complications
associated with undertreatment. For example, the underuse of diabetes-related
medications among minority patients may in part explain for their higher rates of
diabetes-related complications relative to non-Hispanic White patients (Huang et al.,
2009), such as renal disease, retinopathy, blindness, amputations, amputation-related
mortality, and diabetes-related mortality (Carter et al., 1996; Emanuele et al., 2005;
Harris et al., 1998; Lanting et al., 2005; Lustman et al., 2000; National Center for Health
Statistics, 2008). Similarly, women’s and minorities’ underuse and non-adherence of
medications for prevention of cardiovascular disease (Lewey et al., 2013; Qato et al.,
2010), despite growing evidence for their effectiveness (Weisman & Graham, 2002), may
contribute to marked gender and racial/ethnic disparities in cardiovascular disease (Davis
et al., 2007; Mensah et al., 2005; Qato et al., 2010; Sheifer et al., 2000).
On the other hand, minorities’ resistance from medication usage, relative to non-Hispanic
Whites, may have protective effects against certain medication side effects and may help
explain for their lower prevalence of medical conditions associated with medication side
effects. For instance, social scientists have found it difficult to explain the racial/ethnic
paradox in mental health: that minorities often report better mental health than nonHispanic Whites despite social and environmental conditions that are detrimental to
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mental health (Budhwani et al., 2015; McGuire & Miranda, 2008). Enormous efforts
have attempted to uncover the sources of this paradox, including socioeconomic status,
discrimination, social networks, and religious involvement – and for the most part – have
been unsuccessful. Schnittker and Do (2020) argue that the minority paradox in mental
health is in part rooted in the disparity of medication use: the more frequent use of
medications with depression or suicidal side effects among the non-Hispanic White
population helps explain its higher rates of psychiatric symptoms than that of minorities.
In addition, the use of medications with side effects may also be related to the migration
paradox in mental health. The paradox implies that migrants, especially newly arrived
migrants, often report fewer psychiatric symptoms than native-born Americans, despite
numerous theories suggesting their disadvantages (Budhwani et al., 2015; Foo et al.,
2018). In a preliminary analysis using the National Health and Nutrition Examination
Survey (NHANES), I found that migrants were less likely to use medications with
depression and suicide as side effects than native-born Americans. In analytic models that
controlled for the use of these medications, the migrant disparity in depression was
reduced to statistical insignificance. In addition, I found that pharmaceutical acculturation
plays an important role in the relationship between medication usage and the migrant
disparity in health. As migrants come to resemble the pharmaceutical culture in the U.S.
and consume more medications with depressive or suicidal side effects, their reported
prevalence of depressive symptoms increases and becomes similar to that of the nativeborn population. Moreover, the use of medication with depression or suicidal side effects
can also help explain the gender disparities in mental health. In additional analyses not
presented here, I found that the higher prevalence of psychiatric symptoms among
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women, relative to men, can be partially explained by the use of medications with
depression and suicidal side effects. More than half of these medications are estrogen or
hormone therapies that resulted from the medicalization of menopause in the 1930s and
1940s (Bell, 1987; Qato et al., 2018). Collectively, these findings suggest a new
explanation for differences in health outcomes: that much can be explained by the side
effects of commonly used medications.

Conclusion
While the processes of medicalization and pharmaceuticalization may have improved the
standard of medical care in the United States, they have also contributed tremendously to
the rise in medication use and polypharmacy. These processes did not affect every
individual equally, which in part resulted in vast disparities in medication use across
subgroups. Although the underuse of medications among certain demographic groups
might have led to medical complications associated with undertreatment, it also had
protective effects against serious medication side effects. A handful of studies has
focused on the former to explain for population-level disparities in health, whereas the
role of medication side effect has likely been underappreciated, especially under the
condition of polypharmacy. Therefore, the investigation of medication side effects is an
important frontier for future social science research and could help explain important
trends in health disparities. Moreover, conceptualizing how people are initially exposed
to the use of medications with side effects will shed light on patterns and disparities in
population health and speak directly to the role of broader social, economic, cultural, and
institutional inequalities in generating and maintaining health disparities.
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